ISS

N 17

25

-45

58

Key achievements and governance: a year in review

GE

NE

RA

L RE

PO

RT

OF

AC

TIV

ITIE

S 2

01

5 K

ey achievem

ents an

d govern

ance: a year in

review

EN

2015

General Report of Activities

including the annual activity report of the emcdda’s authorising officer

2015

General Report of Activities

Legal notice

This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by

copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the

data contained in this document. The contents of this publication do not necessarily reflect the official opinions of

the EMCDDA’s partners, any EU Member State or any agency or institution of the European Union.

Europe Direct is a service to help you find answers to your questions about the European Union.

Freephone number (*): 00 800 6 7 8 9 10 11

(*) The information given is free, as are most calls (though some operators, phone boxes or hotels may

charge you).

More information on the European Union is available on the Internet (http://europa.eu).

Luxembourg: Publications Office of the European Union, 2016

Print: ISBN 978-92-9168-915-6 doi:10.2810/932159

Web: ISBN 978-92-9168-914-9 doi:10.2810/15377

© European Monitoring Centre for Drugs and Drug Addiction, 2016

Reproduction is authorised provided the source is acknowledged.

Printed in Luxembourg

Printed on elemental chlorine-free bleached paper (ECF)

Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal

Tel. +351 211210200

info@emcdda.europa.eu I www.emcdda.europa.eu

twitter.com/emcdda I facebook.com/emcdda

I Contents

(*) Available online at: emcdda.europa.eu/publications/gra/2015

5 Foreword

7 Introduction

PART IReport of activities: key achievements and governance

13 I CHAPTER 1

Management Board´s analysis and assessment

17 I CHAPTER 2

Executive summary

23 I CHAPTER 3

Core business: monitoring and reporting on the drugs problem in Europe

52 I CHAPTER 4

Cooperation and collaboration with key partners

61 I CHAPTER 5

Supporting the achievement of results

PART IIManagement and internal control systems: annual activity report as per the Financial Regulation applicable to the EMCDDA

79 I CHAPTER 1

Management

92 I CHAPTER 2

External evaluations

95 I CHAPTER 3

Assessment of the effectiveness of the internal control systems

98 I CHAPTER 4

Management assurance

ANNEXES

100 ANNEX 1: Organisational chart

101 ANNEX 2: Staff details

104 ANNEX 3: Outputs and products

113 ANNEX 4: Key external events, conferences and meetings, 2015 (*)

113 ANNEX 5: Implementation of the 2015 work programme by objectives, activities and

expected outputs/results (*)

113 ANNEX 6: Key performance indicators (*)

114 ANNEX 7: Members of the EMCDDA’s statutory bodies

116 ANNEX 8: Use of the available resources

125 ANNEX 9: List of acronyms and abbreviations

1 1995 1996 1997

1998 1999 2000 2001 2002 2003 2004 2005 2006

2007 2008 2009 2010 2011 2012 13 2014 2015 20

2016 2017 2018

5

Foreword

Further to my election as Chair of the Management Board in December 2015, I have the

honour to introduce the 21st General Report of Activities of the European Monitoring

Centre for Drugs and Drug Addiction, which provides an account of the EMCDDA’s

activities and achievements in 2015.

First of all let me pay tribute to my predecessor, João Goulão, who steered the

Management Board over the past six years with a constructive approach by continuously

seeking to build consensus for decision-making.

The Management Board also selected a new Director in September. As a result, and

following his public hearing at the European Parliament later that month, Alexis Goosdeel

was formally appointed by the Management Board in October for a five-year mandate and

took up his position on 1 January 2016. I look forward to our fruitful collaboration and to

maintaining and strengthening the relation of trust between the Management Board and

the EMCDDA Director.

My special thanks go to Wolfgang Götz, who completed two mandates as Director of the

agency on 31 December 2015. Mr Götz’s lead turned the EMCDDA into a mature and

internationally recognised agency, dedicated to scientific excellence and efficiency. I am

particularly pleased that Mr Götz has been nominated as European Parliament

representative on the Management Board and will continue to enrich our work with his

experience.

In 2015 the EMCDDA commemorated 20 years of monitoring the drugs problem in

Europe. Over the last two decades, much has changed in the extent and nature of the

phenomenon and the centre’s work has developed to keep pace with this complexity. As

this report of activities for 2015 shows, the agency is clearly fulfilling its mission to

communicate solid evidence and inform policy in the drugs field in Europe. Building its

analyses on scientific evidence and reliable data provided by the European Information

Network on Drugs and Drug Addiction (Reitox), consisting of one focal point in each

Member State, Norway and Turkey, the EMCDDA plays a key role in the understanding of

the drug phenomenon. The agency also makes an essential contribution to strengthening

the capacity of EU and non-EU countries to monitor the drug situation.

The year 2015 is the last of the EMCDDA’s three-year strategy and work programme for

2013–15. At the same time 2015 was a crucial year for shaping the future of the EMCDDA

as it saw the adoption by the Management Board of the agency’s new strategy and work

General Report of Activities 2015

6

programme for 2016–18, and the commitment by the EMCDDA’s Director-elect to

develop and implement a long-term strategy.

I would like to express my gratitude to all colleagues on the Management Board for their

cooperation, as well as to the Chair and members of the Scientific Committee for their

work and commitment.

My very special thanks also go to all the staff of the agency as well as the Heads of the

Reitox national focal points and their staff for their dedication and expertise, which

helped us to fulfil our legal obligations and achieve a very good level of implementation of

the work programme despite the challenges encountered during the year.

Laura d’Arrigo

Chair of the EMCDDA Management Board

7

Introduction

The year 2015 was outstanding for the agency. It marked a historical milestone — the

commemoration of 20 years of European drug monitoring. It also saw the completion of

the successful mandates of the Chair of the Management Board, João Goulão, and of the

Director, Wolfgang Götz, whom I have the privilege to succeed, and it closed the three-

year strategic cycle that ran under the umbrella of the European Monitoring Centre for

Drugs and Drug Addiction’s (EMCDDA’s) 2013–15 strategy and work programme.

The agency could not be prouder of its accomplishments at the end of these three fruitful

years. The EMCDDA consolidated its monitoring system in close partnership with its data

providers, especially the European Information Network on Drugs and Drug Addiction

(Reitox) national focal points (NFPs). Keeping pace with rapid developments, the agency

became stronger with regard to detecting new trends and assessing the threats posed by

drugs to the health and security of Europeans. A striking example of this is the

implementation of the European Union (EU) Early Warning System (EWS) on new drugs,

managed by the agency in cooperation with its partners, which led to the detection of

almost 300 new psychoactive substances (NPS) between 2013 and 2015 (i.e. almost half

of the total number of NPS that have been monitored by the agency since the EU EWS

was set up in 1997), and eight NPS were risk assessed (i.e. 40 % of the total number of

NPS ever risk assessed). This is a good indication of how our work has developed in this

area. Threat assessment was also carried out in the area of harm reduction, in response to

concerns regarding the rise in human immunodeficiency virus (HIV) infection among

injecting drug users in some Member States.

Strategic analysis was significantly enhanced, as work to produce the second edition of

the EU Drug Markets Report (EDMR), prepared jointly with Europol and first published in

2013, was carried out by these two agencies in 2015. The global perspective of the drug

phenomenon also became a more important dimension of our analyses. The agency

worked with its global partners and closely followed developments in other regions,

including the United States and Latin America; technical assistance was provided to 14

third countries, candidate and potential candidate countries, and neighbouring countries,

which are a priority for the EU. Several analyses based on data from the Western Balkans

were performed and disseminated in this context.

The communication of our findings became timelier, and more interactive means and

tools were developed and used. In 2013, the European Drug Report (EDR) package

replaced the former annual reports and new features have been added to this multimedia

package ever since. Since its launch, great importance has been attached to the EDR,

both at EU level — for instance, on two occasions (in 2013 and 2015), the report was

General Report of Activities 2015

8

released in the presence of the Commissioners for Home Affairs — and at the level of

Member States, as 26 national launches were also organised.

In addition to the annual EDR and the first EDMR, more than 100 other scientific or

institutional outputs were released in 2013–15, and, during the same period, almost 80

scientific articles, co-authored by EMCDDA staff, were published in renowned journals.

A key event for scientists, policymakers and professionals alike (more than 600

participants in total) was the 2015 Lisbon Addictions Conference. The EMCDDA was the

main contributor to this event, the first one of its kind ever organised.

Finally, the 2013–15 period was marked by the revision of the national reporting package.

In a joint effort, the EMCDDA and its Reitox partners succeeded in developing and

starting to implement the changes necessary for the functioning of a more efficient

national reporting package.

These outstanding achievements have paved a solid ground for the next stage in the life

of the EMCDDA; and at the beginning of my mandate as Director, I could not be more

confident that the agency will now rise to its future challenges.

I know that I can rely on a committed team of professionals, my dedicated staff, on the

valuable guidance of our Management Board and of our Scientific Committee, and on the

support of all our partners, in particular the Reitox NFPs. I would like to thank them all for

their ongoing efforts, which have made and will make the past and future achievements of

the EMCDDA possible.

I could not sign my first General Report of Activities as Director without paying tribute to

my predecessor, Wolfgang Götz. My gratitude goes to Wolfgang, who has steered the

EMCDDA successfully for the last 11 years and had a critical role in building its reputation

as the reference point on drugs in Europe.

The ‘Observatory of the Future’ that I am committed to build throughout the course of my

mandate will benefit strongly from the solid foundation laid by his work.

Alexis Goosdeel

Director

I

11

PART I

Report of activities: key achievements and governance

Chapter 1Management Board s analysis and

assessment

Chapter 2Executive summary

Chapter 3Core business: monitoring and reporting the

drugs problem in Europe

Chapter 4Cooperation and collaboration with key

partners

Chapter 5Supporting the achievement of results

1

13

The Management Board has analysed and assessed the Authorising Officer’s (Director’s)

General Report of Activities for the financial year 2015.

The Management Board appreciates the results achieved by the Centre and notes in

particular the following:

On the content of the report

The EMCDDA made significant progress in the implementation of its work programme for

most planned activities. Of particular note are the achievements in the following areas:

• Data collection, analysis and quality assurance: in June, the EMCDDA presented its

annual overview of the European drug situation — the European Drug Report (EDR),

together with a multimedia package. In terms of the data collection tools and

processes, the main development during the year was the entry into force of the

revised Reitox national reporting package. The EMCDDA internal statistics code of

practice was published.

• Key epidemiological indicators: the third triennial assessment of the implementation of

the key epidemiological indicators in the EU Member States, Norway and Turkey was

carried out in close collaboration with the focal points. The Swedish Government

addressed a formal request to the EMCDDA to assume full coordination of the European

School Survey Project on Alcohol and Other Drugs (ESPAD) in the future. In the

meantime, the activities agreed upon for 2015 were implemented. The EMCDDA

published several analyses based on the results of the key epidemiological indicators

monitoring work and annual European expert meetings. An EMCDDA technical

conference was held in Lisbon on 21–22 September to understand the dynamics, nature

and scale of drug use in Europe, including lessons learnt and challenges for the future, in

commemoration of the agency’s 20 years of monitoring the drug situation in Europe.

• Demand reduction responses: some new analyses in the prevention field were released

and new evidence on environmental strategies was produced. In the area of treatment,

harm reduction and social reintegration, three new publications were released on relevant

topics. The Best practice portal continued to be improved and new modules were added.

In October the EMCDDA organised, for the first time, a meeting dedicated to the topic of

health responses to new psychoactive substances (NPS). The agency continued to work

with its partners at European and international levels in the field of harm reduction and

provided its expertise in the prevention of infectious diseases amongst people who inject

drugs, with a main focus on HIV and the hepatitis C virus (HCV).

• Supply and supply reduction interventions: the EMCDDA made important progress in

the development of the reporting tools. Jointly with Europol, the agency also drafted

the second edition of the EU Drug Markets Report, to be released in 2016. The annual

CHAPTER 1Management Board s

analysis and assessment

General Report of Activities 2015

14

meeting of the reference group on drug supply was organised. Finally, the EMCDDA

fulfilled the tasks assigned to it in the operational action plans within the EMPACT

framework developed under the new EU Policy Cycle for organised and serious

international crime 2013–17 within the Council of the EU’s Standing Committee on

Operational Cooperation on Internal Security (COSI).

• New trends and developments: 98 NPS were formally notified in 2015. The EMCDDA–

Europol 2014 Annual Report on the implementation of Council Decision

2005/387/JHA was submitted to the EU institution stakeholders and published.

EMCDDA–Europol joint reports on two NPS, α-PVP and acetylfentanyl, were produced,

sent to the European Commission, the Council and the European Medicines Agency,

and published. A risk assessment exercise was carried out by the EMCDDA´s Extended

Scientific Committee on α-PVP.

• Drug policy analysis: the EMCDDA contributed to the biennial progress review of the

European Commission as required by the EU action plan on drugs 2013–16. New

policy analyses were published. The annual meeting of the legal correspondents of the

European Legal Database on Drugs was organised in Lisbon in September.

• Scientific coordination and content support: a top priority was to ensure the quality

and coherence of the agency’s information collection and reporting system in

collaboration with the NFPs. The EMCDDA co-organised the first European conference

on addictive behaviours and dependencies — Lisbon Addictions 2015 — on

23–25 September. The agency continued its work on monitoring new trends and

misuse of medicines.

In 2015 the EMCDDA continued to collaborate with key external partners, such as the EU

Member States, the EU institutions, other EU agencies and international organisations.

In terms of international cooperation, cooperation with candidate and potential candidate

countries continued in 2015 within the framework of the new Instrument for Pre-

Accession Assistance (IPA 5) technical assistance project, which was awarded to the

EMCDDA in June. The EMCDDA published three publications based on its work within the

IPA projects in the Western Balkan region. In 2015 the EMCDDA continued the

implementation of the first European Neighbourhood Policy technical assistance project,

which started in 2014.

The Director signed a Memorandum of Understanding (MoU) between the EMCDDA and

the National Security Council of Armenia in Yerevan in July and another with the Georgian

Ministry of Justice in Tbilisi in November.

In the area of communicating the EMCDDA’s findings, the Centre’s product range

continued to be adapted to reflect the priority towards online dissemination and to seek

the most cost-efficient solution. New dissemination options were explored and social

media and targeted electronic updates were used throughout the year in order to enhance

communication with stakeholders and target groups. Some 45 scientific and institutional

publications were released by the EMCDDA (including a few joint products with our

partners) and 27 scientific articles authored or co-authored by EMCDDA staff were

published in prestigious journals. EMCDDA staff coordinated or organised 50 visits by

external parties, involving 468 visitors.

The agency made significant efforts to further improve its operational efficiency, and once

again achieved an outstanding budget execution rate at the end of the year.

Chapter 1 I Management Board´s analysis and assessment

15

On the structure of the report

The Management Board welcomes the 2015 General Report of Activities, which reflects

the agency’s achievements as set out in the work programme adopted by the Board. The

document, which mirrors the structure of the 2015 work programme, presents the most

important achievements for each of the 12 main areas of work. A more detailed

presentation of the implementation of the 2015 work programme, by objectives, activities

and expected outputs/results, is presented in Annex 5.

In conclusion, the Management Board finds the report to be a transparent and

representative overview of the implementation of the work programme.

2

Chapter 2 I Executive summary

17

This report presents the implementation of the activities of the European Monitoring

Centre for Drugs and Drug Addiction’s (EMCDDA’s) work programme for 2015 (1). The year

2015 was the final year of the EMCDDA’s three-year strategy and work programme for

2013–15. It therefore closed a multi-annual planning cycle in the life of the EMCDDA,

during which important projects that were designed to contribute to the triennial key

expected results were completed. At the same time, 2015 was a crucial year for shaping

the future of the EMCDDA, as it saw the adoption, by the Management Board, of the

agency’s new strategy and work programme for 2016–18.

In 2015, the agency made further progress towards its mission to provide a solid evidence

base to support the drug debate. Through its outputs, its direct technical support and its

knowledge dissemination activities, the agency offered policymakers the data and

analysis required to draw up informed drug laws and strategies; it also helped

professionals and practitioners working in the field to pinpoint best practice and new

areas of research.

EMCDDA publications

The most tangible results of our work during a year are our publications. In 2015, 45

scientific and institutional publications were released by the EMCDDA (including a few

publications that were produced jointly with our partners), and 27 scientific articles

authored or co-authored by EMCDDA staff were published in prestigious journals. The

complete list of publications is presented in Annex 3 of this report and brief overviews

can be found in the different ‘Main Area’ sections of this report.

On 4 June 2015, the EMCDDA launched its flagship publication, the European Drug

Report 2015: Trends and Developments, and its associated multimedia package, at

a press conference in Lisbon, Portugal, in the presence of Dimitris Avramopoulos,

European Commissioner for Migration, Home Affairs and Citizenship. The Commissioner

expressed his concerns and called for a unified response by the European Union (EU) to

the increasingly dynamic drug phenomenon.

The year 2015 also saw the development of an impressive list of thematic products,

including in-depth reviews on mental health disorders associated with drug use, the

prevention of addictive behaviours and the treatment of cannabis-related disorders in

Europe. These were complemented by updates on drug-related infectious diseases in

Europe, and analyses of mortality among drug users and the effectiveness of naloxone

take-home programmes in preventing fatal overdoses.

(1) Available at: emcdda.europa.eu/publications/work-programmes/2015

CHAPTER 2Executive summary

General Report of Activities 2015

18

Further evidence on the effectiveness of interventions, including new modules on new

psychoactive substances (NPS), the misuse of prescribed medicines and interventions in

prison, were provided by the EMCDDA’s interactive ‘Best practice portal’ (BPP).

Targeting mainly policymakers, the EMCDDA published a review on alternatives to punishment

for drug-using offenders and an overview of drug policies in different cities in Europe.

A much improved understanding of current drug markets will be provided by the second

edition of the strategic EU Drug Markets Report (EDMR), the launch of which will take

place in April 2016. The EMCDDA and Europol (European Police Office) jointly carried out

intensive work in 2015 to produce this major output. Collaboration and consultation with

other partners, including the European Commission through DG HOME, the EMCDDA’s

partner DG, and Member States, took place throughout the year, and other different

contributions have also been factored into this new flagship report.

The EMCDDA also published four outputs related to the implementation of Council

Decision 2005/387/JHA on NPS, and produced a further two reports that were submitted

in accordance with this Council decision; these will be published in early 2016. This

decision states that the agency has a central role in the implementation of the EU Early

Warning System (EWS) on new psychoactive substances, together with the European

Commission, Europol and Europol National Units, the European Medicines Agency (EMA)

and the European Information Network on Drugs and Drug Addiction (Reitox) (see also

below and Main Area 5).

Knowledge exchange

Scientific and technical meetings and conferences, training and capacity-building

activities were other means that were used to disseminate our knowledge in 2015.

During 2015, the EMCDDA contributed its expertise to around 300 key external scientific

meetings and conferences, as well as institutional events (see list in Annex 4 of this

report).

A major new event in the field of addiction research was the first European conference on

addictive behaviours and dependencies — Lisbon Addictions 2015. Hosted by the

Portuguese General-Directorate for Intervention on Addictive Behaviours and Dependencies

(SICAD), the event was held in collaboration with the scientific journal Addiction, the

International Society of Addiction Journal Editors (ISAJE) and the EMCDDA. The conference

comprised 350 presentations, including keynote speeches, oral presentations and posters,

and provided participants (more than 600) with a comprehensive overview of the main

issues on the current research agenda of the addictions field.

Training initiatives included the fourth European drugs summer school, ‘Illicit drugs in

Europe: demand, supply and public policies’, which was organised in partnership with

ISCTE — Lisbon University Institute (ISCTE-IUL), and a training programme for law

enforcement professionals implemented by CEPOL (the European Police College).

Capacity building was mainly implemented through the Reitox Academy Training

Programme. During the year, approximately 171 professionals from Member States and

third countries were trained as part of events organised or supported by the EMCDDA.

Experience exchange and knowledge sharing were also achieved through network

development and management. The EMCDDA relies on different networks of experts, who

Chapter 2 I Executive summary

19

contribute their national expertise to the EMCDDA’s European drug information and

analysis system. In addition to the ongoing technical support and exchange that took place

throughout the year in collaboration with these networks, nine expert meetings were held

in 2015, with more than 400 participants in total. These included the following annual

events: expert meetings on key epidemiological indicators (KIs); a meeting of the EMCDDA

Reference Group on Drug Supply Issues; the annual meeting of the Reitox Early Warning

System Network; and the Legal Correspondents meeting. Ad hoc (i.e. non-regular)

technical meetings on different thematic areas that were priorities for the EMCDDA, such

as drug supply reduction measures and responses to NPS, also took place. In addition, the

EMCDDA hosted the meetings of relevant project groups (e.g. the Customs Laboratories

European Network (CLEN) and the European Drug Emergencies Network (Euro-DEN)).

The agency also received almost 470 visitors during the year. Among the guests were

high-level policymakers from EU institutions, Member States and third countries, and

practitioners, members of academia and journalists.

Developments in the EMCDDA’s core monitoring system

The basis of the work developed by the EMCDDA to produce its outputs and services and

disseminate its knowledge is its complex core monitoring system. This encompasses data

collection tools and processes which support the entire annual reporting system of the

agency. This includes five KIs, health and social responses instruments, key indicators of

supply, and tools to monitor research, policies and laws. Methodological improvements were

made to most of these tools in 2015. The third triennial assessment of the implementation of

the KIs was carried out in close collaboration with the national focal points (NFPs), and

recommendations for improvements were developed for each country and indicator.

The year 2015 also marked the first year of implementation of the revised national

reporting system endorsed by the NFPs in 2014. Throughout the year, the EMCDDA

supported countries with the implementation of this new system. Further to this joint

effort, good performance was achieved by the NFPs with regard to implementing the new

reporting package.

New psychoactive substances and emerging trends

In 2015, 98 NPS were reported for the first time within Europe. This brings the total number

of NPS monitored by the EMCDDA through the EU EWS to more than 560, and more than

half of these were reported in the last three years alone. The EMCDDA also produced two

joint reports with Europol after the EMCDDA identified signals suggesting that serious

harms are associated with α-PVP (α-pyrrolidinovalerophenone) and acetylfentanyl in

Europe. At the request of the Council of the European Union, the extended Scientific

Committee of the EMCDDA undertook a risk assessment of α-PVP, noting that more than

100 deaths and 200 non-fatal acute intoxications have been linked to the drug.

In 2015, the Council adopted a decision to subject the new substances 4,4′-DMAR

(4,4′-dimethylaminorex) and MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) to

control measures associated with criminal penalties throughout the EU. This important

decision came in response to a proposal from the European Commission, which was

based on the risk assessment reports produced by the Scientific Committee of the

EMCDDA in 2014 — this reflects the strong evidence of action by the agency to EU

policymaking. This is the ultimate policy response, at EU level, to a rapidly growing

phenomenon.

General Report of Activities 2015

20

The EMCDDA also took further steps in 2015 towards understanding the current health

responses to NPS in Europe. For the first time, an expert meeting on this topic was

organised by the agency; this provided an opportunity for leading European health

professionals and researchers to meet in order to identify and discuss existing best

practice, as well as training and intervention needs in Europe. The findings will inform an

upcoming EMCDDA publication addressing NPS-related harms and health-related

interventions.

A publication on the legal responses to NPS and a new module of evidence on the BPP,

both produced in 2015, will further improve our knowledge in this area.

In addition to implementing the EU EWS, a key task was to monitor new trends in the drug

phenomenon. The internet is becoming an increasingly important vehicle for drug supply,

and the agency has started to follow this emerging trend closely. Further to the expert

meeting conducted in 2014, a report on the internet and drug markets was published in

2015. This was followed by the preparation of an in-depth review of the phenomenon,

which will be published in February 2016. In addition, the EMCDDA launched

a ‘Trendspotter’ study on critical new developments within Europe’s MDMA

(methylenedioxyphenethylamine)/ecstasy market. This included an exploration of signals

suggesting that there has been an increase in MDMA production and availability, that new

online markets have opened and that there has been an increase in use and serious

adverse events in some countries.

Working in partnership

In fulfilling its tasks, the agency relies on a large number of partners and, in particular, the

Reitox NFPs. These NFPs exercise the critical role of providing national data from the 30

countries that report to the EMCDDA, namely the 28 EU Member States, Norway and

Turkey. Together with the information collected from other networks of experts and

partners, these data feed the European and global analyses performed by the agency,

thereby forming the basis of its world-renowned knowledge and its reputation as a centre

of excellence on drugs in Europe. For Reitox, 2015 marked the first year of the

implementation of the revised national reporting system, which will be further developed

and implemented throughout 2016. Two meetings of the heads of the national focal

points (HFPs) took place in 2015, in June and November.

In performing its work and achieving its objectives, the EMCDDA also relies on its other

EU and international partners. At EU level, the agency’s key stakeholders are the EU

institutions (the European Parliament, the Council of the EU (i.e. the Council) and the

European Commission) and the Member States. Ongoing technical support was provided

throughout the year for issues such as NPS, which remained one of the most important

topics on the policy agenda, monitoring minimum quality standards for demand reduction

interventions in the EU and the misuse of medicines. The EMCDDA provided written

inputs, attended hearings at the European Parliament and meetings of the Horizontal

Drugs Group (HDG) of the Council, and participated in other meetings with the

Commission’s services, as requested.

The agency further enhanced its cooperation with the European School Survey Project on

Alcohol and Other Drugs (ESPAD). In 2015, the Swedish Government sent a formal

request to the EMCDDA to assume full coordination of this study; as a result, and given

the need to employ additional resources, the agency, in cooperation with the European

Commission, namely DG HOME as its partner DG, will explore realistic options for the

future.

Chapter 2 I Executive summary

21

Other important partners are EU agencies and international organisations. There were

many joint activities and events in 2015. Cooperation was particularly fruitful with the

European Union’s Judicial Cooperation Unit (Eurojust), the European Centre for Disease

Prevention and Control (ECDC), the EMA, CEPOL and Europol. In addition, synergies with

the European Maritime Safety Agency (EMSA), our neighbouring agency in Lisbon,

Portugal, were further enhanced. The international organisations most involved with joint

work were the World Health Organization (WHO), the United Nations Office on Drugs and

Crime (UNODC), the Inter-American Drug Abuse Control Commission (CICAD), which is

an agency of the Organization of American States (OAS), and the Pompidou Group.

In terms of cooperation with third countries, 2015 marked the launch of the new

Instrument for Pre-Accession Assistance (IPA), IPA 5, technical assistance project; the

objective of this project is to further build the capacity for drug monitoring in several

candidate and potential candidate countries (i.e. Albania, Bosnia and Herzegovina, the

former Yugoslav Republic of Macedonia, Kosovo (*), Serbia and Montenegro). During the

year, the agency disseminated three analyses that were produced with data from the

western Balkan countries on drug use and its consequences, drug law offences and the

prevention of infectious diseases among people who inject drugs. Together with the

regular reports provided to the European Commission, these new analyses will contribute

to the understanding of our stakeholders on the global dimension of the drug

phenomenon. The agency also continued to provide technical assistance to European

Neighbourhood Policy (ENP) partner countries (i.e. Armenia, Azerbaijan, Georgia, Israel,

Moldova, Morocco and Ukraine) in the framework of the technical cooperation project

started in 2014. Memorandums of Understanding (MoUs) were signed with Armenia and

Georgia.

Institutional developments

At institutional level, the year was marked by important changes in the governance

structure of the EMCDDA. Following the elections held in December 2015, Laura d’Arrigo

(France) and Franz Pietsch (Austria) were elected to the positions of Chair and Vice-Chair,

respectively, of the EMCDDA Management Board.

Furthermore, a new Director was selected by the Management Board in September 2015.

As a result, and following his public hearing at the European Parliament later that month,

Alexis Goosdeel was formally appointed by the Management Board in October for

a five-year mandate; he took up his new position as EMCDDA Director on 1 January 2016.

In 2015, the EMCDDA commemorated 20 years of monitoring the drugs problem in

Europe. Over the last two decades, much has changed with regard to the extent and

nature of the phenomenon, and the agency’s work has developed to keep pace with this

complexity. As this report of activities for 2015 shows, the agency is clearly on the right

track in its mission to communicate evidence and inform policy in the drug field in Europe.

The new three-year strategy and work programme for 2016–18, which was adopted by the

Management Board in December, and the long-term strategy, which the new EMCDDA

Director has committed to develop and implement during his mandate, will ensure that

the agency remains on target to become the most authoritative voice on drugs in Europe.

(*) This designation is without prejudice to positions on status, and is in line with UNSCR 1244/99 and the ICJ Opinion on the Kosovo declaration of independence. It applies to all mentions of Kosovo in this report and its annexes.

3

23

I Data collection, analysis and quality assurance (Main Area 1)

Data collection and management tasks are central to the work of the EMCDDA.

Policymakers, researchers, the European civil service and the general public have access

to reliable and valid data on the drugs situation in each of the 28 Member States, Norway

and Turkey through the outputs of the agency.

I Highlights and main achievements

The European Drug Report

In 2015, the EMCDDA presented its annual flagship publication package — the European

Drug Report (EDR) package. This timely, interactive and interlinked annual update on the

European drugs situation encompasses the work carried out in all the other core

business areas.

The report was launched on 4 June 2015

at a press conference at the EMCDDA,

attended by Dimitris Avramopoulos,

European Commissioner for Migration,

Home Affairs and Citizenship (see also

Main Area 9).

He said: ‘The report shows that we are

confronted with a rapidly changing,

globalised drug market and, therefore, we

need to be united, swift and determined in

our response to the drugs threat. I am

particularly concerned that the Internet is

increasingly becoming a new source of

supply, for both controlled and

uncontrolled psychoactive substances’.

During the year, work also started on the

preparation of the 2016 EDR package.

CHAPTER 3Core business: monitoring and reporting on the drugs

problem in Europe

EDR press conference on 4 June in Lisbon: European Commissioner for Migration, Home Affairs and Citizenship, Dimitris Avramopoulos and EMCDDA Director, Wolfgang Götz

General Report of Activities 2015

24

Data collection instruments and processes

The main development in this area was represented by the entering into force of the

revised Reitox national reporting package (NRP), after its seal of approval at the HFP

meeting held in Lisbon, Portugal, in November 2014. The NRP is composed of three

components: standard tables for reporting standardised quantitative information;

structured questionnaires for reporting qualitative information; and thematic workbooks.

To date, 10 thematic workbooks have been endorsed on the following themes: drug

policy; legal framework; drugs; prevention; treatment; best practice; harms and harm

reduction; drug market and crime; prison; and drug-related research.

The implementation of the package was designed to be progressive, with only 5 of the 10

workbooks compulsory in the first year (i.e. 2015). The implementation of the new

package was carried out as planned, and, despite the inherent challenges, all 30 countries

managed to complete the five mandatory workbooks; furthermore, 25 out of the 30

reporting countries managed to fully implement the revised NRP and send all 10

workbooks to the EMCDDA.

The 2015 EDR (1) is our 20th annual analysis of the drug problem in Europe. The annual overview of the European drug situation offers a rich analysis of the latest trends in drug supply, drug use, and the health and social responses. Changing dynamics in the heroin market, the latest implications of cannabis use, and new features and dimensions of the stimulant and ‘new drugs’ scene are among the issues highlighted in the European Drug Report 2015: Trends and Developments.

In print and online in 24 languages, this multilingual, multimedia package offers easy access to evidence-based information on drugs for the 28 EU Member States, Turkey and Norway.

The report is accompanied by Perspectives on drugs (PODs), online interactive windows on key aspects of the drugs problem. The 2015 PODs are Opioid trafficking routes from Asia to Europe; Drug consumption rooms: an overview of provision and evidence; The role of psychosocial interventions in drug treatment; and Misuse of benzodiazepines among high-risk opioid users (2).

The European Drug Report: Data and statistics (Statistical bulletin) (3) and 30 country overviews (4) completed the picture. The Statistical bulletin provides access to the data the EMCDDA uses for reporting on the drug situation. The country overviews consist of a summary of the national drug situations, key statistics at a glance and a barometer showing the ranking of drug use prevalence for each of the 30 countries (5) that report to the EMCDDA.

A motion graphic video (6) was produced by the agency to mark the launch of the EDR. This snapshot summary of the main issues of the 2015 edition was translated into French, German, Polish, Portuguese and Spanish, which contributed to the multilingualism of the EMCDDA audio-visual content. On its first day, the video received more than 1 400 views.

Furthermore, the EMCDDA participated in national launches organised in nine EU Member States (Croatia, the Czech Republic, Finland, Greece, Lithuania, Poland, Slovakia, Slovenia and Sweden) (7).

(1) Available at: emcdda.europa.eu/edr2015(2) All PODs available at: emcdda.europa.eu/edr2015(3) Available at: emcdda.europa.eu/data/2015(4) Available at: emcdda.europa.eu/countries(5) The 28 EU Member States, Turkey and Norway.(6) Available at: https://www.youtube.com/watch?v=zPrRlRWaIbk(7) Another Member State, Portugal, organised the national launch on 3 February 2016.

Chapter 3 I Core business: monitoring and reporting on the drugs problem in Europe

25

The guidelines for 2016 national reporting, including the revised standard questionnaire on

prevention, were adopted by the HFPs at their meeting in November (see Main Area 10).

Quality assurance framework

One of the objectives of the 2015 work programme was to strengthen the quality

assurance framework with regard to supporting data collection, analysis and reporting. In

light of this, an EMCDDA internal statistics code of practice was published in February

2015 (2). The code was drawn up in consultation with the EMCDDA Scientific Committee,

Reitox and Eurostat, whose European statistics code of practice formed the basis of the

work, and was adopted by the EMCDDA Management Board.

The EMCDDA code defines a set of principles that provide the agency with guidance and

objectives for its own work. It serves as a declaration of the EMCDDA’s intent to pursue

a programme of continuous improvement and evaluation of efforts, in order to provide

‘factual, objective, reliable and comparable information’.

I Monitoring and understanding drug use and problems: key indicators and epidemiology (Main Area 2)

Building on national efforts and formative European-level activities, the EMCDDA has

worked for the last two decades to improve the monitoring of Europe’s drug problems.

A core element of this work has been the epidemiological monitoring work. This is based

on a range of core indicators, namely KIs, and is supported by expert groups.

These KIs include the prevalence and patterns of drug use in the general population

(based on a general population survey (GPS)); the prevalence and patterns of problem

drug use; the number and characteristics of drug users that contact drug services,

particularly treatment services (treatment demand indicator (TDI)); the number of

drug-induced deaths and mortality rates among drug users (drug-related deaths

indicator); and the infectious diseases related to drug use (drug-related infectious

diseases (DRID) indicator).

I Highlights and main achievements

Methodological development and analysis

The third triennial assessment of the implementation of the key indicators in the EU

Member States, Norway and Turkey was carried out in close collaboration with the NFPs.

The purpose of this exercise was to document the progress made since the second

assessment (in 2012) and formulate recommendations to support the further work of the

NFPs. The assessment included a description of the activities conducted at national level

to implement the key indicators and a detailed analysis of the scientific quality of the data

delivered by each Member State to the EMCDDA, based on a set of predefined criteria

developed in consultation with the NFPs.

(2) Available at: emcdda.europa.eu/publications/manuals/statistics-code-of-practice

General Report of Activities 2015

26

The exercise led to the conclusion that the overall level of implementation was relatively

high, although specific problems with data availability exist in some countries.

Recommendations for improvements in the implementation of the indicators have

therefore been developed for each country and indicator, in order to facilitate coordinated

actions from the EMCDDA and the Member States concerned.

In 2015, the EMCDDA published several analyses based on the results of the key indicator

monitoring work, as described below.

Comorbidity of substance use and mental

disorders in Europe (EMCDDA Insights No 19,

November 2015) (3)

This publication looks at the co-occurrence of

drug use problems and mental health

disorders, and describes the theoretical

background of psychiatric comorbidity, the

tools for clinical diagnosis, and the

prevalence and clinical relevance of the

problem in Europe. This work, which was

based on an exhaustive review of the

literature and a wealth of information provided by the Reitox NFPs, will give policymakers,

professionals in the drugs field and other interested readers a detailed overview of the

concept of comorbidity in the context of drug use, and the tools available for its

assessment.

Drug-related infectious diseases in Europe. Update from the EMCDDA expert network

(EMCDDA Ad hoc publication, September 2015) (4)

This report provides an update on infectious diseases related to injecting drug use in

Europe up to June 2015. The report covers both the EMCDDA DRID indicator, which

collects data on the situation, and the responses in the area. It includes highlights and

new findings discussed during the annual expert meeting on indicators, held in Lisbon,

Portugal, on 15 and 16 June 2015 (see later section below). This report also presents an

analysis of the information provided to the EMCDDA by the NFPs and their experts during

the 2014 annual reporting exercise. The multi-indicator data set used in the analysis

covers and integrates aspects of the epidemiology (prevalence of injection; prevalence of

infections among drug users; notifications of newly diagnosed infections; harm; morbidity;

and outbreaks) and responses (prevention; infection testing; drug and infection

treatments; and harm reduction), and it aims to provide policymakers with early warnings

in order to allow prompt responses.

Estimating trends in injecting drug use in Europe using national data on drug treatment

admissions (EMCDDA Technical report, June 2015) (5)

The report describes trends in drug injection in EU Member States, Norway and Turkey

between 2000 and 2011, through an analysis of data on those admitted for the treatment

of drug-related problems. The results indicate that drug injection has declined in recent

years in Europe. While heroin remains the drug most frequently used for injection, data

show that people who inject drugs are now more likely to inject stimulants than they were

in the past.

(3) Available at: emcdda.europa.eu/publications/insights/comorbidity-substance-use-mental-disorders-europe(4) Available at: emcdda.europa.eu/publications/rapid/2015/drug-related-infectious-diseases-in-europe(5) Available at: emcdda.europa.eu/publications/technical-reports/estimating-trends-injecting-drug-use-europe-

using-national-data-drug-treatment-admissions

Chapter 3 I Core business: monitoring and reporting on the drugs problem in Europe

27

In 2015, the EMCDDA continued to invest in the emerging area of monitoring wastewater,

as a potential new indicator of population drug consumption (see also Main Area 7).

A collaboration with the Sewage Analysis Core Group Europe (SCORE), the Europe-wide

network that works to standardise the approach to wastewater analysis and to coordinate

national studies, continued; this allowed the EMCDDA to receive, analyse and

disseminate the data collected by the project.

To this end, the Perspective on drugs (POD) on wastewater analysis, which was produced

in 2014, benefited from a substantial update in 2015, in order to incorporate the most

recent data and allow for higher interactivity. A comprehensive overview of the different

aspects of wastewater-based epidemiology, covering the latest developments and

research results in the domain, was prepared in 2015, and is due for release in spring

2016 as part of the EMCDDA Insights series.

Support to ESPAD and other partners in the area of monitoring polydrug use

In response to growing concerns regarding the harm associated with the interaction

between alcohol and drug use in Europe, the remit of the EMCDDA was broadened in

2006 to include the monitoring of polydrug use, that is, the use of illicit drugs in

combination with licit substances or medication.

As part of the effort to develop this part of its mandate, the EMCDDA’s three-year strategy

and work programme for 2013–15 included a commitment to increase collaboration with

ESPAD. ESPAD provides useful and harmonised information on long-term patterns of

substance use, including polydrug use, for many EU countries and neighbouring

countries. As the Swedish Government is no longer able to host ESPAD, the EMCDDA

Management Board, the Swedish Government and the Commission have acknowledged

the agency as an appropriate institutional home for the study: they have stressed the

need for ESPAD, while remaining as an individual entity, to be progressively anchored in

the EMCDDA.

In 2015, the EMCDDA received a formal request from the Swedish Government to fully

assume the coordination tasks for the study. While the agency, in close cooperation with

the European Commission (DG HOME as its partner DG), will look at options that would

make that possible in the future, some important developments already took place in

2015. This included participation of the EMCDDA in two Steering Committee meetings

(held on 28–29 January in Stockholm, Sweden, and 15–17 November in Larnaca,

Cyprus); preparatory work for the publication, in 2016, of the 2015 ESPAD report;

preparatory work related to ensuring that ESPAD will have a strong web presence

(website also to be launched in 2016); and the hosting of the study database.

In addition, the EMCDDA published The ESPAD validity study in four countries in 2013 (6).

After the publication of the 2011 ESPAD report and in view of the preparation of the 2015

survey, a review of the questionnaire used to collect the data was conducted. The results

of that exercise are presented in the aforementioned validity study.

The EMCDDA also continued its collaboration with the ‘Joint action on reducing alcohol-

related harm’ (RARHA) project, funded by the European Commission, in 2015. Led by

SICAD, this initiative involves 32 associated partners and 28 collaborating partners from

(6) Available at: emcdda.europa.eu/publications/joint-publications/espad-validity-study

General Report of Activities 2015

28

both EU and non-EU countries. The EMCDDA is among the project’s associated partners

and is also part of its advisory group.

One of the core activities of the RARHA project (as part of work package 4: ‘Monitoring’) is

to improve the monitoring of alcohol use, risky alcohol use and abuse or dependence, and

alcohol-related harms (to the drinker and others), particularly via survey methodology. The

EMCDDA plays an active role in implementing work package 4 by, for instance, developing

instruments (i.e. questionnaires and scales) and methodologies. The agency plans to build

on the work of the project by including a subset of the instruments developed under work

package 4 in its ‘European Model Questionnaire’ (EMQ). The EMCDDA also participated in

the meeting of the RARHA project in Athens (13–14 March 2015).

Finally, the third Contemporary Drug Problems Conference, with the theme ‘Encountering

alcohol and other drugs’, was held at the EMCDDA on 16–18 September 2015. Hosted by

Contemporary Drug Problems, the EMCDDA, the National Drug Research Institute (Curtin

University, Australia), the Centre for Alcohol and Drug Research (Aarhus University,

Denmark), the Centre for Population Health (Burnet Institute, Australia) and the

Department of Science and Technology Studies (Rensselaer Polytechnic Institute, USA),

the conference brought together leading international researchers in drug use and

addiction studies from a range of research disciplines and methods — both qualitative

and quantitative.

Capacity building and network support

The added value of the EMCDDA’s epidemiological information is, to a considerable

extent, based on the work of NFPs and the networks of national experts on the relevant

KIs. To that end, an important role of the EMCDDA is the technical support it provides to

the NFPs and other national experts with regard to implementing KIs at national level.

Support needs, among others, are identified through the analysis of the final activity

reports submitted by the countries.

In 2015, ongoing assistance was provided by means of daily exchanges between the

agency’s staff and the local experts. In addition, EMCDDA representatives attended

meetings organised at national level with the objective of helping with the implementation

of the new reporting method (e.g. visit to the Italian NFP on 24–25 June in Rome).

Another effective means of fostering experience exchange and supporting network

development are the annual European expert meetings organised by the EMCDDA. Two

events were held in Lisbon in the course of the year, the DRID annual meeting on 15–16

June and the ‘20 years of monitoring’ event on 21–22 September.

The DRID expert meeting was organised as a stand-alone two-day event which offered

a platform for discussion among experts from the 28 EU Member States, Norway and

Turkey. Topics that received particular attention included an update on the situation

regarding human immunodeficiency virus (HIV) infection and the related concerns in

some countries; bacterial infections, including botulism outbreaks in Scotland and

Chapter 3 I Core business: monitoring and reporting on the drugs problem in Europe

29

Norway; and changing patterns of injection in Europe and their implications for public

health. The challenges of scaling up treatments for HCV infection and good national

examples in this area were also discussed. The results of the meeting are presented in the

report Drug-related infectious diseases in Europe. Update from the EMCDDA expert

network (see section ‘Methodological development and analysis’ above).

Technical support to third countries

The quality and consistency of epidemiological monitoring at European level is based on

the implementation of the common EMCDDA standards and key indicators in Member

States. However, many third countries (e.g. candidate countries, neighbouring countries

and others) also use the key indicators as models to develop their own drug monitoring

strategies; EMCDDA support is invaluable for this.

For example, the EMCDDA supports third countries with the conduct of their ESPAD

surveys. In 2015, three countries — Georgia, Moldova and Ukraine — completed their

ESPAD surveys with support from the ENP project implemented by the EMCDDA. In the

case of Georgia and Moldova, the surveys were co-funded by the national authorities, and

in the case of Ukraine, the survey was co-funded by UNICEF (United Nations Children’s

Emergency Fund) (see Main Area 8).

Furthermore, Israeli and Moldovan experts attended the DRID expert meeting in June

2015, and experts from Georgia, Israel, Moldova, Morocco and Ukraine participated in the

‘20 years of monitoring’ conference held in September.

The EMCDDA also contributed to MedNET seminars organised by the Council of Europe,

namely the Pompidou Group, in Algeria, Egypt, Morocco and Tunisia (see also Main Area 8).

Understanding the dynamics, nature and scale of drug use in Europe, including lessons learnt and challenges for the future, was the thrust of an EMCDDA technical conference, which was held in Lisbon, Portugal, on 21–22 September. The event, organised ahead of Lisbon Addictions 2015, commemorated 20 years of the EMCDDA monitoring the drug situation in Europe

This technical conference brought together over 180 experts from across the globe including representatives of the EMCDDA key indicator expert networks; the Reitox NFPs; other technical domains covered by the agency; and the EMCDDA. The event furthered the agency’s ongoing efforts to inspire cross-disciplinary, multi-indicator analyses of the drugs problem and the sharing of perspectives from different technical domains.

The two-day agenda featured over 70 interventions, 8 sessions and 11 workshops. The issues covered included maximising the value of information collected; incorporating new tools and topics; and ensuring that the European drug monitoring system remains fit for purpose in the face of new challenges. The final workshop was entitled ‘Making monitoring speak louder to policy and more clearly to inform best practice’.

General Report of Activities 2015

30

I Monitoring demand reduction responses applied to drug-related problems (Main Area 3)

The work of the EMCDDA in the area of monitoring demand reduction responses covers

prevention, treatment, harm reduction and social reintegration.

Some new analyses in the prevention field were released and new evidence on

environmental strategies was produced in 2015. In the areas of treatment, harm reduction

and social reintegration, a key task was to continue to support the 30 countries reporting

to the agency with the production of harmonised and comparable data on treatment

systems in Europe. Three new outputs were released on some highly relevant topics:

cannabis treatment, naloxone and consumption rooms.

The EMCDDA continued to work with its partners at European and international levels,

and provide its expertise on the prevention of infectious diseases amongst people who

inject drugs, with a particular focus on HIV and HCV infections. In this respect, close

collaboration was maintained with the EMCDDA’s traditional partner in this area,

the ECDC.

An important tool for disseminating information on effective interventions is the BPP. In

2015, the EMCDDA continued to develop this portal as a key European resource for

evidence of high-quality interventions; new modules were launched and the existing ones

were kept updated. New reviews of evidence were also produced, and innovative features

and graphics were introduced.

I Highlights and main achievements

Prevention

In the area of prevention, online resources were further developed and updated. New data

on alcohol control score and tobacco control scale were added for all countries. In

addition, new data for family-based prevention were added for a number of countries.

A BPP module on interventions that target the general population was created to host

new evidence on environmental strategies (7).

Furthermore, in 2015, the EMCDDA published Prevention of addictive behaviours (as part

of the Insights series) (8), which is an update of Prevention of substance abuse, published

in 2007. Like the previous analysis, this report is a translation of a German state-of-the-art

review of prevention science. Although originally targeted at a German audience, the

evidence base addressed is global in its scope. The review is broad in its considerations,

covering not only the main topic of drug abuse but also alcohol and tobacco, as well as

behavioural addictions, such as gambling.

The EMCDDA contributed to the Sixth Conference and Members’ Meeting of the

European Society for Prevention Research (EUSPR) (held on 22–24 October 2015 in

Ljubljana, Slovenia). The presentation delivered by the EMCDDA, entitled ‘Quality

standards in drug demand reduction: prevention gave the example’, offered an

(7) Available at: emcdda.europa.eu/best-practice(8) Available at: emcdda.europa.eu/publications/insights/preventing-addictive-behaviours

Chapter 3 I Core business: monitoring and reporting on the drugs problem in Europe

31

opportunity to discuss the Council’s conclusions on the implementation of minimum

quality standards on drug demand reduction in the EU, as adopted by the Council of the

European Union in September 2015 (CORDROGUE 70 (SAN 279)). The Council

conclusions document lists 16 standards, which represent a minimum benchmark of

quality for interventions in drug use prevention, risk and harm reduction, treatment, social

integration and rehabilitation. The EMCDDA disseminates these standards via its BPP

(see later section, ´Best practice´) and will monitor their implementation.

A national Reitox Academy on ‘Best practice in prevention’ was organised by the

EMCDDA and the Moroccan National Observatory on Drugs and Addictions (ONDA), and

held on 8–9 December in Rabat, Morocco (see also Main Area 8). Approximately 40

prevention professionals attended the event from non-governmental organisations as well

as from the education, health and law enforcement sectors. The aim of the meeting was

to look at prevention from the perspective of evidence-based approaches to the drugs

problem, and to promote information exchange on the tools available to help develop and

implement prevention programmes. The meeting provided a unique opportunity for

professionals from various regions of Morocco to present their work, network and

exchange information. Those attending showed particular interest in the EMCDDA’s

methodological guidelines and standards, in view of an ongoing national debate on the

development of national prevention standards.

Treatment, harm reduction and social reintegration

During 2015, the EMCDDA

continued to provide an ongoing

overview of treatments for drug

problems in Europe. A consistent

picture of this area is provided by

the 2015 EDR package (see Main

Area 1), including the recent POD

analysis Drug consumption rooms:

an overview of provision and

evidence (9). This looks at supervised

drug consumption facilities, in which

illicit drugs can be used under the

supervision of trained staff. The primary aim of these facilities is to reduce the acute risks

of disease transmission through unhygienic injecting, to prevent drug-related overdose

deaths, and to connect high-risk drug users with addiction treatment and other health

and social services. To mark the launch of this POD, a video was produced and released

in June (10). It was filmed in a consumption room in Barcelona and it features interviews

with various experts. Between its launch in June and 31 December, the video received

some 2 600 views.

Another important resource is the in-depth review Treatment of cannabis-related

disorders in Europe, published in April (as part of the EMCDDA Insights series) (11).

Cannabis is the illicit drug used most widely and most frequently in Europe; this

publication reviews the interventions used in the treatment of cannabis-related disorders

and maps out cannabis treatment in Europe from a geographical perspective.

(9) Available at: emcdda.europa.eu/topics/pods/drug-consumption-rooms(10) See: https://www.youtube.com/watch?v=YhLoLbORzi0(11) Available at: emcdda.europa.eu/publications/insights/2015/treatment-of-cannabis-related-disorders

General Report of Activities 2015

32

Another publication — Preventing fatal overdoses: a systematic review of the

effectiveness of take-home naloxone (EMCDDA Paper) — was released in

January 2015 (12). Drug overdose is one of the major causes of death among young

people in Europe. This paper considers how naloxone — an effective antidote to opioid

intoxication — combined with first aid training in coping with an overdose for people who

are not health professionals can help save lives.

Recognising the importance of the topic, an in-depth topical review on naloxone was also

prepared in 2015, for publication in 2016 (as part of the EMCDDA Insights series).

The recreational drug scene has evolved rapidly over the last decade, with NPS posing

additional challenges. However, at present, there is no robust pan-European system in

place for capturing data from hospital emergency services on the acute toxicity (harms)

associated with the use of both ‘established drugs’ and NPS.

To address deficiencies in the data available, the Euro-DEN project was established in

2013, funded through the European Commission’s Drug Prevention and Information

Programme. The EMCDDA is a member of the Euro-DEN Steering Committee and the

agency hosted a project meeting on 27 February 2015. To mark the occasion, the agency

published, in its BPP (see next section under this area), the latest Euro-DEN guidelines

‘When to call the emergency services for unwell recreational drug users’.

In 2015, the EMCDDA organised, for the first time, a meeting dedicated to the topic of

health responses to NPS (held on 28–29 October in Lisbon, Portugal). The event aimed to

identify existing best practice and training and

intervention needs, as well as related policy

considerations for Europe. It brought together 15

European health professionals and researchers

experienced in providing interventions related to NPS,

or knowledgeable in this domain. They focused on

responding to NPS in a variety of health and

intervention settings (i.e. in family and school settings;

in hospital accident and emergency departments and

poison centres; in bars and clubs and at festivals; in

sexual health clinics, specialised treatment centres and

low-threshold agencies; in prisons; and via helplines

and e-health facilities). The meeting laid the

foundations for an EMCDDA report, which will be

published in 2016, that addresses NPS-related harms

and health-related interventions. The publication will be

practice oriented and of particular value to

professionals working in these settings.

In 2015, the agency also made further progress in the development and implementation

of treatment monitoring instruments. This relates, in particular, to the European Facility

Survey Questionnaire (EFSQ) and the treatment maps, which support countries to

improve their national estimates on the total number of people in treatment. The EFSQ

pilot version was finalised and piloting countries (Greece and Hungary) reported their

data in the new treatment workbooks, which were submitted in October 2015. The

treatment system map was presented in the EDR 2015; furthermore, its integration into

(12) Available at: emcdda.europa.eu/publications/emcdda-papers/naloxone-effectiveness

Chapter 3 I Core business: monitoring and reporting on the drugs problem in Europe

33

the workbook data collection exercise led to an increase in the number of countries that

reported improved estimates.

In 2015, the agency also continued to strengthen its work in the field of harm reduction

(see also Main Area 2, particularly the activities related to the implementation of the

DRID key indicator). To this end, the EMCDDA continued to work with its partners at

European and international levels, and provide its expertise in the prevention of infectious

disease amongst people who inject drugs, with a particular focus on HIV and HCV

infections.

In June 2015, the EMCDDA published HIV and hepatitis B and C in Latvia (13), a report

that presents the results of a mission to Latvia, which was carried out jointly with the

ECDC in September 2014 at the request of the Latvian Ministry of Health, based in Riga.

The mission confirmed that there is a very high rate of hepatitis B and C and HIV

infections in Latvia, and that there is a large number of people with acquired immune

deficiency syndrome (AIDS), mainly among certain high-risk populations. Based on the

findings of this country visit, the mission team prepared a comprehensive list of remedial

actions.

The EMCDDA and the ECDC co-organised a sponsored session entitled ‘Scaling up

responses to hepatitis C (HCV) among people who inject drugs (PWID) in Europe: what

are the priorities?’ and held on 24 September in the margins of Lisbon Addictions 2015

(see Main Area 7). This session brought together drug specialists, user representatives,

a hepatologist and staff members from the two co-organising agencies to discuss the

challenges ahead with regard to scaling up treatment for HCV infection among people

who inject drugs.

On 11 March 2015 in Vienna, Austria, in the framework of the 58th session of the

Commission on Narcotic Drugs (CND), the EMCDDA co-organised the side event

‘Developing and promoting quality standards in drug demand reduction’ and co-chaired

another side event, organised by the Government of the Netherlands, entitled ‘The public

health approach: prevention, treatment, risk and harm reduction, recovery, social

reintegration and rehabilitation’.

Best practice

The BPP (14), which was revamped in 2014, continued to be improved in 2015. In an effort

to keep up with the rapidly growing new drugs phenomenon, a new module on NPS was

developed and launched in 2015. Although research is ongoing in this area, and evidence

on what works best is currently lacking, the new module provides useful links to the

different analyses that have been carried out by the EMCDDA and other organisations in

recent years. As evidence on what works becomes available, this will be captured and

disseminated promptly through the BPP. Two more modules, on the misuse of

prescription medicines and interventions in prison, were also released.

(13) Available at: emcdda.europa.eu/publications/ad-hoc-publication/hiv-and-hepatitis-b-and-c-latvia(14) Available at: emcdda.europa.eu/best-practice

General Report of Activities 2015

34

A comprehensive update of the harm reduction module was also performed. Furthermore,

a new analysis entitled The role of psychosocial interventions in drug treatment (15) was

published in June as part of the POD series. As psychosocial interventions are used to

treat many different types of drug problems and behavioural addictions, this analysis

explains what these are and to whom they are provided.

An interactive tool was released, along with the PODs, to allow users to ‘accompany’

someone with a drug problem through the different stages of the treatment path:

‘Recognising’, ‘Treating’ and ‘Staying’.

Another development was the publication, in December 2015, of a map presenting the

different quality assurance approaches adopted at national level. This map is based on

a questionnaire sent by the EMCDDA to its network of NFPs. Within each country, each

focal point was asked the question: ‘Are there some types of quality standards implemented

in your country to ensure the quality of interventions in drug demand reduction?’ The

responses were compiled into a useful graphic representation of the situation at EU level.

Finally, the revamped Evaluation Instruments Bank (EIB), which is an online archive of

freely available instruments for evaluating drug-related interventions, was launched in

December 2015.

I Monitoring drug supply and supply reduction interventions (Main Area 4)

In 2015, the EMCDDA focused on three main priorities: developmental work to improve

tools and concepts for reporting on drug supply (drug markets, drug-related crime and

drug supply reduction); the production of the second EDMR jointly with Europol; and the

fulfilment of the tasks assigned to the agency in the operational action plans (OAPs) of

the European Multidisciplinary Platform Against Criminal Threats (EMPACT) framework,

developed under the 2013–17 EU policy cycle for organised and serious international

crime of the Council’s Standing Committee on Operational Cooperation on Internal

Security (COSI).

Central to the work of the EMCDDA in this area is the EMCDDA European Reference

Group on Drug Supply Issues. The third meeting of the national correspondents took

place in 2015, which provided opportunities for expert advice and consultation on

EMCDDA core projects in the supply field.

I Highlights and main achievements

One of the core tasks of the EMCDDA in the current three-year strategy and work

programme is to further develop and improve data collection instruments in three areas,

namely drug markets, drug-related crime and drug supply reduction, with a view to

improving the accuracy, reliability, comparability and quality of the collected data at EU

level. This involves close collaboration with the European Commission and Europol, as

well as with the Reitox NFPs and other data providers. The EMCDDA has the leading role

in the process, in terms of both conceptualising the work, and developing and reaching

consensus on the necessary mechanisms to implement the findings.

(15) Available at: emcdda.europa.eu/topics/pods/psychosocial-interventions

Chapter 3 I Core business: monitoring and reporting on the drugs problem in Europe

35

In 2015, incremental progress was achieved in the development of all the planned

instruments, in line with their level of priority (as defined in the EMCDDA work

programme) and the available resources.

The level 1 priority instruments, namely ‘drug seizures’, ‘drug law offences’, ‘drug

production facilities’ (including synthetic drug production sites) and ‘drug precursors’,

were all implemented as planned, as outlined below.

The drug seizures core data set supports the monitoring of both drug markets and drug

supply reduction activities. In 2015, the revised data collection instrument was endorsed

by the EMCDDA Reference Group on Drug Supply (see later section under Main Area 4).

Pilot data collection was carried out as planned and feedback was provided to the HFPs

during their meeting in November 2015. Full implementation is planned for 2016.

The drug law offences core data set supports the monitoring of all three areas (i.e. drug

markets, drug-related crime and drug supply reduction). The pilot data collection was

implemented using the revised instrument, which was developed in 2014 in cooperation

with Eurostat. Data validation and initial analyses were completed in 2015 and the results

will be evaluated in 2016.

The drug production facilities core data set allows the monitoring of drug markets and

drug supply reduction activities. This includes data related to dismantled synthetic drugs

labs, dismantled cocaine secondary extraction labs and cannabis cultivation sites. The

activity was implemented in close collaboration with Europol and it is one of the tasks

assigned to the EMCDDA as part of the OAPs on heroin/cocaine trafficking and synthetic

drugs of the EU policy cycle within COSI (see also below).

With regard to the dismantled synthetic drugs labs (level 1 priority), a joint training course

was organised by EMCDDA and Europol (held on 24 March in Lisbon, Portugal) on the use

of the European Reporting on Illicit Synthetic Substances Production Sites (ERISSP) tool,

which is a data collection tool for the collection of reliable data on the number and

characteristics of sites related to the production of synthetic drugs and their precursors

(including facilities related to NPS) that have been dismantled by law enforcement

agencies. The training course was attended by 22 professionals from 21 Member States.

The event also provided the opportunity to collect feedback from participants, based on

which the tool was revised before being used for the data collection exercise. During this

exercise, 14 Member States provided data, which were analysed and used for the

production of the second EDMR (see below).

Progress was also achieved in the implementation of the reporting instrument for dismantled

cocaine extraction labs, which was developed in 2014. This tool, known as ERICES (European

Reporting Instrument for Cocaine Extraction Sites), was used in 2015 by Europol for data

collection from the Member States. These data will be analysed in 2016 by the EMCDDA.

Finally, work continued on the European Reporting Instrument for Cannabis Production

(ERICP), which was presented to Member States during an expert meeting held at Europol

and was later revised to incorporate their feedback. Implementation will start in 2016.

With regard to drug precursors, after close cooperation with the Directorate-General (DG)

for Taxation and Customs Union (TAXUD), data for the last three years were provided to

the EMCDDA and have been included in the 2015 EDR. Furthermore, a representative

from DG TAXUD attended the Reference Group on Drug Supply Meeting and actively

contributed to the 2016 EDMR, including the analysis of precursor monitoring data from

the perspectives of both the EU and the International Narcotics Control Board (INCB).

General Report of Activities 2015

36

In line with the available resources and the lower assigned priority level (i.e. level 2

priority) for ‘drug prices’ and ‘drug purity and content’, less progress was made in the

development of the reporting instruments for these activities. With regard to drug prices,

the mapping exercise has been prepared and it will be launched in 2016. With regard to

drug purity and content, the pilot study was launched and the data were collected

through the questionnaire sent to all Member States; these data were presented at the

meeting of the EMCDDA Reference Group on Drug Supply in November 2015.

A technical meeting on drug supply reduction measures was held on 1–2 July at the

EMCDDA. The topics included drug supply indicators; drug supply reduction and strategic

drugs intelligence in Europe; the EU policy cycle for serious and organised crime and the role

of Europol; and national intelligence models and law enforcement intelligence strategies. The

event was attended by law enforcement professionals from Belgium, Germany, the

Netherlands, Sweden and the United Kingdom, and by analysts from the EMCDDA, Europol

and the Maritime Analysis and Operations Centre — Narcotics (MAOC-N).

A key event for Main Area 4 was the third meeting of the national correspondents of the

EMCDDA European expert Reference Group on Drug Supply Issues, which took place on

5–6 November 2015 in Lisbon, Portugal. This reference group is composed of

representatives from each Member State, the European Commission (DG HOME and

Eurostat), Eurojust and Europol. At the meeting, the supply reporting instruments were

discussed and endorsed as appropriate, and the reference group provided expert advice on

the drafting and structuring of the second EDMR.

Possibly the most important activity of 2015, in terms of resources employed and the

importance of its outcome, was the preparation of the second EDMR jointly with Europol. This is

a top priority product for the EMCDDA, as it is one of the agency’s flagship publications. The

work to produce it involves many of the agency’s resources, including scientific analysts, data

managers, editors and other communication experts, and ultimately the EMCDDA’s Director and

Scientific Director. This important joint project involved an efficient collaboration between the

EMCDDA and Europol. Good cooperation was also ensured with external contributors to the

report (e.g. Eurojust, Frontex, CEPOL and MAOC-N), and consultations with stakeholders, such

as the Commission, the EMCDDA Reference Group on Drug Supply Issues and Europol National

Units, were held throughout the year.

As with the first EDMR, this second edition will be launched in Brussels (on 5 April 2016)

by the EU Commissioner in charge of Migration, Home Affairs and Citizenship and the

EMCDDA and Europol Directors.

The analysis Opioid trafficking routes from Asia to Europe was published as part of the

POD series in June 2015 (16). It describes the main routes by which heroin reaches the

European market from producers located mainly in South-East Asia.

In 2015, the agency fulfilled the tasks assigned to it under the OAPs within the EMPACT

framework developed under the 2013–17 EU policy cycle for organised and serious

international crime of COSI. The EMCDDA provided contributions in the field of synthetic

drugs, cocaine and heroin.

The primary task was the preparation of the 2016 EDMR. Other activities included

contributing to training initiatives organised by CEPOL (for details see Annex 6 — key

performance indicator (KPI) 4.4.1), including residential courses and webinars; and

(16) Available at: emcdda.europa.eu/topics/pods/opioid-trafficking-routes

Chapter 3 I Core business: monitoring and reporting on the drugs problem in Europe

37

assisting Europol with the follow-up of activities initiated under the previous policy cycle

(2012–13), particularly the reporting of drug production facilities (see section ‘Main

highlights and achievements from Main Area 4’ on the reporting instruments for synthetic

drugs (ERISSP), cannabis production sites (ERICP) and secondary cocaine extraction

sites (ERICES)). Furthermore, the fourth law enforcement expert meeting on NPS was

organised jointly and co-chaired by the EMCDDA and Europol, and held on

14–15 September 2015 in Warsaw, Poland.

The meeting was hosted by the Polish

Ministry of the Interior and Administration,

and chaired by the driver of the EMPACT

‘Synthetic Drugs’ priority. At this meeting,

24 Member States were represented.

Finally, on 10 March 2015, under the

framework of the 58th session of the CND

in Vienna, Austria, the EMCDDA Scientific

Director, Paul Griffiths, acted as an expert,

nominated by the Western European

Group, for the panel discussion ‘Supply

reduction and related measures; responses

to drugs-related crime; countering money-

laundering and promoting judicial

cooperation’.

I Monitoring new trends and developments, and assessing the risks associated with new substances (Main Area 5)

The EMCDDA has been assigned a key role in the detection and assessment of new drugs

in the EU under the terms of Council Decision 2005/387/JHA on the information

exchange, risk assessment and control of NPS. To ensure efficient information exchange,

as specified by this Council decision, ongoing and dynamic work is required. In 2015, as in

previous years, the EMCDDA, together with the European Commission, the EMA, Europol,

the Reitox NFPs and the Europol National Units, ensured that the information exchange

component of this Council decision — known as the EU EWS on NPS — was

implemented.

In 2015, 98 NPS were identified on the European drug market for the first time. In total,

the EMCDDA monitors more than 560 substances — which is more than double the

number of substances controlled under the international drug conventions of the United

Nations — and more than half of these were reported in the last three years alone.

However, while the number and type of NPS reported each year is critical to

understanding the development and growth of the market, these data fail to convey the

enormous amount of work undertaken, by the EMCDDA and partners in the EU EWS

network, at national and EU levels to help ensure that emerging threats are identified,

reported and responded to in a timely manner.

CND panel discussion on ‘Drugs and Crime’ on 10 March in Vienna: EMCDDA Scientific Director Paul Griffiths as expert nominated by the Western European Group

General Report of Activities 2015

38

In addition, it is clear from recent developments that earlier identifications of and

responses to emerging threats will increasingly benefit from more proactive data

collection systems. As a result, the EMCDDA has started working to improve the ability of

the EU EWS to detect signals of public health relevance from open source information

(OSI). This requires the development and implementation of OSI monitoring and analysis

systems that can provide new data on areas such as serious adverse events, online drug

markets and epidemiology.

I Highlights and main achievements

At a glance, the main highlights and achievements in Main Area 5 in 2015 were:

• 98 NPS were formally notified;

• 101 new substance profiles were created and 328 existing substance profiles were updated — the total number of NPS currently monitored is now over 560;

• 17 public health alerts (including updates) were produced and provided to EWS correspondents;

• a risk assessment exercise was carried out, by the EMCDDA’s Extended Scientific Committee, on α-PVP, and this revealed that α-PVP was associated with 116 deaths and 205 non-fatal acute intoxications in 2015;

• as a result of the decision adopted by the Council in October 2015, in response to the recommendation formulated by the European Commission on the basis of risk assessments carried out by the EMCDDA in 2014, two new substances — 4,4′-DMAR and MT-45 — were subjected to control measures and criminal penalties throughout the EU;

• two risk assessment reports were published on 4,4′-DMAR and MT-45, which were risk assessed in September 2014;

• an EMCDDA–Europol joint report on α-PVP was produced and sent to the European Commission, the Council and the EMA, and published.

The European Database on New Drugs (EDND) — Europe’s information hub on NPS —

was expanded further in 2015 to include 101 new substance profiles; in addition,

a further 328 existing profiles were updated, including the provision of further analytical

data; this is essential in order to allow laboratories across Europe to detect these new

substances. Furthermore, a total of 564 reporting forms (new substances, first

notifications, and significant updates from the Reitox NFPs and Europol National Units)

were received, reviewed, validated and analysed in a timely manner. The resulting data

and information were then incorporated into monitoring strategies.

Network management and the provision of technical assistance on a daily basis to the

members of the Reitox NFPs continued to be a central activity of the EMCDDA in 2015.

This reflects the importance of maintaining strong networks to ensure that early warning

activities are effective.

The 15th Annual Meeting of the Reitox Early Warning System Network took place on 8–9

June 2015. Prior to this meeting, a questionnaire on recent developments in national

EWSs was disseminated and the results were collated, reviewed, validated and analysed

in order to identify relevant themes and issues for discussion at the meeting, as well as to

inform the development of the Toxicovigilance System Framework and the Risk

Communication System Framework; this work will help strengthen Europe’s ability to

identify and react to emerging threats. All presentations given at the meeting and the

minutes of the meeting were made available in the EDND.

Chapter 3 I Core business: monitoring and reporting on the drugs problem in Europe

39

In accordance with Article 10 of Council Decision 2005/387/JHA, the EMCDDA–Europol

2014 annual report on the implementation of Council Decision 2005/387/JHA was

prepared by the two agencies, submitted to the EU institutions in June 2015 and

published in July 2015 (17). The report presented the key activities performed by the

EMCDDA and Europol in 2014, including a list of the NPS that were notified, the joint

reports produced, the risk assessments conducted and the public health alerts issued.

Substances posing serious health risks were intensively monitored throughout 2015. Two

substances, α-PVP and acetylfentanyl, met criteria for the launch of a joint report, in

accordance with Article 5 of Council Decision 2005/387/JHA.

To that end, an ad hoc data collection for the preparation of a joint report on α-PVP was

launched in May 2015. Structured data were requested from the Reitox NFPs, the EMA

and the WHO. In addition, a search of OSI was performed and the results were collated,

reviewed, validated and analysed.

The data from the joint report questionnaire on α-PVP and the results from the OSI search

and review were collated, reviewed, validated and analysed, and a joint report was prepared

within a four-week period. The joint report was submitted to the Council, the Commission and

the EMA in August 2015, by the legal deadline stipulated by Council Decision 2005/387/JHA.

This was followed by a request from the Council to carry out a risk assessment on α-PVP,

which was conducted by the extended Scientific Committee of the EMCDDA in November

2015. Prior to this exercise, and in order to support the work of the Scientific Committee,

a detailed technical report was produced by the EMCDDA in accordance with the

EMCDDA Risk Assessment Operating Guidelines, based on the information collected from

Member States and Europol, and on a comprehensive analysis of all the available data.

The risk assessment report was subsequently submitted to the Council and the

Commission within the timeline stipulated in Article 6 of Council Decision 2005/387/JHA.

Following the same procedure as for α-PVP, an ad hoc data collection for the preparation

of a joint report on the other substance deemed to pose a serious health risk, namely

acetylfentanyl, was launched in September 2015. The joint report was submitted to the

Council, the Commission and the EMA in December, by the legal deadline stipulated by

Council Decision 2005/387/JHA.

These developments in 2015 suggest that there are no signs that the emergence of NPS

is slowing down. On the contrary, this phenomenon continues to generate significant

public health concerns: hence it remains very high on the EU policy agenda. For the

EMCDDA, this translates into an increased amount of work, which is necessary in order to

cope with the demanding implementation of Council Decision 2005/387/JHA,

particularly with large to the EWS and risk assessments, and the ability to respond

promptly to the large number of requests for information or technical support from the

EMCDDA’s stakeholders and partners, including Member States, EU institutions, other

agencies and international organisations, and third countries, as well as from the large

majority of visitors (of which there were more than 400) to the agency in 2015.

(17) Available at: emcdda.europa.eu/publications/implementation-reports/2014

General Report of Activities 2015

40

Furthermore, as a world-renowned authority in the

area, the EMCDDA delivered presentations and

keynote speeches at more than 15 important drug-

related conferences and technical meetings; this

helped to increase the understanding of the NPS

phenomenon and the visibility of EU actions in this

area (for details, see Annex 4).

In the margins of the 58th session of the UN CND,

which took place in March 2015 in Vienna, Austria, the

agency released the short report New psychoactive

substances in Europe. An update from the EU Early

Warning System (18). The report highlights recent

developments, including the growth of the market over

the last few years, as illustrated by seizures by law

enforcement and other indicators, as well as the

growing number of serious harms that have been

reported as a result of NPS.

A poster/wall chart was also published to accompany this EMCDDA publication (19).

In addition, the agency was invited to disseminate its knowledge at training initiatives

carried out in Member States (see Main Area 10) and third countries (see Main Area 8).

In 2015, the EMCDDA further strengthened its links with informal forensic science and

toxicology networks. Ongoing exchange took place throughout the year between the

agency’s staff and international leading forensic, toxicology and law enforcement experts

in the field of NPS. The EMCDDA also delivered presentations at the 2015 Annual Meeting

of the European Network of Forensic Science Institutes (5–8 May 2015, Dublin, Ireland).

Furthermore, the agency, together with the Portuguese Taxes and Customs Authority,

hosted the second meeting of the European Commission’s CLEN project group, funded by

the European Commission Customs 2020 Programme. The meeting, which took place on

5–6 February 2015, focused on ‘Designer drugs and other illicit products’. The event was

organised by the European Commission, DG TAXUD, and the Institute for Health and

Consumer Protection of the Joint Research Centre, with the participation of DG HOME.

The CLEN project group is composed of customs laboratories from the 28 EU Member

States and aims to promote cooperation among them. The two-day meeting provided

a unique opportunity for representatives of these laboratories to share experiences,

compare their practices and discuss the next steps of the project. One of the objectives

of this project is to strengthen the ability of customs labs to detect NPS — this, in turn,

will strengthen Europe’s early warning capacity.

The information exchange with the EMA and the EU pharmacovigilance system on medicines

and substances with medicinal properties was ongoing in 2015, as required by Regulation

1235/2010 and Council Decision 2005/387/JHA. Among other things, this included

a request for information on α-PVP and acetylfentanyl from the EMA, and the production by

the EMCDDA, at the request of the EMA, of a report on ketamine use in Europe.

(18) Available at: emcdda.europa.eu/publications/2015/new-psychoactive-substances(19) Available at: emcdda.europa.eu/publications/2015/new-psychoactive-substances/poster

Chapter 3 I Core business: monitoring and reporting on the drugs problem in Europe

41

A coordination meeting took place with the EMA in March 2015. This meeting addressed

cooperation, with a specific focus on strengthening data collection on the misuse and

abuse of medicinal products defined as NPS, under Article 3 of Council Decision

2005/387/JHA.

The Toxicovigilance System of the EU EWS was further developed in 2015. To this end,

a reporting tool to monitor serious adverse events associated with NPS was developed;

the final implementation of this tool is planned for mid-2016. Also, more than 30 reporting

forms on serious adverse events associated with NPS were received, reviewed, validated

and analysed in 2015, and the resulting data and information were prioritised. The

resulting data and information were then incorporated into monitoring strategies. In

addition, with a view to detecting signals of NPS that pose health concerns, daily

searches and reviews of major English-language OSI, including scientific and medical

literature, were performed. A dedicated EMCDDA Twitter feed was also used to identify

and disseminate relevant signals from social media. The resulting data and information

were then incorporated into monitoring strategies, and this has helped to strengthen the

EMCDDA’s capacity to detect signals regarding public health at an earlier stage

than before.

Based on information received from the EU EWS network that was then reviewed,

validated and analysed, and from searches and reviews of OSI, 17 public health alerts

(including updates) were produced. These alerts were then issued to the EU EWS

network.

A Toxicovigilance System Framework was under development in 2015; this included the

preparation of draft standard operating procedures for the signal management system. In

order to support this, a study on the role of poison control centres in monitoring acute

intoxications associated with NPS was undertaken. Another study examining the current

body of knowledge and practice with respect to communicating, to drug users and the

general population, the serious hazards and risks of an urgent nature that are associated

with NPS and illicit drugs is also in progress.

The development of the next-generation replacement for the EDND made slower progress

in 2015. This activity is resource intensive and implemented in parallel with the already

very demanding tasks of ensuring the functioning of the EU EWS. A prototype system was

designed and produced; this prototype focuses on the reporting and review of event-

based data and is currently being tested by the EMCDDA. The prototype will be used to

inform the development of the EDND, as outlined in the 2016 work programme.

The methodology for monitoring OSI was strengthened, allowing daily monitoring of

events, reported in English-language OSI, that may be classified as serious and requiring

an urgent response. Any relevant information identified was cross-referenced with data

reported by Member States in order to prioritise monitoring and responses. This included

the issuance of public health alerts on the synthetic cannabinoid ADB-CHMINACA after

detection by the EMCDDA of a large multi-state outbreak in the United States (20).

(20) Available at: https://www.federalregister.gov/articles/2016/02/05/2016–02302/schedules-of-controlled-substances-temporary-placement-of-the-synthetic-cannabinoid-mab-chminaca

General Report of Activities 2015

42

I Improving Europe’s capacity to monitor and evaluate policies (Main Area 6)

In response to overarching indicator number 14 of the EU action plan on drugs 2013–16,

work in Main Area 6, to monitor developments in legislation, national drug strategies,

coordination mechanisms and public expenditure estimates in EU Member States,

continued in 2015.

One important aspect of this effort is the monitoring and analysis of EU-level policy. In

parallel, the EMCDDA also closely follows developments in drug policies at the

international level. The agency is tasked with supporting the decision-making process by

providing neutral, non-partisan, reliable information on all aspects of the drugs

phenomenon.

I Highlights and main achievements

In 2015, the EMCDDA contributed to the biennial progress review of the European

Commission as required by the EU action plan on drugs 2013–16 (specifically Action 47:

Promote scientific evaluations of policies and interventions at national, EU and

international level) (see Main Area 8).

Furthermore, the agency launched its analysis Drugs policy and the city in Europe in June

2015 (21). Drug problems often emerge, and are most acutely felt, in urban environments,

making Europe’s cities a valuable observation window for new drug trends. The EMCDDA

Paper Drugs policy and the city in Europe describes how modern cities play host to

a diverse set of drug-using populations, and the related health, social and security

problems.

The term ‘open drug scene’ is used to describe the congregation of people who take drugs

in public spaces. Such open drug scenes were found in several cities. These open drug

scenes vary in visibility, size and the type of location in which they occur.

Also in June 2015, the agency published the short report New psychoactive substances in

Europe: Innovative legal responses (22), which provides an overview of how European

countries are developing innovative legal responses to the challenges presented to public

health and drug policy by the rapidly evolving market for NPS (see Main Area 5).

The rehabilitative measures of treating, educating or reintegrating drug users as alternatives

or additions to conviction or punishment were considered in the framework of the EMCDDA

Paper Alternatives to punishment for drug-using offenders (23), published in July 2015.

(21) Available at: emcdda.europa.eu/attachements.cfm/att_240226_EN_TDAU15001ENN1.pdf(22) Available at: emcdda.europa.eu/publications/ad-hoc-publication/new-psychoactive-substances-europe-

innovative-legal-responses(23) Available at: emcdda.europa.eu/publications/emcdda-papers/alternatives-to-prison

Chapter 3 I Core business: monitoring and reporting on the drugs problem in Europe

43

The European Legal Database on Drugs (ELDD) and the network of legal correspondents

are the main resources that support the EMCDDA’s reporting on drug laws. The agency

also continued to provide Member States with support for their evaluation of drug policies

on request. In 2015, input and/or technical support was provided to policymakers and

professionals from EU Member States such as Germany, Ireland and Luxembourg.

The 16th Meeting of the Legal Correspondents of the ELDD was held in Lisbon, Portugal,

on 8–9 September 2015. The two-day meeting brought together representatives from the

30 EMCDDA reporting countries and experts from the Russian Federation, Armenia and

Ukraine, and provided delegates with the opportunity to exchange up-to-date information

on national and EU drug-related legal issues, including updates on laws controlling new

drugs.

The meeting included four main sessions: ‘National and EU updates on legislative

developments’; ‘Medicinal cannabis and derivatives’; ‘Drugs and driving — legislative

developments and enforcement practices’; and a special session entitled ‘Alternatives to

punishment’, following the publication of an EMCDDA paper on this topic in July 2015 (24).

The paper found that alternatives to punishment are available across Europe to varying

degrees, and evaluations suggest that these alternatives to punishment have been

associated with positive results; however, these evaluations are inconclusive. This topic was

also highlighted by a study funded by the European Commission (‘Study on alternatives to

coercive sanctions as response to drug law offences and drug-related crimes’), for which

the EMCDDA was tasked with providing support throughout the process.

Knowledge exchange in this field was further reinforced at international level, in the

framework of a study visit of an EMCDDA staff member to CICAD, under the OAS, which

led to the EMCDDA’s contribution to a CICAD/OAS report entitled Technical report on

alternatives to incarceration for drug-related offences (25).. In addition, an intense

exchange of views and information on various topics of common interest, such as

developments in the area of cannabis legislation, took place; this was incorporated into

the ongoing preparation of the EMCDDA Paper Cannabis legislation in Europe — an

overview. This analysis, to be published in 2016, aims to summarise our knowledge on

cannabis legislation at a time of great interest in legalisation and decriminalisation.

The terms ‘depenalisation’, ‘decriminalisation’ and ‘legalisation’ are often used in the

debate on how to control the supply

and use of drugs. An EMCDDA video

entitled ‘What is decriminalisation of

drugs?’ was released in June 2015 (26).

There is no universal agreement on the

precise meanings of these terms, but it

is helpful to explore the different ideas

associated with them in order to better

understand what they mean in the

context of the debate on different

approaches to controlling the supply

and use of drugs.

(24) Available at: emcdda.europa.eu/system/files/publications/1020/TDAU14007ENN.pdf(25) Available at: https://drugpolicydebateradar.files.wordpress.com/2015/05/report-on-alternatives-to-incarceration.pdf(26) Available at: https://www.youtube.com/watch?v=9NKhpujqOXc

General Report of Activities 2015

44

To mark the first European conference on addictive

behaviours and dependencies — Lisbon Addictions

2015 (see Main Area 7) — the EMCDDA released

various posters on topics linked to this area, such as

‘Drugs policy and the city in Europe’ (27), ‘Regional drug

strategies across the world’ (28) and ‘Financing health

and drug policy in the wake of the economic

recession’ (29).

Public expenditure in the areas encompassing most

drug-related initiatives was negatively affected by

austerity. Some countries reorganised drug-related

treatment and harm reduction provisions, and changed

co-financing systems and shifted towards outpatient or

day-care treatment rather than inpatient treatment for

drug problems, in order to make treatment more

cost-effective.

A current project in the area of drug-related public expenditure aims to gather a set of

representative examples of methods for estimating public expenditure on treatment for

drug problems in Europe and internationally. The analysis Methods to estimate the costs

of drug treatment, which should be published in 2016, envisages the monitoring of public

expenditure estimates and an improvement of the European capacity to provide tools for

evaluating policies.

I Scientific coordination, research and content support (Main Area 7)

The commitment to improve the scientific quality of our work is a prerequisite for fulfilling

our role as a centre of excellence for the collection, analysis and dissemination of drug-

related information. This primary objective, laid down in the three-year strategy and work

programme 2013–15, was implemented in 2015 through a number of separate quality-

related projects that addressed both substantive and process issues.

The top priorities in this area in 2015 were to ensure the development, quality and

coherence of the agency’s information collection and reporting system through the

adoption of a revised national reporting system (in collaboration with the NFPs). In

addition, the EMCDDA aims to ensure a high quality of scientific publishing and the

coordination of other cross-cutting activities, particularly in the areas of training,

emerging trends and monitoring the misuse of medicines in the context of polydrug use.

(27) Available at: emcdda.europa.eu/attachements.cfm/att_242521_EN_03_LXAddictions_EQ_cities_FINAL.pdf(28) Available at: http://www.lisbonaddictions.eu/start, then go to section e-posters(29) Available at: emcdda.europa.eu/attachements.cfm/att_242515_EN_04_LXAddictions_CCS_recession_FINAL.pdf

Chapter 3 I Core business: monitoring and reporting on the drugs problem in Europe

45

I Highlights and main achievements

Scientific Committee

In performing its scientific work, the EMCDDA benefits from the support of the Scientific

Committee. This is one of the two statutory bodies of the EMCDDA and it plays an

important scientific advisory role.

The 42nd Scientific Committee Meeting was held in Lisbon on 28–30 April. This meeting

focused on the EMCDDA’s draft 2016–18 strategy and the 2016 work programme.

Discussions were organised in break-out sessions, allowing all Committee members to

provide input on their particular areas of expertise and to exchange views with EMCDDA

scientific staff. Also addressed at the meeting was the implementation of the agency’s

recently adopted policy on conflicts of interest and the preparation of contributions to the

EU action plan on drugs (2013–16), namely on drug-related research priorities and the

scientific evaluation of policies. In addition, the Committee reviewed the 54 eligible

articles nominated for the fifth round of the EMCDDA Scientific Paper Award.

A formal opinion on the agency’s 2016–18 strategy and work programme was adopted by

written procedure.

The second meeting of the Scientific Committee in 2015 took place on 18–20 November.

During this meeting, the extended Scientific Committee, and additional experts from the

EU Member States, the European Commission, Europol and the EMA, carried out a formal

risk assessment of the synthetic cathinone α-PVP, after over 100 deaths and 30 non-fatal

poisonings associated with this substance were reported to the agency. After the

meeting, on 18 December 2015, the European Commission published a proposal for

a Council decision subjecting α-PVP to control measures (see Main Area 5).

During the days after the meeting, the new concept of EMCDDA multi-annual

programming was also discussed, along with the Committee’s contributions to the EU

action plan on drugs (2013–16). Furthermore, the Director-elect, Alexis Goosdeel,

addressed the Scientific Committee, and presented his vision for the EMCDDA. A debate

followed, during which the members of the Scientific Committee and the Director-elect

exchanged views on the topic.

In line with the agency’s new policy on the prevention and management of conflicts of

interest, members’ declarations have now been published on the EMCDDA website. As

decided by the Management Board in December 2015, the mandate of the Scientific

Committee and reserve list was extended to cover the period 2017–19.

Members of the Scientific Committee were also actively involved in the 2015 EMCDDA

Scientific Paper Award process, as reviewers of the concept, nominators of articles and

members of the jury. The Committee also prepared and adopted its final contribution to

the HDG’s annual dialogue on research, which took place in November 2015.

The Scientific Committee members who reviewed EMCDDA publications during the year

were (in alphabetical order) Anne Line Bretteville-Jensen, Gerhard Bühringer, Paul

Dargan, Brice De Ruyver, Gabriele Fischer, Henk Garretsen, Dirk Korf and Rainer

Spanagel. The publications peer reviewed were: European Drug Report: Trends and

Developments; The internet and drug markets (EMCDDA Insights, released in February

2016); Preventing opioid overdose deaths with take-home naloxone (EMCDDA Insights,

released in January 2016); Emergency department-based brief interventions for

General Report of Activities 2015

46

individuals with substance-related problems: a review of effectiveness (EMCDDA Papers,

released in January 2016); Strategies to reduce diversion of substitution drugs for the

treatment of opioid dependence (EMCDDA Papers, 2016 release); and Drug supply

reduction and external security (EMCDDA Papers, also to be released in 2016).

MEETINGS OF THE SCIENTIFIC COMMITTEE

28–30 April

18–20 November

Lisbon

Lisbon

42nd meeting of the Committee

43rd meeting of the Committee

Scientific coordination

A key priority in 2015 was to further improve the quality and coherence of the EMCDDA’s

information collection and reporting system. A revised Reitox NRP entered into force in

2015; this determines how data from Member States are reported to the EMCDDA, in

order to provide an overall picture of Europe’s drug phenomenon. The aim of the new NRP

is to ensure efficiency, match priorities and resources, and better address the information

needs of European and national stakeholders (see also Main Area 1).

In terms of quality assurance measures, a proposal for a top-level data quality assurance

model at the EMCDDA was finalised. The EMCDDA internal statistics code of practice was

published in February. This represents a milestone in the path to reassessing quality

standards: it establishes the goals to be pursued by the agency and reflects its

commitment to ensuring high-quality data collection, analysis and reporting

(see Main Area 1).

Furthermore, the work on the implementation of

a mechanism to check the quality and coherence of data

collection tools has continued under the framework of the

work carried out by the Data Coherence Group (DCG).

The EMCDDA also has a duty to share knowledge, and

partnerships with academic institutions help us to achieve

this. One example is the European drugs summer school.

The agency continued its partnership with the ISCTE —

University Institute of Lisbon (ISCTE-IUL) in 2015 and,

together, these two organisations held the fourth summer

school on ‘Illicit drugs in Europe: demand, supply and public

policies’ (30). The initiative was also supported by the US

National Institute on Drug Abuse (NIDA).

The two-week summer school, which took place from 29

June to 10 July 2015, brought to Lisbon a record 37 academics and professionals from

Asia, Europe, Latin America and North America, four of whom had received scholarships

from ISCTE–IUL or NIDA.

As in previous years, the students expressed their views on the course via evaluation

questionnaires. The overall satisfaction score, on a scale of 1 to 10 (not satisfied to very

satisfied), was 8.73, and the large majority of participants (97 %) indicated that they

would recommend the summer school to others.

(30) For more information: http://www.drugsummerschool.cies.iscte-iul.pt/np4/home

Chapter 3 I Core business: monitoring and reporting on the drugs problem in Europe

47

Another important channel for knowledge dissemination is scientific publishing. In 2015,

45 scientific publications were released by the EMCDDA (including a few joint products

with our partners), and 27 scientific articles authored or co-authored by EMCDDA staff

were published in prestigious journals.

The complete list of publications is presented in Annex 3, and brief overviews of these

publications are given under the different Main Areas discussed in this report.

A crucial element for ensuring the high value of our publications is the implementation of

the EMCDDA overall scientific quality control framework. This includes a robust quality

control procedure, which is supported by an internal tool — the products database — that

includes all EMCDDA products in different stages of preparation, with clear indications of

the staff responsible and the production timeline. Furthermore, a peer-review system sets

out the procedures for internal coordination, quality control processes, and internal and

external peer-review mechanisms for products.

Emerging trends

Monitoring new developments was also an important field of work in 2015. The activities

of the agency in this field reflect an increasing recognition of the importance of facilitating

the development of early responses to potential threats by strengthening the systems for

identifying, tracking and understanding new and emerging trends in drug use and

availability, and the associated adverse consequences.

The speed with which the internet is transforming drug markets poses a major challenge

to law enforcement, public health, research and monitoring agencies, according to the

EMCDDA Technical report The Internet and drug markets — summary of results from an

EMCDDA Trendspotter study, which was released in January 2015 (31).

The study kicked off with data collection and a literature review in September 2014, and

culminated in an expert meeting in Lisbon on 30–31 October 2014. Insights were

provided from experts in the fields of information and communication technology (ICT),

research, monitoring and law enforcement, and with regard to the internet and drug users.

Special focus was placed on the online sale of NPS and medicinal products for illicit use;

the role of social media and apps; and drug sales on the ‘deep web’ (inaccessible via

standard web browsers). The terms ‘surface web’, ‘deep web’ and ‘dark net’ are explained

in an EMCDDA video, which will be released in 2016 (32).

This topic will be further explored in the EMCDDA Insights publication The internet and

drug markets, to be published in early 2016.

In addition, the EMCDDA launched a ‘Trendspotter’ study on critical new developments

within Europe’s MDMA/ecstasy market, such as signs of increased MDMA production and

availability, the opening of new online markets, and reports of increased use and even

MDMA-associated deaths in some countries. The study commenced with a phase of data

collection and literature review, and culminated in an expert meeting in Lisbon on 22–23

October 2015. This resulted in an in-depth analysis of the topic, providing insights from

the perspectives of drug research and monitoring, wastewater analysis, law enforcement

and health, which is due for publication in the first half of 2016.

(31) Available at: emcdda.europa.eu/publications/technical-reports/internet-drug-markets(32) Available at: https://www.youtube.com/watch?v=x2lAqiLxj98

General Report of Activities 2015

48

Monitoring the misuse of medicines

In 2015, the EMCDDA continued its work in the area of monitoring the misuse of medicines

and released a new analysis that places the spotlight on benzodiazepine misuse among

high-risk opioid users, who may take these medicines to self-medicate or to enhance the

effects of opioids. This analysis was released in June as part of the POD series under the

framework of the EDR 2015 (33). This POD aims to provide a better understanding of the

motives for, and the consequences of, the co-use of opioids and benzodiazepines, the

pharmacological interactions between opioids and benzodiazepines, the clinical

implications, the responses and the existing medical guidelines.

Benzodiazepines are a widely

prescribed group of medicines with

a range of clinical uses, including the

treatment of anxiety and insomnia, and

the management of alcohol withdrawal.

For a number of reasons, this group of

medicines are often misused by

high-risk opioid users and are

associated with morbidity and mortality

among this group. The analysis shows

how the combined use of opioids with

benzodiazepines or other central nervous system depressants (e.g. alcohol) contributes

to an increase in the risk of overdose-related deaths. Prescribing and clinical practice

guidelines could play a key role in the management of this complex issue. Furthermore,

the agency released a video on this topic, showcasing not only interviews with renowned

experts in the field, but also with users (34).

The case study was designed with the objective of testing the EMCDDA’s data collection

tools, existing networks and mechanisms, and their potential for future in-depth analyses

in the area of the misuse of medicines. Therefore, the analyses in the publication are

based on the EMCDDA’s expert meetings and main data sources, but also on literature

reviews and external sources (e.g. the Euro-DEN project (see Main Area 3)).

Drug-related research

The EMCDDA continued to follow EU and national drug-related research projects closely

and to present the information on its public website (35), as well as on dedicated intranet

pages. Ongoing contacts and collaboration with drug-related research consortia and

projects took place in 2015. These included ALICE-RAP (36), SEWPROF (a sewage

profiling project), SCORE (Sewage Analysis Core Group Europe), LINKSCH (37),

ERANID (38) and DECIDE (Developing and evaluating communication strategies for

supporting informed decisions and practice based on evidence). Furthermore, the

(33) Available at: emcdda.europa.eu/topics/pods/benzodiazepines(34) Available at: https://www.youtube.com/watch?v=hKnQ6-HLjws(35) http://www.emcdda.europa.eu/topics/research(36) ALICE-RAP (Addiction and Lifestyles in Contemporary Europe — Reframing Addictions Project) is a five-year

research project funded through the Socio-economic Sciences and Humanities theme of the European Commission’s Seventh Framework Programme for Research and Development (FP7) (see http://www.alicerap.eu/).

(37) LINKSCH is a project that was set up under the FP7 and unites researchers from France, Germany, the Netherlands and the United Kingdom.

(38) ERANID (European Research Area Network on Illicit Drugs) is a European Research Area Network (ERA-NET) project funded through the Socio-economic Sciences and Humanities theme of the FP7 (see http://www.eranid.eu/).

Chapter 3 I Core business: monitoring and reporting on the drugs problem in Europe

49

EMCDDA provided support for the satellite events of the ERANID and ALICE-RAP

projects, held in the margins of Lisbon Addictions 2015.

The EMCDDA co-hosted, on 11–15 October in Ascona (Switzerland), the second

international conference on the analysis of drugs in wastewater, ‘Testing the Waters

2015’, organised by the Swiss Federal Institute of Aquatic Science and Technology

(Eawag) in association with EU-funded SEWPROF and SCORE.

The conference hosted presentations on the latest research findings and technical

advances in the field. Wastewater analysis is a rapidly developing and novel scientific

discipline with the potential for monitoring near-real-time, population-level trends in illicit

drug use. The EMCDDA, which was represented on the conference’s organising and

scientific committees, described its work in this domain, and also presented an award for

the best poster at the event.

In 2015, over 50 papers in five categories were nominated for the fifth round of the

EMCDDA Scientific Paper Award. The

primary authors of the five winning papers

gathered in Lisbon on 23 September in the

margins of Lisbon Addictions 2015. The

award, inaugurated in 2011 by the

EMCDDA and its Scientific Committee,

celebrates scientific writing and

distinguishes high-quality research in the

field of illicit drugs. The six primary authors

of the winning papers were Monique Vallée

(France), Christoph Ort (Switzerland), Tim

Weaver and Nicola Metrebian (United

Kingdom), Ricardo Gonçalves (Portugal),

and Pierre-Arnaud Chouvy (France) (39).

In 2015, the agency continued to

contribute to various studies and research.

The EU action plan on drugs 2013–16

indicates that the EMCDDA’s Scientific

Committee had an important role to play in

three of the plan’s actions (Actions 30, 46

and 47), all of which are related to drug

research in Europe. The EMCDDA, advised by its Scientific Committee, supports the

European Commission in the preparation of the Council’s annual dialogues on drug-

related research; these dialogues take place under the framework of the HDG. The 2015

contribution of the Scientific Committee was submitted to the HDG on 15 October 2015.

In 2015, the EMCDDA co-organised a major new event in the field of addiction research:

the first European conference on addictive behaviours and dependencies — Lisbon

Addictions 2015 — which was also held in Lisbon on 23–25 September 2015 (40). Hosted

by SICAD, the event was held in collaboration with the scientific journal Addiction and the

ISAJE

(39) Available at: emcdda.europa.eu/activities/scientific-paper-award(40) For more information: www.lisbonaddictions.eu

Scientific paper awardees 2015: Ricardo Gonçalves; Nicola Metrebian; Tim Weaver; Monique Vallée; Kenza Afsahi (representing primary author Pierre-Arnaud Chouvy); Christoph Ort, with EMCDDA Director and the Chairs of the EMCDDA Management Board and of the Scientific Committee

General Report of Activities 2015

50

The 350 presentations, comprising keynote speeches, oral presentations and posters,

provided participants at Lisbon Addictions 2015 with a comprehensive overview of the

main issues on the research agenda in the addictions field today.

The agency was not only co-organiser of

the event, but it was also represented

by numerous oral and poster

presentations. Lisbon Addictions 2015

included a one-week-long array of

satellite meetings and side events, as

well as 10 sessions ‘sponsored’ by

organisations to address specific

themes (41).

The EMCDDA organised several sessions:

• ‘EMCDDA face-to-face’ to showcase the work of the agency as it commemorates 20

years of monitoring the drug phenomenon;

• ‘Scaling up responses to hepatitis C (HCV) among people who inject drugs (PWID) in

Europe: what are the priorities?’ (co-organised with the ECDC);

• ‘Capacity building in research and programme implementation in the addictions:

promoting synergies and sustainability’ (co-organised with NIDA);

• ‘Understanding the risks and benefits of OST in Europe: triangulating data from

monitoring and research sources’ (Reitox).

Alongside the conference, the EMCDDA organised an event, held on 21–22 September

2015, on the main issues arising from 20 years of drug monitoring, with a focus on KIs

(see Main Area 2).

(41) EMCDDA contributions are available at: emcdda.europa.eu/events/lisbon-addictions-2015/emcdda-staff

Lisbon Addictions 2015 reached its maximum capacity three months ahead of its opening. Over 600 participants — researchers, practitioners and policy experts from 58 countries and a range of specialist areas — attended the event.

The success of the conference, however, is reflected not only in this high level of interest and attendance, but also in the satisfaction expressed by participants in a post-conference survey. Over half of the conference participants responded to the online questionnaire and the results speak for themselves. A notable 86 % of respondents rated the 16 conference keynote speakers as ‘excellent’ or ‘very good’, while two-thirds of respondents also rated the 200 oral presentations in this way. There were more than 100 rapid communications (posters) and these were also considered to be of high quality by the participants: half of respondents rated them as ‘excellent’ or ‘very good’.

Finally, over 80 % of respondents rated the ‘overall impression’ of the conference as ‘excellent’ or ‘very good’, which explains why 85 % of respondents said that they would recommend the event to others.

As a result of this success, the organisers have decided to launch Lisbon Addictions 2017, which will take place from 24 to 26 October 2017.

4

General Report of Activities 2015

52

The cooperation with key external partners, namely EU institutions and bodies, national

policymaking bodies, international organisations, civil society organisations and third

countries, represented an important part of the EMCDDA’s work within the 2013–15

strategy and work programme, which committed the agency to strengthening and

enhancing cooperation with European, national and international partners.

Throughout 2015, the agency provided technical support to EU institutions and Member

States, and continued to build synergies with other EU agencies and international

organisations; furthermore, the EMCDDA continued its successful work with candidate

and potential candidate countries, and ENP countries, with a view to supporting them

with the development of their drug monitoring capacities, in line with the EMCDDA’s data

collection tools and methods. This transfer of knowledge was mainly accomplished

through the implementation of the latest technical assistance project funded by the

European Commission under the new IPA — IPA 5 — and the continuation of the

technical assistance project in partner ENP countries, which started in 2014.

I Highlights and main achievements

The EU institutions

In 2015, the EMCDDA continued to support drug policy dialogue at EU level by providing

expertise and technical information to the European Parliament, the Council and the

European Commission.

With regard to the collaboration with the European Parliament, the findings from the most

important EMCDDA publication — the 2015 EDR (see Main Areas 1 and 9) — were presented

by the Director, Wolfgang Götz, to the Civil Liberties, Justice and Home Affairs Committee of

the European Parliament (LIBE Committee) in Brussels on 17 June. This was followed by

meetings of the Director with Members of the European Parliament (MEPs) Péter Niedermüller

(Hungary), Tomáš Zdechovský (Czech Republic) and Gérard Deprez (Belgium), on issues

concerning the work of the agency. Furthermore, the Director participated in an exchange of

views with European members of the Global Commission on Drug Policy at the European

Parliament on 27 January 2015, and the Scientific Director attended the event ‘EU policies on

the fight against drugs trafficking and organised crime: assessing a new approach for soft

drugs’, which was co-hosted by the MEPs Ignazio Corrao and Elly Schlein (Italy) on 13 July.

The Director also met the MEP Tomáš Zdechovský on 13 May during a visit of the latter to

the EMCDDA. A written answer was prepared in response to a request from the MEP

CHAPTER 4Cooperation and collaboration with key partners (Main Area 8)

Chapter 4 I Cooperation and collaboration with key partners

53

Michal Boni about an outbreak of approximately 200 serious adverse events associated

with a branded ‘legal high’ product called ‘Mocarz’ in Poland, and agency staff

participated in the United Nations General Assembly Special Session on Drug Policy

(UNGASS) at the European Parliament in Brussels, which was organised by the MEP

Michal Boni and EURAD (Europe Against Drugs), on 23 September.

Finally, the candidate selected by the Management Board for the post of Director, Alexis

Goosdeel, had an exchange of views with members of the LIBE Committee at the

European Parliament in Brussels on 22 September; on the basis of the subsequent

positive opinion of the European Parliament, the EMCDDA Executive Committee adopted,

on behalf of the EMCDDA Management Board, the formal decision to appoint Mr

Goosdeel as the new Director of the EMCDDA (see also Main Area 10).

The EMCDDA also contributed to the latest LIBE Committee newsletter, providing

updates on its activities of interest to EU citizens.

In terms of cooperation with the Council, the EMCDDA presented the EDR 2015 to the

HDG of the Council on 16 June 2015 in Brussels. The agency also participated in nine

other meetings of the HDG held throughout the year under the Latvian Presidency and

the Luxembourgish Presidency of the Council, and provided presentations and active

contributions to the discussions, particularly with regard to NPS, which remained one of

the topics of highest interest, the monitoring of EU minimum quality standards of

interventions and the misuse of medicines.

Contributions were also made to the dialogues with Russia, the Western Balkans, the

Eastern Partnership countries and the United States, and to the meetings of the National

Drug Coordinators, EU-CELAC (CELAC is the Community of Latin American and

Caribbean States) and the Dublin Group. A comprehensive list of the events attended by

the EMCDDA in this area can be found in Annex 4.

Another important task of the EMCDDA is to support the 2013–17 EU policy cycle for

organised and serious international crime under COSI. In 2015, the EMCDDA fulfilled the

tasks assigned to it in the OAPs, namely by providing contributions in the fields of

synthetic drugs, cocaine and heroin (see Main Area 4).

The cooperation with the European Commission was further strengthened in 2015, in

particular with the DG for Migration and Home Affairs (DG HOME) being the EMCDDA’s

partner DG. Coordination dialogues with other DGs, such as the DG for Health and Food

Safety (DG SANTE), the DG for Neighbourhood and Enlargement Negotiations (DG

NEAR) and the European External Action Service (EEAS) took place throughout the year.

A key contribution was the input provided by the EMCDDA to the first bi-annual progress

assessment of the EU action plan on drugs 2013–16, at the request of DG HOME.

At a technical level, cooperation was ongoing, particularly in the areas of NPS (with DG

HOME and DG TAXUD — see Main Area 5) and supply (with DG HOME and Eurostat —

see Main Area 4). In addition, the EMCDDA participated in the meetings of the EU’s HIV/

AIDS Think Tank, organised by the European Commission (DG SANTE). These meetings

gather representatives from EU Member States, as well as the main European and

international organisations working in the infectious disease field.

The EMCDDA provided the European Commission, upon request, with briefing notes on

the drug situation in third countries (see last two sections under this main area) such as

Brazil, Kosovo, Morocco, Russia, Serbia, Tunisia, Turkey, Pakistan and Peru. These briefing

General Report of Activities 2015

54

notes supported visits of high-level European Commission representatives to these

countries and the preparation of various subcommittee meetings. Furthermore, country

situation analyses for each of the candidate and potential candidate countries were

drafted and sent to DG NEAR for the preparation of its progress reports. The EMCDDA

also participated in the oral consultation, organised by DG HOME and DG NEAR, held on

15–16 June in Brussels, on the progress reports for the candidate and potential

candidate countries.

The agency also contributed to the drafting of the evaluation report of the Cooperation

Programme between Latin America and the European Union on Drugs Policies

(COPOLAD) 1 project.

As part of the inter-agency networks, the EMCDDA provided input and contributions as

required to the work of and meetings between the European Commission (DG for Human

Resources and Security (DG HR) and the DG for Budget (DG BUDGET) and agencies on

issues regarding the implementation of new staff regulations (see Main Area 11).

Member States

The cooperation between the EMCDDA and EU Member States is key to the successful

implementation of EMCDDA activities. The monitoring systems of the agency rely on the

information provided by the 30 reporting countries, including the 28 Member States.

Throughout 2015, technical support was provided to national data providers through, for

instance, ongoing contact and assistance, and the Reitox Academy Training Programme

(see Main Area 10).

In addition, the EMCDDA participated in various bilateral meetings with Member State

representatives. Examples include meetings with the Governmental Commission on

Drugs of the Slovenian Ministry of Health in March; the Slovak authorities in April; the

Italian NFP in June; and the United Kingdom Home Office and NFP in July. The EMCDDA

also accepted an invitation to attend an event to mark the International Day Against Drug

Abuse and Illicit Trafficking, which was organised by the Cyprus Antidrug Council and held

on 26 June. In the margins of the event, Alexis Goosdeel of the EMCDDA received an

award from the national drug coordination committee, the Cyprus Antidrug Council, for

his valuable contribution to its work since 2001 and for the creation of a national drug

monitoring centre and Reitox NFP in Cyprus (known as EKTEPN).

In addition, the agency received visits from several high-level Member State delegations.

The Minister of Health of Luxembourg, Lydia Mutsch, and other delegates visited the

EMCDDA in April 2015. The German Drug Commissioner, Marlene Mortler, and members

of the Health Committee of the German Parliament also visited the EMCDDA in April.

Another highlight was the visit of members of the Committee on Justice, Defence and

Equality of the Irish Parliament on 4–5 June; these visitors were given the opportunity to

attend the launch of the EDR 2015 on 4 June.

Because Portugal is the host country of the EMCDDA, particular attention has been paid

to continuously improving the collaboration with its authorities, namely with the

Portuguese Parliament and Government, and the Presidency of the Portuguese Republic.

In 2015, there was ongoing contact between the EMCDDA and the Portuguese

authorities, within the framework of the Seat Agreement, and there were also institutional

and technical visits to the agency. To that end, representatives of the Portuguese Ministry

of Defence and members of the Committee on European Affairs of the Portuguese

Parliament visited the EMCDDA in June and July, respectively.

Chapter 4 I Cooperation and collaboration with key partners

55

EU agencies and international organisations

The year 2015 also saw important developments in the collaborations with other EU

agencies, within existing agreements and work programmes.

At institutional level, the EMCDDA contributed to the Heads of Agencies network meetings

(held on 20 February and 28 May in Brussels and 22–23 October in Dublin). EMCDDA staff

also contributed to work carried out within inter-agency networks, such as the EU Agencies

Network of Scientific Advisors (EU-ANSA); the Heads of Administration network; the Heads

of Communication network; the Performance Development network; the Inter-Agency

Legal network (IALN); and the Inter-Agency ICT Managers’ network (ICTAC).

Joint work was also carried out under the framework of the network of Justice and Home

Affairs (JHA) agencies, which was created in 2006 to foster JHA inter-agency cooperation.

The newly elected EMCDDA Director attended the annual meeting, which was organised

and held by the 2015 Chair of the JHA network, eu-LISA, in Tallinn, Estonia, on 3

November. In 2015, the EMCDDA was in charge of organising the 5th Informal Strategy

Meeting between the European Commission’s Director-General for Migration and Home

Affairs and the directors of the DG HOME agencies, which took place on 8–9 May in

Grândola, Portugal. The EMCDDA also contributed to the meetings of the JHA agencies’

contact group (42), which took place in Tallinn (on 4 March, 11 June and 6 October) and

the meeting of the working group on training (on 10 June in Tallinn).

Building on the already existing excellent collaboration, further synergies continued to be

built with EMSA, particularly in the areas of staff training, logistics and infrastructure

management, and information and ICT.

Finally, the EMCDDA consulted the JHA agencies, as well as the ECDC and the EMA, on

its draft strategy and work programme for 2016–18. In turn, the agency was invited to

provide feedback on the work programmes developed by Eurojust, the European Asylum

Support Office (EASO), CEPOL and Europol.

On a technical level, the collaborations were further strengthened with Europol (see Main

Areas 4 and 5), CEPOL and Eurojust (see Main Area 4), the EMA (see Main Area 5) and the

ECDC (see Main Areas 2 and 3). A coordination meeting with the ECDC took place on 9

October 2015 in Lisbon, during which Michael Catchpole, ECDC Chief Scientist, paid

a visit to the EMCDDA.

Cooperation with international organisations was also enhanced in 2015, in particular

with the UNODC, the WHO, CICAD and the Pompidou Group.

Extensive participation in UNODC meetings took place throughout the year in Vienna,

Austria. Examples of such meetings include the 58th session of the CND (9–17 March —

see also Main Areas 3 and 4); the Global SMART Advisory Board meeting, (17 March); and

the reconvened 58th session of the CND (9 December). The agency contributed to a side

event, organised by SICAD, of the reconvened 58th session of the CND; this side event

was entitled ‘A public health approach as a base for drugs policy’.

(42) The JHA agencies’ contact group is composed of representatives from Europol, Eurojust, CEPOL, Frontex, the Fundamental Rights Agency, eu-LISA, EASO, OLAF (European Anti-Fraud Office) and the European Commission (DG HOME, DG JUST and the Secretariat-General). This informal group was set up by Europol under the Swedish Presidency of the Council to support and prepare the annual meetings of the JHA agencies’ directors, and to monitor multilateral cooperation.

General Report of Activities 2015

56

The EMCDDA also contributed its NPS data to the UNODC Global SMART programme,

namely by providing a list of newly notified NPS and the aggregated data on NPS seizures;

and to the annual risk assessment meeting of the WHO Expert Committee on Drug

Dependence by providing data on serious adverse events and seizures.

In recent years, cooperation with the WHO Regional Office for Europe (WHO Europe) has

covered issues related to prison and infectious diseases, whereas cooperation with WHO

headquarters has focused on the quality standards of interventions and the monitoring of

treatment systems. In 2015, the EMCDDA contributed to work on defining a minimum

public health data set for prisons, and provided input to the European consultation on

health sectorial strategies launched by WHO Europe. As a member of the steering group

of the Health In Prisons Programme (HIPP) of WHO Europe, the EMCDDA attended two

meetings related to prisons and drug use organised by the latter: one was held in

Copenhagen, Denmark, on 28–29 May, and one was held in Bishkek, Kazakhstan, on

27–29 October.

In terms of collaboration with CICAD, the EMCDDA edited a CICAD/OAS report on

alternatives to incarceration (Technical report on alternatives to incarceration for drug-

related offenses). Furthermore, an exchange programme took place with CICAD in 2015,

during which an EMCDDA staff member was assigned to work with CICAD for one month.

In terms of cooperation with the Pompidou Group, the EMCDDA participated in several

MedNET meetings during 2015 (in Tunis, Tunisia, on 19 May; in Cairo, Egypt, on 3–5

September; and in Paris, France, on 15–16 December). Furthermore, the agency

contributed to the MedNET Euro-Mediterranean seminar on substitution treatment and

harm reduction, which took place in Algiers, Algeria, on 21–22 April. The agency also

contributed to the Pompidou Group’s expert group on ‘Possible adverse effects and

associated cost of drug control policies’ during a meeting that took place in Oslo, Norway,

on 8–9 June.

Candidate and potential candidate countries

Cooperation with candidate countries and potential candidate countries continued in

2015 within the framework of the new IPA (IPA 5) technical assistance project, which was

awarded to the EMCDDA in June. Within the 24-month project, seven IPA beneficiary

countries (Albania, Bosnia and Herzegovina, Montenegro, Kosovo, Serbia, the former

Yugoslav Republic of Macedonia and Turkey) will be provided with further capacity

building and technical support in order to prepare them for their participation in the work

of the EMCDDA.

The EMCDDA drafted roadmaps which assess the level of progress made by each country

towards being fully prepared to participate in EMCDDA activities (i.e. what each country

has in place and still needs to put in place in order to establish a functional drug

observatory and meet the EMCDDA’s requirements for data collection and reporting). In

particular, data collection mechanisms were analysed and recommendations for

improvement were formulated. These recommendations will be the basis for developing

and implementing further activities in 2016–17, in close cooperation with the countries

and depending on their commitment to participate.

Based on the needs identified so far at country level and on EU-specific priorities, overall

support for establishing functional observatories, harmonising data collection in the drug

supply area and establishing national EWSs will be the main areas of upcoming

cooperation. To this end, country visits by the EMCDDA to Albania, Montenegro and

Chapter 4 I Cooperation and collaboration with key partners

57

Serbia were organised in order to agree upon future activities, and a meeting entitled

‘Establishing national EWS in Serbia’ took place on 17 December in Belgrade, Serbia, at

the request of the Drug Monitoring Centre of the Serbian Ministry of Health.

Approximately 45 participants, representing a wide range of governmental partners,

attended the event at which the setting-up of an EWS for new drugs in Serbia was

discussed.

Furthermore, experts from IPA 5 beneficiary countries attended different EMCDDA

meetings throughout the year. These included the ‘20 years of monitoring’ event (see Main

Area 2) and the 4th extended Reitox Week (in Lisbon on 22–26 November) (see European

Neighbourhood Policy countries and other third countries section under this Main Area).

In 2015 the EMCDDA published three publications based on its work within IPA projects,

as follows:

• Drug use and its consequences in the Western

Balkans 2006–14 (43) (EMCDDA Ad hoc

publication, March 2015). This report is the result

of many years of cooperation between the

EMCDDA and countries in the Western Balkans,

and is the first of its kind. It gives insights into the

drug-related problems faced by six countries in

this region, based on the data gathered by

a range of partners and the EMCDDA. Funded by

the European Commission’s IPA instrument, the

report is a starting point for building a more

detailed and accurate picture of the drug

situation and related responses in the Western

Balkans, and will lead to information and analyses

that represent an added value for the countries

involved, as well as European and national

stakeholders.

• Drug law offences in the Western Balkan region: from definition to monitoring: A report

based on the Reitox Academy ‘Drug law offences in the Western Balkan region: from

definition to monitoring’, organised on 2 and 3 April 2014 in Podgorica, Montenegro (44)

(EMCDDA Technical report, February 2015). This report was prepared based on

materials from the Reitox Academy ‘Drug law offences in the Western Balkan region:

from definition to monitoring’, which took place on 2–3 April 2014, and was organised

by the EMCDDA under the framework of the IPA 4 project ‘Preparation of IPA

beneficiaries for their participation with the EMCDDA’.

• Prevention of infectious diseases among people who inject drugs in some Western

Balkan countries: A report based on the Reitox Academy organised on 29–30 October

2013 in Sarajevo, Bosnia and Herzegovina (45) (EMCDDA Technical report, February

2015). This report was prepared based on materials from the Reitox Academy

‘Prevention of infectious diseases among people who inject drugs in some Western

Balkan countries’, which took place on 29–30 October 2013, and was organised by the

EMCDDA under the framework of the IPA 4 project ‘Preparation of IPA beneficiaries for

their participation with the EMCDDA’.

(43) Available at: emcdda.europa.eu/publications/2015/western-balkans-report(44) Available at: emcdda.europa.eu/publications/technical-reports/drug-law-offences-western-balkan-countries(45) Available at: emcdda.europa.eu/publications/technical-reports/prevention-infectious-diseases-western-balkan-

countries

General Report of Activities 2015

58

European Neighbourhood Policy countries and other third countries

In 2015, the EMCDDA continued to implement the first ENP technical assistance project

started in 2014. This project, called ‘Towards a gradual improvement of ENP partner

countries’ capacity to monitor and to meet drug-related challenges’, aims to strengthen

the capacity of ENP partner countries (Armenia, Azerbaijan, Georgia, Israel, Moldova,

Morocco and Ukraine) to react to new challenges and developments in the drugs

situation.

Capacity development activities are central to the project. In 2015, three Reitox

Academies were organised for 88 participants, as follows:

• The Reitox Academy ‘Monitoring and control of new psychoactive substances’ took

place on 16–17 April in Tbilisi, Georgia. Twenty-seven professionals, representing

national monitoring bodies, national law enforcement agencies and national forensic

laboratories, from Azerbaijan, Belarus, Georgia, Israel, Moldova and Ukraine,

participated in the event.

• The National Reitox Academy in Israel, ‘Building the Treatment Demand Indicator:

Challenge for monitoring and evaluation systems to support coherent national policies’,

was hosted by the Israel Anti-Drug Authority (IADA) in Jerusalem on 10 and 11

November. The event was attended by 22 participants in total.

• The National Reitox Academy in Morocco, ‘Best practices in drug use prevention’, took

place in Rabat on 8 and 9 December. A total number of 39 participants were involved

in the event (see Main Area 3).

In addition, one study visit was organised, to Romania, for four experts from Moldova. The

participants visited the Romanian NFP from 26 to 28 May with a view to sharing

experiences on issues related to the organisation of the NFP and the management of data

collection. Furthermore, the ENP technical assistance project team visited Armenia,

Georgia and Moldova, which allowed next year’s work programme and the framework for

cooperation to be agreed.

Other key project results include the completion of three ESPAD studies, co-funded

through the ENP project, in Georgia, Moldova and Ukraine. Furthermore, ONDA launched,

in Rabat on 2 March, its first national report on the drug situation, with the support of the

Council of Europe’s Pompidou Group and the EMCDDA. The agency also accepted an

invitation to the MedNET meeting on NFP building, organised by the Pompidou Group in

Tunis on 20–21 May, at which the EMCDDA presented the added value and outcomes of

national drug observatories in Europe.

At the institutional level, important events were the signing of two Memorandums of

Understanding (MoUs) with authorities from Armenia and Georgia.

The MoU between the EMCDDA and the National Security Council of Armenia (NSC) was

signed in Yerevan, Armenia, on 28 July, by the EMCDDA Director and the NSC Chief of

Staff, Aram Tananyan. The agreement will allow an exchange of technical expertise and

knowledge between the two bodies, the co-sponsoring of technical meetings, and the

pooling of human and financial resources to launch joint programmes. The NSC will

endeavour to present to the EMCDDA an annual report on the drug situation in Armenia.

The EMCDDA, for its part, will facilitate training as well as the exchange of expertise and

scientific research findings on issues of mutual interest.

Chapter 4 I Cooperation and collaboration with key partners

59

Furthermore, the ENP project supported the participation of drug monitoring experts from

Georgia, Israel, Moldova and Morocco in Lisbon Addictions 2015, held in September (see Main

Area 7). A session entitled ‘Capacity building in research and programme implementation in

the addictions: Promoting synergies and sustainability’ was held during the conference in

order to share the agency’s extended experience of working in the ENP region.

The agency contributed to a training course organised by CICAD (held on 26–27 March in

San José, Costa Rica) on national reporting under the framework of the national drug

observatories of Central America.

Upon invitation, the EMCDDA also supported a training course on the national drug

observatory in Abu Dhabi (United Arab Emirates) on 23–26 March, which was attended

by approximately 30 participants.

The MoU between the EMCDDA and the

Georgian Ministry of Justice was signed by

the EMCDDA Director and the Georgian

Minister of Justice, Tea Tsulukiani, in Tbilisi,

Georgia, on 4 November. The agreement will

boost cooperation between the two bodies

with regard to monitoring the drugs problem,

and will facilitate the collection, processing

and dissemination of information.

The fourth Reitox Week took place on

22–26 November in Lisbon. This annual

event, initiated in 2012 and enlarging the

regular HFP meeting (see Main Area 10),

brought together representatives from

almost 45 nations, including representatives

from the 30 Reitox network members (i.e.

the 30 EMCDDA reporting countries),

Albania, Armenia, Azerbaijan, Bosnia and Herzegovina, the former Yugoslav Republic of

Macedonia, Georgia, Israel, Kosovo, Lebanon, Moldova, Morocco, Serbia and Ukraine. The

purpose of this annual event is to broaden the scope of regular Reitox meetings, underline

the importance of the EU drug monitoring model and add impetus to the agency’s technical

cooperation with countries outside the EU.

In addition, the 2015 event focused on a question of potential interest for national drug

observatories from all countries: ‘What do we know about women using illicit drugs, what

are the gaps in our knowledge, and what are the consequences for the monitoring of the

situation and the organisation of responses?’.

Signature of Memorandum of Understanding between the EMCDDA and the Georgian Ministry of Justice on 4 November in Tbilisi: Director Wolfgang Götz and Minister of Justice of Georgia, Tea Tsulukiani

On 24 November 2015, under the framework of the fourth Reitox Week, the EMCDDA organised, for the first time, a meeting dedicated to the topic ‘Women and drugs’.

The aim of the event was to share the knowledge and experience of the participating countries on the implications of gender for drug use and treatment for drug problems, in order to identify the potential needs and opportunities for monitoring and research, and explore how this knowledge could be used to inform national decision-makers and feed the planning and organisation of services. The meeting brought together researchers, as well as participants from 40 different countries.

5

61

I Communicating the EMCDDA’s findings to external audiences (Main Area 9)

Communication is a core activity of the EMCDDA in terms of both supporting its role as

an information agency and promoting its reputation as the ‘reference point on drugs in

Europe’. Work in 2015 was guided by the integrated EMCDDA communication

strategy (46), which sets out the EMCDDA’s fundamental principles for communicating

knowledge and presents the tools available for building and nurturing relationships with

stakeholders, target audiences and partners.

The EMCDDA product range continued to be adapted in 2015, which reflects the priorities

to disseminate information online and to seek the most cost-efficient solution. New

dissemination options were explored, and social media and targeted electronic updates

were used throughout the year to enhance communication and dialogue with

stakeholders and target groups.

I Highlights and main achievements

Ongoing development of communication tools

Identifying the most effective channels for communicating with our audiences and

innovating and constantly developing our means to reach these audiences are core tasks

of the agency. This involves close collaboration between the internal teams in charge of

content production and publication, coordination with external partners, close contact

with stakeholders, and ongoing monitoring of the external environment in order to make

sure that our dissemination efforts are coordinated with key drug events and policy

developments.

Efficient communication also implies a constant effort to review and rationalise the

EMCDDA product range. Work aimed at achieving a better mix of print and online

products continued in 2015, while taking into account new information-seeking

behaviours but also the need to save costs. As an information agency, the EMCDDA is

constantly innovating and making use of creative solutions for the dissemination of its

knowledge. To this end, new formats were trialled for rapid communication products

(e.g. the NPS-related products which were disseminated at major events, such as the

58th session of the CND, the International Day Against Drug Abuse and Illicit

Trafficking, etc.). Furthermore, various audio-visual formats were conceived, including

(46) Available at: emcdda.europa.eu/publications/communication-strategy

CHAPTER 5Supporting the

achievement of results

General Report of Activities 2015

62

motion graphics, as well as interactive products and explanatory and exploratory data

visualisations.

The EMCDDA has also made efforts to implement a revised linguistic policy, which, on the

one hand, observes the EU multilingual policy, but, on the other hand, follows efficiency

principles. Budget constraints, however, meant that choices had to be made: during 2015,

in addition to the multilingual editions of the European Drug Report 2015: Trends and

Developments, only a few other reports were translated, namely those that are particularly

relevant to certain Member States. For example, the ECDC and EMCDDA guidance.

Prevention and control of infectious diseases among people who inject drugs (Joint

publication, 2011) was translated into Latvian; Building a national drugs observatory:

a joint handbook (Joint publication, 2010) was translated into Portuguese; and some

PODs of strategic importance were identified for translation into French, German,

Portuguese and Spanish.

In 2015, the EMCDDA made some further progress in the implementation of the

terminology/glossary project and continued the efforts made in previous years in

collaboration with the NFPs. This is part of the EMCDDA strategy to improve translation

quality. A total of 42 translated terms were sent to the NFPs for checking and validation.

Keeping abreast of the needs of our customers requires a regular review of how we are

serving them and by what means. The audience engagement strategy and action plan

were adopted internally and six training sessions were held throughout the year for staff

responsible for managing the six stakeholder categories identified in the EMCDDA

communication strategy. Action plans for better engagement with each of these

categories were drafted by the group and presented in a final project report. This will be

taken forward in 2016 and analysed in line with the new EMCDDA strategy to 2025, which

will define the agency’s stakeholder priority groups.

Publishing high-quality and timely products

In 2015, 45 products were published, including:

• the EDR package, which comprised the European Drug Report: Trends and developments; four PODs; a Statistical bulletin; 30 country overviews; and 30 national reports;

• three EMCDDA Insight publications;• two Joint publications;• four outputs linked to the implementation of the Council decision on NPS (2005/387/

JHA) – see Main Area 5;• four EMCDDA Papers;• two Brochures;• one Manual;• four Technical reports and literature reviews;• five Ad hoc publications;• one national report from the former Yugoslav Republic of Macedonia;• seven institutional publications;• four issues of Drugnet Europe.

In addition, nine PODs that were produced as part of previous EDR packages were updated.

Significant updates were made to the POD on wastewater analysis and drugs (to which an

exploratory data visualisation option was added) and the POD on legal approaches to

cannabis (to which a motion graphic that explains related definitions was added).

Furthermore, 27 scientific articles co-authored by EMCDDA staff were published in

prestigious journals.

Chapter 5 I Supporting the achievement of results

63

For a full list of EMCDDA publications in 2015, see Annex 3.

As mentioned before, keeping abreast of the numerous products that the EMCDDA

produces has been greatly facilitated by the processes and tools that were put in place as

part of the overall publication quality assurance framework. These include a products

database, which is kept up to date, and regular Editorial Board and follow-up meetings,

during which work is planned and decisions are made with regard to the best use of the

available resources.

All of the 2015 products were disseminated via the EMCDDA website and social media

channels, along with news releases to mark the launch of key products.

Increasing the relevance and impact of the EMCDDA’s online presence

The EMCDDA website is the agency’s primary means of communicating to all target

audiences and is the key to reinforcing the agency’s profile as the main source of drug

information in Europe.

In 2015, as part of the new website development project that started in 2013, significant

resources were invested in preparing the infrastructure necessary for integrated web

content development and the associated migration. During the year, various technical

difficulties were encountered and solved, and an architecture for the new platform was

launched, along with reviews of security. The migration of various sections (home page,

news and publications) of the new content management system (Drupal) was completed.

The launch of the new website will take place in 2016. A particularly positive development

during the year was the implementation of the useful monitoring instrument Piwik, which

is a web metrics application that provides reliable statistics on website visits. As a next

step, the agency will ensure that these metrics feed back into the conception process and

inform decisions on what products and content are suitable for web-based dissemination.

In parallel, work continued to improve the presentation of key EMCDDA outputs. Special

attention was given to the EDR 2015 package (see Main Area 1), which was fine-tuned

according to the feedback received. In particular, the graphics were overhauled with the

use of an external graphic designer (e.g. the ‘At a glance graphic’). A fully responsive

HTML version of the report was developed for integration into the website, as well as an

e-book version for use on handheld devices. A motion graphic video that summarises the

key findings was also produced.

Out of the four PODs produced in 2015, two had supporting interactive elements and two

had audio-visual elements. The new method and process for displaying data tables in

Statistical bulletin publications (introduced in 2014) was further developed. The methods

and definitions section was also overhauled.

The web interface of the 30 country overviews was redesigned, the country data sheets

were better integrated and new display features were introduced (e.g. modal dialogue,

view in one page and star charts). Furthermore, the other country-specific products,

namely health and social responses profiles, prevalence maps, drug-related research

pages, and information on public expenditure and national drug strategies, were also

updated.

The interactive development of the ways in which data collected under the EWS are

displayed was a significant step forward.

General Report of Activities 2015

64

Enhancing visibility, reputation and recognition

The channels at our disposal to promote the results of the EMCDDA’s work include the

internet, publications and print products, events and conferences, media relations,

audio-visual material and social media. Exploring new dissemination options and tools is

part of our commitment to efficiency, and participation in external events must be

rationalised in line with the existing resources and priorities.

Exchanging experience with other EU agencies is an important means of keeping abreast

with rapid developments in this area. The agency is a member of the inter-agency Heads

of Communication and Information network (HCIN), to which it continued to actively

contribute in 2015. One of the highlights of this contribution was the organisation, jointly

with the European Training Foundation in Turin and neighbour agency EMSA, of the Data

Visualisation Workshop (held on 16–17 July 2015 in Lisbon). The event brought together

almost 90 participants from European Commission and EU agencies that are members of

HCIN. The three organising agencies provided an update of their work on data

visualisation and presented recent projects. Topics included ‘Data, story, chart, design’;

‘Flat graphics: how to tell stories and designing visual stories’; and ‘The right chart:

interactive data visualisation’.

In order to enhance their visibility and increase uptake by

audiences, all of the EMCDDA products in 2015 were

launched via news releases, fact sheets, news items,

newsletters, the website and social media, when

appropriate. A total of 23 campaigns were publicised in 2015

via ‘Mailchimps’, which issued, for instance, ‘Just published’

e-mail updates, best practice updates, summer school

updates and information about Lisbon Addictions 2015.

In terms of the web presence, the structure and metadata of

the EMCDDA website were adjusted to improve the

‘findability’ of information.

There were approximately 990 000 unique visitors to the

EMCDDA website in 2015 and 1.23 million unique page views.

Social media activities were particularly dynamic in 2015. An external consultancy contract

was launched to take stock and assess the progress made so far in this regard, and to gather

ideas on how the agency can develop its social media channels further. In this context,

attention was paid to better tailoring the content of these channels for their audiences.

The EMCDDA successfully increased its social media presence on Facebook, Twitter and

LinkedIn. In addition, its audio-visual service has been further developed. EMCDDA

videos were viewed nearly 25 000 times in 2015. For the first time, multilingual content

was offered on YouTube (the EDR 2015 motion graphic was made available in French,

German, Polish, Portuguese and Spanish). Furthermore, a ‘live’ Twitter account was

established to cover two high-profile meetings — ‘Responses to NPS’ (see Main Area 3)

and ‘Women and drugs’ (see Main Area 8). At the end of 2015, we had 6 800 followers on

Twitter.

In addition, the EMCDDA organised, or was at least represented at, several prominent

events throughout 2015. To name but a few, the agency had displays at the 58th

session of the CND (Vienna, 9–17 March); the ‘Exhibition Futurália, Representation of

the European Commission in Portugal’ (Lisbon, 11–14 March); the third Contemporary

Chapter 5 I Supporting the achievement of results

65

Drug Problems conference: ‘Encountering alcohol and other drugs’ (Lisbon, 16–17

September); Lisbon Addictions 2015 (Lisbon, 23–25 September); and the 2nd

international conference on ‘Wastewater-based drug epidemiology’ (Ascona,

Switzerland, 11–15 October).

Annex 4 presents a comprehensive list of events attended by EMCDDA staff in 2015.

A number of feature articles were written for specialised journals and magazines. A more

comprehensive campaign to promote the EDR was introduced with audio-visual

elements, and advertisements were posted on viEUws, E!Sharp, EP magazine, etc.

Building sound contacts and relationships with journalists and providing media-friendly

information continued to be priorities in 2015. During the year, 11 news releases, 10 fact

sheets, 14 web news items and one feature article were released to mark major events. In

total, 36 items were issued in 2015, almost 10 % more than in 2014.

In 2015, 331 requests were received by the press office, which was 86 more requests

than the previous year; this shows constant and significant annual growth (166 requests

in 2012, 194 in 2013, and 245 in 2014). Timely responses were ensured to all these

requests. Furthermore, in line with the communication strategy, a new product (‘A look

ahead’) aimed at improving the advance warnings given to journalists ahead of key events

was launched, and two editions of this new product were released prior to EDR

2015-related events and Lisbon Addictions 2015. Two media training courses were also

organised in 2015: one to prime staff members on key messages ahead of the EDR launch

and one that focused specifically on crisis communication. These courses resulted in

a final training report at the end of the year.

The full EDR 2015 package was launched to the media on 4 June at a press conference in

Lisbon in the presence of Dimitris Avramopoulos, European Commissioner responsible

for Migration, Home Affairs and Citizenship. Also on the panel were the Chairman of the

EMCDDA Management Board, João Goulão, the EMCDDA Director, Wolfgang Götz (who

presented the main findings), and the EMCDDA Scientific Director, Paul Griffiths. In

addition to the visiting journalists, a further 27 journalists from the Portuguese media and

foreign press in Portugal attended the press conference, bringing the total to 51. This is

the highest number of journalists that have attended an EDR press conference since the

EMCDDA began launching the report in Lisbon in 2010. There were 2 871 items of media

coverage of this launch, which was 40 % more items than in 2014.

Visits are another important aspect of the communication policy of the agency. They

support the EMCDDA in its role as an information agency and help to promote its

reputation as the ‘reference point on drugs in Europe’. Target groups are perceived as any

groups with a potential interest in EMCDDA outputs and authoritative information on

drugs. This approach is in line with the ‘European Parliament resolution of 29 April 2015

on discharge in respect of the implementation of the budget of the EU agencies for the

financial year 2013: performance, financial management and control’, in which the

European Parliament invites EU agencies to expand their visibility in order to ensure that

European citizens are well informed, in a transparent manner, about EU agencies’ work.

In 2015, EMCDDA staff coordinated or organised 50 visits for external parties, involving

468 visitors, meaning that, on average, the EMCDDA received approximately one visit per

week. The number of visitors in 2015 was 15 % more than it was in 2014 (407 visitors);

this reflects a growing interest in the agency’s activities. These visits help to improve

visitors’ understanding of the EMCDDA’s mandate and activities. Visitors included

General Report of Activities 2015

66

students from the Netherlands, France and Germany, lawyers of the Regional Courts of

Germany, and interpreters from the European Parliament.

Other types of visit focused more on discussions about possible cooperation and

exchanges of technical knowledge in specific scientific areas. In 2015, such visits

included those by the Regional Director for the Europe and Africa Division and the

Regional Intelligence Manager of the Drug Enforcement Agency (DEA) of the USA; the

Chief Scientist of the ECDC; the Home Office Director-General of Crime and Policing

Group of the United Kingdom; a representative of the National Crime Agency of the United

Kingdom; and professionals working in the drug and alcohol field in regional competence

centres in Norway.

There was also a high level of interest in the EMCDDA’s activities among policymakers

and professionals from third countries. For example, leaders of treatment centres from

Switzerland, a delegation from the Ukraine Ministry of Health, university students from

the USA, representatives of the Family Drug Treatment Court of Melbourne, Australia,

a Judge of the Supreme Federal Court of Brazil and the Deputy Director-General of the

Centros de Integración Juvenil of México visited the agency in 2015.

Supporting scientific knowledge and research

In 2015, the EMCDDA ensured the availability of an efficient public information desk,

which operated in line with guidelines set by the European Ombudsman. A total of 149

enquiries made to enquiries@emcdda.europa.eu were responded to promptly.

In addition, tailored information was proactively distributed to EMCDDA staff, and

literature searches were carried out to support projects. The library answered over 620

individual requests during the year (compared with 540 in 2014). Over 1 500 resources in

various media were also ordered, catalogued and made available.

I Governance, management and networks (Main Area 10)

The year 2015 was the final year of the EMCDDA’s three-year strategy and work

programme for 2013–15. It therefore closed a multi-annual planning cycle in the life of the

EMCDDA, during which important projects that were designed to contribute to the

triennial key expected results were completed.

At the same time, 2015 was a crucial year for shaping the future of the EMCDDA, as it saw

the adoption, by the Management Board, of the agency’s new strategy and work

programme for 2016–18.

There was also a change in the leadership of the agency in 2015. The 10-year mandate of

the EMCDDA Director, Wolfgang Götz, came to an end, and the new Director, Alexis

Goosdeel, was appointed by the Management Board.

Chapter 5 I Supporting the achievement of results

67

I Highlights and main achievements

Management

The management of the agency was the responsibility of the EMCDDA Director, who was

supported by his team of managers, namely the heads of units, who were, in turn,

assisted by the heads of sectors.

Regular heads of unit meetings were held throughout the year. These meetings are the

agency’s main managerial forum, during which both strategic and operational issues are

addressed. Furthermore, regular scientific coordination meetings took place during the

year, involving the heads of unit, and the heads of sector, from the Scientific Division.

The main issues on the agenda were regular reviews of the performance with regard to

implementing the agency’s work programme, the preparation and implementation of the

new programming cycle introduced by Article 32 of the EMCDDA’s Financial Regulation

(see the section ‘Strategic planning, monitoring and reporting’ later under this area), and

measures to ensure efficient budget execution, to name just a few.

In the final part of 2015, after the appointment of the new EMCDDA Director, ongoing

dialogue and close collaboration took place between the outgoing and the incoming

directors with a view to preparing the ground for the start of the new EMCDDA Director’s

mandate, effective from 1 January 2016.

EMCDDA Director — main activities in 2015

As in previous years, the Director, through his external activities, contributed to increasing

the visibility of the EMCDDA and consolidating the credibility of its work by building and

improving partnerships.

For instance, Director Götz strengthened relationships with the European Parliament. In

January 2015, he had a working lunch in Brussels with the President of the European

Parliament, Martin Schulz. On 21 January, Mr Götz attended a meeting of the LIBE

Committee, during which he presented the EMCDDA’s work programme for 2015, as well

as an overview of the situation in Europe with regard to NPS. At the end of January, he

also participated in an exchange of views between the members of the LIBE Committee

and European members of the Global Commission on Drug Policy (GCDP). The Director

presented the European Drug Report 2015: Trends and Developments to the LIBE

Committee on 17 June. The MEP Tomáš Zdechovský, member of the CONT (Committee

on Budgetary Control) and LIBE Committees and Shadow Rapporteur for the Discharge

of Agencies for the year 2013, visited the EMCDDA on 13 May.

Throughout the year, the Director had regular meetings with the European Commission’s

services, including meetings with the Cabinet of Commissioner Avramopoulos and the

Director-General of Migration and Home Affairs, Matthias Ruete.

With regard to building relationships with the other EU agencies, the Director participated in

two meetings of the Heads of Agencies and organised the Fifth Informal Strategy Meeting of

the Heads of Home Affairs Agencies, held on 8–9 May in Grândola (Portugal), which was also

attended by the Director-General for Migration and Home Affairs.

General Report of Activities 2015

68

In March 2015, the Director participated in

the high-level segment of the 58th session of

the CND, and in December, he participated in

the reconvened 58th session of the CND

organised by the UNODC and held in Vienna.

Mr Götz had bilateral meetings with EU

Member State ambassadors and attended

a number of receptions held to mark

national days at the embassies of various

EU and non-EU countries.

On 8 September, Mr Götz was awarded the

Grand Decoration of Honour in Gold for

Services to the Republic of Austria in

a ceremony hosted by the Austrian

Embassy in Lisbon.

The award was bestowed on Mr Götz by His

Excellency the Ambassador of Austria, Thomas Stelzer, on behalf of the President of the

Federal Republic of Austria, Dr Heinz Fischer.

Tribute to Wolfgang Götz, EMCDDA Director between 2005 and 2015

EMCDDA Director Wolfgang Götz (centre) receives the Grand Decoration of Honour in Gold

for Services to the Republic of Austria on 8 September in Lisbon. Left: Ambassador of

Austria, Thomas Stelzer; right: Vice-Chair of the EMCDDA Management Board, Franz Pietsch

Director Wolfgang Götz ended his two mandates as leader of the EMCDDA on 31 December 2015. He joined the agency in December 1996, when he was recruited to head the agency’s then Information unit, to oversee, among other things, the early editions of the Annual report on the state of the drugs problem in Europe.

In April 2005, the EMCDDA Management Board appointed him as EMCDDA Director for an initial five-year term. His mandate was unanimously renewed by the Management Board for a second five-year term, which began on 1 May 2010.

Throughout his tenure as Director, Wolfgang fought hard to attract and secure the best possible personnel and budget for the agency; empower staff; build sound working relationships with the Management Board and Scientific Committee; secure the partnership with the Reitox NFPs; and improve the quality and relevance of EMCDDA products and services.

Wolfgang Götz, EMCDDA Director 2005–15

Data protection activities

Data protection activities were carried out throughout the year, in order to ensure

compliance with rules applicable to EU bodies (Regulation (EC) 45/2001). Some of the

issues addressed included data protection aspects of access to the SIENA (Secure

Information Exchange Network Application) database (Europol); declarations of conflicts

of interest; future EDPS (European Data Protection Supervisor) guidelines on mobile

devices; the recording of images during public events; privacy statements for public

events; and security clearance procedures.

The data protection officer (DPO) participated in two DPO network meetings. The first one

took place in Luxembourg, in June 2015, and the second in Athens, Greece, in November

2015. These meetings have three purposes: firstly, they serve as important training

activities (mainly on future data protection regulations); secondly, they allow contacts

Chapter 5 I Supporting the achievement of results

69

with EDPS services (i.e. on the future compliance survey) to be maintained and

developed; and, finally, they provide an excellent framework for the development of

synergies among the different institutions and bodies of the EU (as is the case with the

European Fisheries Control Agency.

Strategic planning, monitoring and reporting

The General Report of Activities 2014 (47) was published online on 12 June 2015 and sent,

on the same day, to the European Parliament, the Council, the European Commission and

the European Court of Auditors (ECA), as required by the EMCDDA’s recast Founding

Regulation. The content and format of the 2014 report were improved, in comparison with

previous years, and they were fully aligned with the template for the Consolidated Annual

Activity Report for decentralised agencies, as provided in Communication from the

European Commission Communication C(2014) 9641, issued in December 2014.

The communication companion of the general report, entitled A year in review: Highlights

from the EMCDDA’s General Report of Activities 2014, was also published in June

2015 (48). Both documents were printed and made available for dissemination at an event

held on 26 June.

In terms of monitoring the EMCDDA’s activities, a 2015 mid-year monitoring exercise was

conducted and the corresponding performance report was submitted to internal

stakeholders. The report included a comprehensive annex dedicated to the KPIs that the

agency had, for the first time, defined for all the main areas of its annual work programme.

The 2016–18 strategy and work programme and the 2016 work programme were adopted

as parts of a single document by the Management Board in December 2015. This

document was structured into two parts: Part I presents the EMCDDA’s multi-annual work

programme for 2016–18, while Part II introduces the EMCDDA’s annual work programme

for 2016, which will be the first annual work programme in the new three-year strategic

cycle. The EMCDDA implemented this new approach in response to the requirement to

submit a single multi-annual programming document (SPD), as of January 2016, that is,

once Article 32 of the EMCDDA Financial Regulation enters into force.

According to Article 32, by 31 January 2016, the agency will be obligated to submit a SPD

to its stakeholders; this SPD will incorporate the information currently contained in four

different programming documents, namely the multi-annual work programme, the

relevant annual work programme, the applicable multi-annual staff policy plan (MASPP)

and a financial statement. The SPD will need to be updated each year, on a rolling basis.

In parallel, the agency started to develop its first SPD, for 2017–19. The draft document,

which was submitted to the European Parliament, the Council, the European Commission

and the Scientific Committee on 29 January 2016, was fully aligned with the template

provided by the guidelines for programming for decentralised agencies issued by the

European Commission as part of Communication C(2014) 9641 in December 2014.

(47) Available at: emcdda.europa.eu/publications/gra/2014(48) Available at: emcdda.europa.eu/publications/gra/2014-highlights

General Report of Activities 2015

70

Reitox national focal points

In fulfilling its tasks, the agency relies on a large number of partners and, in particular, the

Reitox NFPs. The NFPs exercise the critical role of providing national data from the 30

countries that report to the EMCDDA, namely the 28 EU Member States, Norway and

Turkey. Together with information collected from other networks of experts and partners,

these data feed the European and global analyses performed by the EMCDDA, thereby

forming the basis of its world-renowned knowledge and reputation as a centre of

excellence on drugs in Europe.

In 2015, Reitox coordination tasks focused on two main priorities and challenges: to

coordinate the implementation of the first phase of the revised national reporting system

(see Main Area 1); and to provide adequate institutional and capacity development

support to the NFPs.

The main priority for this area was therefore to support the NFPs with the implementation

of the first phase of the revised national reporting package. Ongoing dialogue took place

throughout the year between the EMCDDA and the NFPs, and progress was extensively

discussed at both meetings of the HFPs held in 2015. As a result, successful

implementation was achieved by the end of this phase: all the NFPs submitted the five

mandatory workbooks and 25 out of the 30 countries submitted all 10 workbooks.

REITOX MEETINGS IN 2015

16–18 June

24–26 November

Lisbon

Lisbon

52nd meeting of the heads of focal points

53rd meeting of the heads of focal points

EMCDDA strategy and work programme for 2016–18: This is the fourth strategy and work programme since the EMCDDA’s Founding Regulation was recast in 2006. At the heart of the new triennial strategy and work programme is the EMCDDA’s vision to contribute to a more secure and healthier Europe. This overarching commitment will drive the agency in the coming years and guide it in delivering added value to its stakeholders. Knowledge transfer, strategic analysis and threat assessment will be the main drivers for the achievement of this goal.

There are three main challenges for our work over the coming period: (1) to gain a better understanding of the global dimension of the drugs problem we face in Europe; (2) to respond more quickly to emerging threats and challenges; and (3) to become more solution oriented in our reporting.

As an organisation, the EMCDDA will be guided by a core set of values in order to ensure that its work is of the highest standard. These values are scientific rigour; neutrality and independence; and service orientation.

In terms of structure, the new strategy and work programme is built around six strategic action areas, composed of three key areas: ‘Communicating evidence and knowledge exchange’; ‘Early warning and threat assessment’; and ‘Situation, responses and trend analysis’. There are also three cross-cutting areas: ‘Information collection and management’; ‘Quality assurance’; and ‘Cooperation with partners’. Together, these areas cover the agency’s core tasks and form the conceptual building blocks needed to assemble a comprehensive understanding of the European drug phenomenon. This structure reflects the EMCDDA’s production flow as an information agency, from inputs to outputs, through monitoring and analysis processes.

In addition, two corporate areas – ‘Governance’ and ‘Administration and ICT’ – will provide the management and support activities that are key to ensuring that the work planned within the strategic areas can be successfully performed.

Chapter 5 I Supporting the achievement of results

71

The 53rd Reitox meeting was preceded by the fourth Reitox Week (see Main Area 8).

During the first half of 2015, the EMCDDA undertook a detailed desk check of all 2014

grant agreement accounting documents, as provided by the EU Reitox NFPs. A more

detailed on-site verification of the accounting system was undertaken in four Member

States, namely Bulgaria, the Czech Republic, Italy and Slovakia. These on-site verifications

complied with the request for increased control by the European Court of Auditors, and

also allowed bilateral feedback to be given, with a view to improving the financial and

narrative reporting under the framework of the grant agreements signed by all 28 EU NFPs.

Furthermore, two Reitox Academies were organised or supported in 2015, as follows:

• The Regional Reitox Academy ‘Monitoring and responses to new psychoactive

substances’ took place in Krakow, Poland, on 3–4 September. The objective was to

allow experts from the Baltic countries, Poland and the EMCDDA to share knowledge

on different aspects of the NPS phenomenon (i.e. markets, laws, user profiles and

responses) and monitoring methods. A total of 21 participants attended this academy.

• The National Reitox Academy ‘Peer involvement’ took place in Vienna, Austria, on 4

December and was attended by 17 experts from Austria. The academy fostered

discussions on how peer projects can be initiated, under which frameworks; how roles

are distributed among peers and professionals; and what the exclusion and inclusion

criteria are for peers.

In addition, in consultation with Reitox NFPs, progress was made in the development of

an initial reference model for accreditation of the NFPs. Several internal discussions took

place throughout the year in order to define the basic principles and scope of a future

accreditation system. The proposal, which was presented at the 53rd Reitox HFP meeting,

defined the scope of the accreditation and three main domains. The HFPs gave positive

feedback on the project and agreed to cooperate with the EMCDDA in the future

developments in 2016.

The development of the management information system (HERMES), which supports the

technical cooperation activities and the management of grants, continued in 2015. All

2015 grant agreements, including applications and addenda, were fully managed through

the HERMES system. In addition, HERMES was used to manage both HFP meetings

in 2015.

I Administration — supporting core business (Main Area 11)

In line with the goals set for the 2013–15 programming period, enhancing efficiency,

further developing the sound management of available resources and providing service-

oriented administrative support to the EMCDDA’s operations continued to be the main

priorities within Main Area 11 in 2015, along with the application of best practice.

The EMCDDA sustained its active cooperation with other EU agencies on administrative

matters. For instance, EMCDDA staff members were formally appointed to represent all

decentralised EU agencies in the network of EU inter-institutional administrative bodies.

Further synergies with EMSA were also promoted and developed in 2015.

General Report of Activities 2015

72

I Highlights and main achievements

Financial and budget management and accounting

As in the previous year, financial management activities in 2015 also focused on aligning

EMCDDA rules and processes with the revised EU Financial Regulation, pursuant to the

entry into force, on 1 January 2014, of the revised Framework Financial Regulation for EU

Agencies and the new Financial Regulation of the EMCDDA.

With regard to procurement activities, the agency continued to implement measures to

rationalise and optimise tendering and other financial processes, in order to execute the

budget and work programme in close cooperation with all units. The EMCDDA

participated — as an active member of the Network of Agencies Procurement Officers

(NAPO) — in the annual NAPO meeting, organised by the then Office for Harmonization in

the Internal Market (OHIM) (held in Alicante, Spain, on 1–2 October 2015); this offered

further opportunities for experience exchange and provided an update on the status of

different procurement initiatives of the EU bodies.

The implementation of digitalised tools and processes contributed to organisational

efficiency gains; however, progress in this area was dependent on available resources.

Work continued on the development of the ICT-based tool for the management of

missions throughout 2015, and it is expected that the final tool will be ready for launch in

2016. Options for a tool for the electronic management of the working time of EMCDDA

staff were explored, taking into account solutions applied by other agencies in order to

allow synergies.

The EMCDDA, once again, achieved an outstandingly efficient management of its budget

(in terms of execution rate) in 2015: a 99.83 % execution rate was achieved for

commitment appropriations and a 97.4 % execution rate was achieved for payment

appropriations (99.8 % for Title 3 payment appropriations). Historically, these are among

the best results for the EMCDDA (in terms of commitments) and exceed the 2015 targets,

namely for 97 % of the total commitment appropriations (KPI 11.1.1) and 93 % of the total

payment appropriations (KPI 11.1.2) (see Annex 6).

Commitment appropriations 99.83 %

Payment appropriations 97.35 %

Consumption of 2014 (C8) credits 93.69 %

Another important parameter that reveals the outstanding budget performance of the

EMCDDA in 2015 is the rate of cancelled payment credits, which was only 0.25 %; the

benchmark used for EU agencies is 5 % (criterion for penalisation).

This excellent budget execution rate was possible only because of the efforts of all staff

involved across all core business and support areas, as well as the improved budget

management practices applied throughout the year.

In addition, the 2016 budget and a preliminary budget for 2017 were adopted by the

EMCDDA Management Board.

Chapter 5 I Supporting the achievement of results

73

Human resources

The implementation of human resources processes and policies by the EMCDDA, in line

with new EU staff regulations, continued successfully in 2015.

As in the previous year, the EMCDDA continued to play an active, and sometimes leading,

role in discussions held by several inter-agency working groups dedicated to the examination

of different issues of interest for all agencies, such as the application and implementation of

the Staff Regulations of Officials of the European Communities and the Conditions of

Employment of Other Servants of the European Communities (CEOS); the revision of the

service level agreement between all agencies and EU bodies and the DG HR, etc.

An important objective in 2015 was to further develop EMCDDA working and production

capacity by maximising training opportunities for EMCDDA staff. Individual training plans

were set during the annual staff performance appraisal exercise, and training was

delivered in line with the available resources.

The target for 2015 was to provide an average number of three training days per staff

member (KPI 11.2.3 — see Annex 6); as presented in the table below, this target was

overachieved.

TRAINING PROVIDED IN 2015

Total number of training days 473.6

Training courses per staff member (average) 1.9

Training days per staff member (average) 4.6

Budget spent on training (EUR) 51 913

Infrastructure and logistics

In the area of logistics and infrastructure management, ensuring a healthy and safe

working environment remained the key priority in 2015. Another priority was to further

optimise the use of space and the functioning of existing facilities. Special attention was

given to the development of solutions for business continuity. In this context, the agency

signed a MoU with EMSA agreeing that EMSA will host the EMCDDA business continuity

systems in its data centre in Madrid (see Main Area 12).

As a result of the annual risk assessment that was delivered in 2015, the information

included in the risk registry was adapted. After the terrorist attacks in November 2015 in

Paris, the agency, in accordance with recommendations from the European Commission,

tightened up its security measures and put the ‘yellow alert code’ into force.

The new internal EMCDDA environmental policy was further implemented in 2015. The

aim of this policy is to adopt an environmental management system that ensures that the

agency complies with EU norms and achieves further savings.

In the same regard, the agency continued to contribute to the Greening Network, whose

ninth annual meeting was organised by the European Food Safety Authority (EFSA) (and

held in Parma, Italy, on 17–18 September 2015); the EMCDDA provided technical input

for this meeting.

General Report of Activities 2015

74

Further measures to rationalise the costs of utilities and service contracts were

implemented in 2015. The identification of health and safety risks for staff remained one

of the main priorities of the agency, as well an increase in effectiveness, efficiency gains

and cost savings through the creation of further synergies with EMSA.

I Information and communication technology (ICT) (Main Area 12)

ICT programmes and services support the agency’s core objectives and guarantee the

smooth operation of all services. They include ICT support for day-to-day work processes,

the maintenance and hosting of enterprise applications, and the management of the data

centre.

Three overarching ICT priorities were identified in the 2013–15 work programme: to

develop and maintain instruments for supporting core business; to implement a ‘business

and information architecture management’ programme; and to implement a ‘technical

services management’ programme, including ongoing service management. These

priorities guided ICT-related work in 2015.

I Highlights and main achievements

Fonte, the EMCDDA’s web-based data collection instrument, and the Drugs Data

Warehouse are the main applications that support the agency’s data collection, validation

and analysis. A substantial part of the work in the area of ICT was dedicated to

maintaining and adjusting these applications to the needs of the 2015 work programme.

A major Fonte update (version 3.0) was developed in 2015. Updates were also applied to

the analytical drugs database.

With regard to the website development project, work continued in close collaboration

with the Communication unit and the other core business units. The production

architecture was defined and set up to support the new platform, the configuration was

refined, penetration tests were performed, and architecture reviews were launched to

mitigate risks and allow full implementation in 2016 (see also Main Area 9).

Further developmental work was carried out on the EDND in order to adapt the tool to the

requirements imposed by the monitoring of NPS, which are appearing on the market at an

unprecedented rate (see Main Area 5). However, the progress made in 2015 was slower

than expected. The EDND is extremely complex, and, therefore, this project requires

significant investment, not only in terms of money, but also in terms of human resources

(e.g. business owners, scientific analysts and ICT staff). These resources were heavily

involved in other level 1 priorities (particularly the management of the EU EWS); therefore,

it was difficult to make any real progress on the development of the EDND. In addition,

again because of project complexity, difficulties were encountered by the internal

business owners with regard to working with the deliverables provided by contractors.

Additional efforts were made to support corporate and administrative projects. This

included the development of a management information system to support the new

performance measuring system (see also Main Area 10). However, progress was also

slower than planned in this area, because of the need to prioritise, from the point of view of

Chapter 5 I Supporting the achievement of results

75

the business owner, the work on the new planning instruments imposed by the Financial

Regulation (see Main Area 10), and, from the ICT perspective, the work on level 1 projects.

Other projects were related to the development of solutions for missions and human

resources management (see Main Area 11), for which work progressed in line with

available resources.

The implementation of the project management methodology approved by the ICT

Steering Committee in 2012 continued and 100 % of the active projects classified as

‘business projects’ by the ICT steering committee were managed accordingly. This was

one of the annual targets for the area, and it was fully achieved (KPI 12.1.1 — see

Annex 6).

The further execution of the ‘Business and information architecture management’

programme was carried out in 2015 through the conclusion of an ex post evaluation on

information security. Work in this area will continue in order to encompass the planning of

business/IT architecture development and its technical implementation, while trying to

keep pace with the changing global landscape of ICT architectures and the related

threats to security and privacy.

The majority of resources were, however, earmarked for the ongoing service management

programme, which accounts for most of the effort dedicated to business-as-usual

services. In addition, measures to rationalise the use of resources and to improve

organisational performance were taken through enhanced cooperation with other

agencies, as well as through the use of shared framework contracts for the acquisition of

services and equipment. In this context, in 2015, the EMCDDA signed a MoU with EMSA

agreeing that EMSA will host the EMCDDA business continuity systems in its data centre

in Madrid.

After an audit by the Internal Audit Service of the European Commission (IAS) on ICT

project management in September 2015, efforts were reinforced to improve ICT project

management. The selection of a project management platform for ICT projects was

finalised in 2015. The further development of the role of the ICT steering committee and

the implementation of best practice are also part of this intervention.

II

77

PART II

Management and internal control systems: annual activity report as

per the Financial Regulation applicable to the EMCDDA

Chapter 1Management

Chapter 2External evaluations

Chapter 3Assessment of the effectiveness of the

internal control systems

Chapter 4Management assurance

1

79

I Management Board

I Main decisions

As usual, the Management Board met twice in 2015, on 9–11 September and

3–4 December.

At the September meeting, the Management Board congratulated Wolfgang Götz, who

was awarded, on 8 September 2015, the Grand Decoration of Honour in Gold for Services

to the Republic of Austria. The award was bestowed by His Excellency the Ambassador of

Austria, Dr Thomas Stelzer, on behalf of the President of the Federal Republic of Austria,

Dr Heinz Fischer. Dr Franz Pietsch, the representative of Austria with regard to

international matters of addiction and drug issues, Deputy Director-General and Head of

Department for Tobacco, Alcohol, Non-substance-related Addictions and International

Affairs of Addiction at the Austrian Federal Ministry of Health, nominated Mr Götz for the

award in appreciation of his accomplishments in the drugs field in general, and in Austria

in particular, and the sound relationships he has forged with the country.

On 10 September 2015 the Management Board decided to select Alexis Goosdeel as the

candidate for the appointment as EMCDDA Director for a five-year term, starting on 1

January 2016. The Board gave the Executive Committee the mandate to adopt, on behalf

of the EMCDDA Management Board, the formal decision on the appointment of the

selected candidate, after the statement made by the Director-elect before the European

Parliament and the answers provided to the questions put by the members of this

institution, as required by the EMCDDA Founding Regulation for first-term appointments.

This exchange of views took place on 22 September at the European Parliament in

Brussels, and the Chair of the LIBE Committee gave a positive opinion to the Chair of the

Management Board on 29 September. On the basis of the positive opinion of the

European Parliament, the EMCDDA Executive Committee adopted, by written procedure,

on behalf of the Management Board, a formal decision on the appointment of the new

Director. The decision of appointment and a contract to engage the appointed Director

was signed by the Chairman of the Board on 15 October.

After an overview by the European Commission on the state of affairs and the priorities

for the years to come, the Management Board first discussed the strategic priorities of the

EMCDDA strategy and work programme for 2016–18. The Board adopted the tools to

implement the EMCDDA policy for the prevention and management of conflicts of

interest, which concern Management Board and Scientific Committee members. The

Board also decided to close the follow-up process to the recommendations made by the

last external evaluation of the EMCDDA, which was completed in 2012. Finally, the Board

mandated the Director to sign a MoU between the EMCDDA and the Ministry of Justice of

Georgia.

CHAPTER 1Management

General Report of Activities 2015

80

Norway presented the aims and thematic priorities of its current Presidency of the

Pompidou Group of the Council of Europe, while Portugal updated the Board members on

the preparation of the first European conference on addictive behaviours and

dependencies, Lisbon Addictions 2015, held in September 2015. The Director provided

feedback on the launch of the EDR to the European press, which took place on 4 June at

the EMCDDA’s headquarters in Lisbon in the presence of Commissioner Avramopoulos

and 51 journalists. He further informed the Board that a new technical cooperation

project for IPA beneficiary countries, referred to as IPA 5, started on 1 July 2015 and will

run for 24 months. Finally, the Management Board discussed a letter from the Federal

Department of Home Affairs of the Swiss Confederation of 7 August 2015 expressing

interest in a more formal framework for cooperation with the EMCDDA, possibly by means

of a MoU. It was agreed that the European Commission would consult with the EEAS and

then provide the members of the Board with an opinion.

At its 52nd meeting on 3–4 December 2015, the Management Board adopted the

EMCDDA’s 2016–18 strategy and work programme, together with the 2016 work

programme, on which the European Commission and the EMCDDA Scientific Committee

gave a favourable opinion.

The Board also adopted the EMCDDA’s 2016 budget and preliminary budget for 2017,

both of which were based on an EU subsidy of EUR 14 794 000. The budget for 2016 is

based on EUR 14 794 000 of main revenue, to be provided by the EU 2016 subsidy to the

EMCDDA; EUR 389 962, which is the contribution expected from Norway; and

EUR 210 000, which is the contribution expected from Turkey for its third year of

participation in the work of the EMCDDA. The preliminary draft budget for 2017 is based

on EUR 14 794 000 of main revenue, to be provided by the EU 2017 subsidy to the

EMCDDA; EUR 389 962, which is the contribution expected from Norway; and

EUR 271 000, which is the contribution expected from Turkey.

Laura d’Arrigo (France), Diplomatic Advisor of the French Interministerial Mission for

Combating Drugs and Addictive Behaviours (Mission interministérielle de lutte contre les

drogues et les conduites addictives (MILDECA)), was elected as Chair for a mandate of

three years, from 1 January 2016 to 31 December 2018. Franz Pietsch (Austria) was

elected as Vice-Chair for the same period.

Claude Gillard (Belgium) was re-elected as a member of the Budget Committee for

a mandate from 1 January 2016 to 31 December 2018. The Management Board also

unanimously elected Mr Gillard as Chair of the Budget Committee. João Goulão

(Portugal) and Susan Scally (Ireland) were elected as members of the Executive

Committee for the same period.

In line with the provisions of Article 32 of the Framework Financial Regulation applicable

to EU agencies and of the EMCDDA Financial Regulation, the Management Board

unanimously adopted the definition of ‘non-substantial amendments’ to the annual work

programme as proposed by the Director, and delegated the power to make such ‘non-

substantial amendments’ to the EMCDDA Director.

The mandate of the EMCDDA Scientific Committee and the validity of the current reserve

list will expire at the end of 2016. The current members indicated that they would like to

continue to serve for the period 2017–19. Upon recommendation by the Executive

Committee, the Management Board decided to renew the mandate for the current

members of the EMCDDA Scientific Committee for a further three-year period from 2017

to 2019, and to extend the validity of the reserve list for the same period.

Chapter 1 I Management

81

The Management Board adopted a temporary modification to the organisational structure

of the EMCDDA. The former ‘Governance’ unit was merged with the ‘Reitox and

international cooperation’ unit to give a new ‘Reitox and external partners’ unit, in order to

group the activities related to relationships between the EMCDDA and its external

partners under the same umbrella. In addition, the ‘Executive Office’ was created to

support the Director with the drafting and implementation of the long-term strategy for

2025, and with the monitoring and reporting on the execution of the three-year and

annual work programmes, including the KPIs, and financial analysis and budgetary

monitoring. The Board also adopted the charter of the EMCDDA accounting officer.

The Management Board considered that ‘Business continuity’ and ‘Management of data

collection, validation and quality assurance’ should be the only topics audited by the IAS

under the Strategic Internal Audit Plan for 2016–18. The Board decided that the

cooperation between the EMCDDA and Switzerland should be clarified through an

exchange of letters that clearly specify the areas of cooperation, after the signing of

working arrangements between the European Commission, represented by DG HOME as

the agency’s partner DG, and the EMCDDA on the agency’s international activities.

The Board took note of an assessment of the implementation of the KIs in Europe and an

overview of recent developments in the implementation of the international cooperation

strategy with third countries and international organisations, and EU agencies. Finally, the

Management Board members welcomed the conclusions presented by Portugal about

the first European conference on addictive behaviours and dependencies (Lisbon

Addictions 2015), which took place in Lisbon on 23–25 September 2015.

MEETINGS OF THE MANAGEMENT BOARD

9–11 September

3–4 December

Lisbon

Lisbon

51st meeting of the Board

52nd meeting of the Board

I Executive Committee

I Main decisions

In 2015, the Executive Committee met three times in Lisbon (see box below).

At its meeting on 13 May, the Executive Committee commented on the draft agenda and

documents of the subsequent Management Board meeting of 9–11 September. The

Executive Committee discussed, in particular, in restricted session, the procedure for the

appointment and selection of the EMCDDA Director. The Executive Committee further

adopted, on behalf of the Management Board, the proposed implementing rules related to

the engagement and use of temporary staff under Article 2(f) of the CEOS, the annual

appraisal of officials and temporary agents, and the annual appraisal of contract agents.

On 9 September 2015, the Executive Committee prepared for the Management Board

meeting starting later that day. The Executive Committee prepared for the selection of the

new EMCDDA Director by the Management Board on 10 September and addressed the

issue of possible conflicts of interest, which was raised by the Commission after the

adoption of the shortlist of candidates. The Executive Committee agreed to recommend

to the Management Board that the mandate for the current members of the EMCDDA

General Report of Activities 2015

82

Scientific Committee be renewed for a further three-year period, from 2017 to 2019, and

to extend the validity of the reserve list for the same period, at the Board meeting of

December 2015. The Executive Committee also adopted general provisions for leave on

personal grounds for officials and unpaid leave for temporary staff and contract staff, on

behalf of the Management Board.

On 22 September 2015, the Director-elect, Alexis Goosdeel, made a statement and

answered questions put by members of the LIBE Committee. On the basis of the positive

opinion of the European Parliament, the EMCDDA Executive Committee adopted, by

written procedure, on behalf of the EMCDDA Management Board, a formal decision on

the appointment of the new Director.

The Executive Committee passed in review on 2 December the items of the draft agenda

of the Management Board meeting of 3–4 December, and prepared the election of the

new Chair and Vice-Chair of the Board. An addendum to the MoU between the Ministry of

Health of Ukraine and the EMCDDA was discussed, in order to take into consideration the

fact that the state agency the Ukrainian Monitoring and Medical Centre on Drugs and

Alcohol of the Ministry of Health of Ukraine (UMMCDA) had become the competent

authority for collecting and processing information on drugs and on the alcohol situation

in Ukraine. It was agreed that the European Commission would consult the EEAS and the

EU delegation in Ukraine on this matter before an exchange of letters between the

EMCDDA and the UMMCDA may take place. The Executive Committee further exchanged

views on a decision of the Director on a working language for day-to-day administration

and internal communication at the EMCDDA.

At the beginning of each meeting of the Executive Committee, the Chair of the Budget

Committee reported on the conclusions of the meetings held prior to the Executive

Committee meetings, and the recommendations made by the Budget Committee.

MEETINGS OF THE EXECUTIVE COMMITTEE

13 May

9 September

2 December

Lisbon

Lisbon

Lisbon

I Summary of main events

In 2015, there were a number of events which will have an important impact on the agency

in the future. These events were the election of a new Chair and a new Vice-Chair of the

Management Board; the selection of a new EMCDDA Director; the temporary modification

of the organisational structure of the agency; and the adoption, by the Management Board,

of a new EMCDDA three-year strategy and work programme. All these events are

presented in detail in earlier sections of this report and a summary is provided below.

I The selection of a new EMCDDA Director

The Management Board decided on 10 September to select Alexis Goosdeel as the

candidate for the appointment of EMCDDA Director for a five-year term, starting 1 January

2016. This was followed, on 22 September, by a statement made by the Director-elect before

the European Parliament. He then answered questions put to him by the members of this

Chapter 1 I Management

83

institution, as required by the EMCDDA Founding Regulation in cases of an appointment for

a first term. On the basis of the subsequent positive opinion of the European Parliament, the

EMCDDA Executive Committee adopted, by written procedure, on behalf of the EMCDDA

Management Board, the formal decision to appoint the new Director.

I The elections of a new Chair and Vice-Chair of the Management Board

Laura d’Arrigo (France), Diplomatic Advisor at MILDECA, was elected as Chair, with

a mandate of three years, from 1 January 2016 to 31 December 2018. Franz Pietsch

(Austria) was elected as Vice-Chair for the same period.

I The adoption of a temporary modification of the organisational structure of the EMCDDA

In December 2015, the Management Board adopted the following temporary change in

the organisational structure of the EMCDDA: the former ‘Governance’ unit was merged

with the ‘Reitox and international cooperation’ unit under a new ‘Reitox and external

partners’ unit, in order to group activities related to relationships between the EMCDDA

and its external partners under the same umbrella. In addition, the ‘Executive Office’ was

created to support the Director with the drafting and implementation of the long-term

strategy for 2025, and with the monitoring and reporting on the execution of the three-

year and annual work programmes, including the KPIs, and financial analysis and

budgetary monitoring.

I The adoption of the EMCDDA’s 2016–18 strategy and work programme

The Management Board adopted, at its 52nd meeting on 3–4 December 2015, the new

EMCDDA three-year strategy and work programme, together with the 2016 work

programme, on which the European Commission and the EMCDDA Scientific Committee

gave favourable opinions.

I Budgetary and financial management

I Information in the report on budgetary and financial management (Article 93 of the Framework Financial Regulation)

Information on budgetary and financial management is covered by the report included in

the EMCDDA Annual Accounts 2015 (available on our website).

In terms of procurement execution, the procurement plan was put in place, in line with the

EMCDDA 2015 management plan, and successfully executed in close collaboration with

all units.

General Report of Activities 2015

84

Tendering 2015 figures

Number of direct

contracts

Number of framework contracts

Negotiated procedures — disp. Article 134 — Rules of implementation of the Financial Regulation (exceptional procedures)

0 0 0

Negotiated procedure — single tender (a) 106 106 0

Negotiated procedure — at least three candidates 6 6 0

Open procedures 4 2 2

European Commission frameworks joined 2

(a) including appointment letters and low-value contracts

The negotiated procedures launched during the course of the year are outlined in the

table below.

Negotiated procedures launched in 2015

Value (EUR)

Works Supplies Services Total for 2015

Number of contracts

Volume of contracts

(EUR)

Number of contracts

Volume of contracts

(EUR)

Number of contracts

Volume of contracts

(EUR)

Number of contracts %

Volume of contracts

(EUR)%

> 1 000 and ≤ 15 000 10 50 927.45 18 67 115.27 78 562 727.16 106 91.38 680 769.88 37.62

> 15 000 and ≤ 60 000 0 0 3 93 153.62 3 143 080.00 6 5.17 236 233.62 13.05

> 60 000 0 0 1 47 771.00 3 845 000.00 4 3.45 892 771.00 49.33

Total 10 50 927.45 22 208 039.89 84 1 550 807.16 116 100 1 809 774.50 100

I Summary information on budgetary operations for 2015 in terms of budget operations, revenue and expenditure

The information about the appropriations transferred in 2015 can be found in the report

on budgetary and financial management included in the EMCDDA Annual accounts 2015.

The EMCDDA Management Board approved two amending budgets in 2015, which were

duly published.

In 2015, the EMCDDA received 100 % of the revenues envisaged in its 2015 budget. In

this context, the EMCDDA once more achieved an outstanding performance in terms of

budget execution, which is reflected by the following rates of execution: 99.83 % for

commitment appropriations, which is the best performance in EMCDDA history; 97.35 %

for payment appropriations; 93.70 % for appropriations carried forward from 2014; and

0.2 % for cancelled/non-used payment appropriations.

I Human resources management

I Major human resources events

The work to align the EMCDDA human resources processes and policies with the reform

of EU staff regulations continued in 2015. This included, in particular, the adoption of

implementing provisions for the use and appraisal of temporary staff. Furthermore,

a more structured process was put in place for the definition and implementation of

annual training plans.

Chapter 1 I Management

85

A table detailing the number of days of leave authorised to each function group and grade,

in accordance with the rules in force concerning flexitime and compensatory leave, is

presented below.

Number of days of leave authorised to each grade under the flexitime and compensatory leave schemes, 2015

Function group and grade Number of days Function group and grade Number of days

AD5 1.5 AST9 0

AD6 29.5 AST10 0.5

AD7 23.0 AST11 0

AD8 42.5 GFI1 0

AD9 18.5 GFI2 0

AD10 5.0 GFI3 11.0

AD11 12.5 GFII4 0

AD12 14.0 GFII5 0

AD13 0 GFII6 27.0

AD14 0 GFII7 30.0

AD15 0 GFIII8 0

AD16 0 GFIII9 5.5

AST1 0 GFIII10 9.5

AST2 0.5 GFIII11 0

AST3 2.5 GFIII12 16.0

AST4 11.5 GFIV13 0

AST5 43.0 GFIV14 7.0

AST6 28.5 GFIV15 0

AST7 5.0 GFIV16 8.0

AST8 26.0

Total 378.0

No major changes occurred in the EMCDDA 2015 establishment plan, apart from the

reduction of two authorised posts compared with 2014, as requested by the European

Commission and adopted by the EU budget authority.

I Brief description of the results of the screening/benchmarking exercise

The results of the EMCDDA 2015 staff screening exercise reflect the EMCDDA’s efforts to

ensure the effective and efficient allocation and use of its resources. It shows that

68.56 % of its human resources were devoted to operational activities in 2015 and only

20.68 % were allocated to administrative support and coordination; the remaining 10.76 %

were assigned to operations considered neutral (see Annex 2).

General Report of Activities 2015

86

I Assessment by management

The EMCDDA has set its internal procedures for budget execution and internal control,

while defining and implementing a partially decentralised management model, in

accordance with the EMCDDA Financial Regulation, which integrally transposes the text

of European Commission Delegated Regulation (EU) No 1271/2013 on the Framework

Financial Regulation for EU agencies.

As a consequence, both the operational and financial decisions required for the

implementation of the EMCDDA’s work programme and budget have been delegated to

the heads of unit and the head of the Scientific Division. The Administration unit provides

support to managers for budgetary and financial management and execution, as well as

for overall internal planning and monitoring.

These procedures have been codified and all of the EMCDDA’s deputy authorising officers

have received specific training and information on their roles, duties and liabilities, in

accordance with the provisions of financial and staff regulations.

The key actors and steps of the EMCDDA procedures for budget execution can be

summarised as follows:

• Project manager: initiates and provides operational input for the administrative and

financial operations related to project implementation (e.g. technical specifications for

tendering procedures, cost estimate and ‘certified correct’ payments).

• Financial management team: financial and contractual support officers help to prepare

administrative and contracting supporting documents with the input of the project

manager involved.

• Budget planning and monitoring team: checks for consistency with work programme

and budget allocations.

• Financial management team: initiating officers carry out operations using the

EMCDDA’s electronic management and accounting system (ABAC), prior to decisions

of the Authorising Officer.

• Governance unit: the verifying officer carries out ex ante checks.

• Head of unit or the head of the Scientific Division: gives authorisation for budgetary and

legal operations, and acts as deputy authorising officer by delegation (by the Director as

EMCDDA Authorising Officer) for the execution of the tasks/activities of his/her unit,

within the limits of the adopted EMCDDA annual work programme and budget.

• Accounting officer: makes the necessary financial transactions.

The procedures presented above are consistent with the EMCDDA’s project-based

working methods, which aim to integrate activity and resource management, in

accordance with activity-based management/activity-based budgeting principles. In this

context, the EMCDDA established procedures for planning, monitoring and reporting,

with a clear indication of the actors involved, their roles and their responsibilities.

After the adoption of the new ‘Operating framework for the Reitox system’ in January 2003,

a new grant agreement model was introduced for the annual co-financing of activities by

the Reitox NFPs. This agreement requires that an external audit is carried out each year by

an independent body or expert, in order to certify that any financial documents submitted

to the EMCDDA comply with the financial provisions of the agreement, that the costs

declared are the actual costs and that all receipts have been declared.

Chapter 1 I Management

87

The EMCDDA’s activities and operations are scrutinised by several processes and actors:

• external audits by the ECA (twice a year);

• external audits for specific projects (e.g. IPA-funded projects, etc.);

• discharges by the European Parliament (once a year);

• internal audits by the IAS (once a year);

• opinions of the European Commission’s services on the agency’s SPD (once a year);

• external periodical evaluations (set as every six years in the EMCDDA Founding

Regulation);

• agreements by the European Commission on implementing rules for staff regulations

(one agreement for each rule);

• consent by the European Commission on the possible deviation of the EMCDDA

Financial Regulation from the European Commission’s Framework Financial Regulation

for decentralised agencies;

• the European Data Protection Supervisor for compliance with Regulation 45/2001 (by

prior notification and upon complaint);

• the European Anti-Fraud Office (upon complaint);

• the Ombudsman (upon complaint);

• the Civil Service Tribunal — Court of First Instance — European Court of Justice

(upon complaint).

Key features of the EMCDDA’s partially decentralised management model

Level of operations (and actors) Role/operations

Decentralised level (operational and technical units)

Operational initiative/input and operational and financial decisions by delegation in order to implement the work programme and budget

Central level (Directorate and Administration unit)

Coordination and management of executive planning, monitoring, reporting and assessment of the implementation of the work programme and budget. Administrative and financial support, management and control of implementation

Key actors and processes involved in the execution of the EMCDDA work programme and budget

Level of operations Actors Role/operations

Decentralised level (operational and technical units)

Project manager and head of the unit concerned/head of the Scientific Division

Initiates and provides operational input to the operations required to implement projects

Central level (Administration unit)

Budget planning and monitoring team

Checks the consistency of operations with the adopted work programme and budget. Budgetary appropriations to be committed are set aside

Human resources management team

Defines rights and checks compliance with staff regulations for staff-related management and expenditure

Financial management team

Prepares the required administrative and legal supporting documents and controls compliance with applicable regulations. Processes the required ABAC operations

Central level (Governance unit) Verifying officer Ex ante verification

Decentralised level (operational and technical units)

Head of unit/deputy authorising officer

Authorises budgetary and legal commitments and payments

Central level (Administration unit) Accounting officerExecutes and records payments and recovery orders

General Report of Activities 2015

88

Ex ante controls of financial transactions were applied exhaustively throughout 2015 to

verify their compliance with the EMCDDA Financial Regulation and the corresponding

implementing rules. These controls were carried out swiftly in order to ensure that payment

deadlines were met, legal commitments were concluded in a timely manner and income was

recovered promptly, without prejudice to the application of corrections, if required.

Financial workflows were properly defined and a sound system of authorisation of access to the

ABAC system was put in place. The manual of procedures was applied and updated, as required.

In line with the applicable provisions of the EMCDDA Financial Regulation, in late 2014,

the need for an ex post control exercise on security-related issues concerning ICT

operations was identified, taking into account the medium to high level of risk affecting

this area. This exercise was performed in early 2015 and relied on external expertise to

complete the existing internal capacity. The recommendations resulting from this exercise

will be implemented throughout 2016 and 2017, along the lines of the action plan

designed to deal with the risks and weaknesses identified therein.

I Assessment of audit results during 2015 and the follow-up of audit plans, audits and recommendations

In 2015, following up on observations and recommendations expressed by the ECA, the

EU Budget Authority and the IAS, the EMCDDA implemented measures to further improve

its management and internal control systems, as outlined below.

I Internal Audit Service

All recommendations related to the 2008 IAS audit have been closed by the internal auditor.

As regards the implementation of IAS recommendations arising from the 2011 audit on

‘Annual activity reporting and building blocks of assurance’, only two recommendations have

not yet been formally closed by the internal auditor. Regarding the first of these (the setting up

of a performance monitoring system that includes KPIs), the EMCDDA is already at an

advanced stage of implementation, as its 2015 annual work programme defines KPIs for all

main areas of work. The second outstanding recommendation, which concerns ex post

controls, has also been followed up. In fact, pursuant to the assessment of ICT security-related

risks, an ex post verification exercise in this area was performed in the first half of 2015.

In February 2013, the IAS carried out an audit on ‘Budget and monitoring within the EMCDDA’,

in respect of which the only main outstanding recommendation (namely recommendation 2 on

documenting and describing the budget preparation process) was formally closed in 2015.

In September 2015, the IAS carried out an audit on ‘IT project management’ within the

EMCDDA; the corresponding draft audit report (dated 9 December 2015) yielded six main

recommendations, covering three main issues, as described below.

Issue No 1: Business–IT alignment

• The finalisation and adoption of a long-term ICT strategy, including a strategic roadmap

for core ICT systems, are required, as well as guidelines for future objectives and

priorities in light of business needs.

• An enterprise architecture management framework should be defined and adopted.

Chapter 1 I Management

89

Issue No 2: IT project management

• The design of an IT project management methodology should be finalised and adopted,

notably by tailoring best practices and actively involving business; in addition, required

resources should be planned and accounted for across the whole project’s life cycle.

• The project management process should be automated, involving a definition of both

business and technical requirements for a project management platform covering the

complete project life cycle.

Issue No 3: Requirements management and systems development

• A requirements management process should be defined and adopted by tailoring

relevant best practices and incorporating lessons learnt from past experiences.

• A systems development methodology should be defined and adopted.

The recommendations above ought to be followed in substance by the EMCDDA, along the

lines established under a suitable action plan and endorsed by the Management Board.

In June 2015, the IAS also visited the EMCDDA to carry out a comprehensive risk

assessment of the agency’s governance, core business and support processes; this

assignment included, notably, desk reviews and interviews of key staff in order to gain

insight into the agency’s processes and related key controls. As a result, the IAS Strategic

Internal Audit Plan for 2016–2018 targeted two main topics for future auditing (namely

‘Management of data collection, validation and quality assurance’ and ‘Publications

Management’); further to these recommendations, a so-called ‘Limited Review’ on

business continuity has also been planned.

I European Court of Auditors

The need to carry forward originated from external factors, namely the unexpected ruling

of the EU Court of Justice on the retroactive adjustment of EU staff members’

remuneration for 2011, 2012 and 2013. The EMCDDA confirmed that this carry-forward

was the result of a well-founded and structured process put in place to ensure the sound

management of these operations. Furthermore, the EMCDDA confirmed its capacity to

properly and effectively use carried forward appropriations (C8), as the rate of use of such

appropriations consistently exceeded 95 %.

I Follow-up on observations from the discharge authority

I Measures taken in light of the observations and comments that accompanied the decision on discharge for 2012

1. Comments on the legality and regularity of transactions

Observations Nos 3, 4 and 5 of the European Parliament discharge decision

Notes from the Court’s report that the Centre launched a procurement procedure to rent

office equipment over a four-year period and that the technical requirements were subject

to a significant modification during the course of the procedure; is concerned that the

General Report of Activities 2015

90

technical requirements were further adjusted for the conclusion of the contract, in

accordance with the option announced in the published specifications, leading to

a decrease in the contract value; regrets that the information published on the contract’s

price structure was not sufficiently clear, which led to a misinterpretation by one bidder

who therefore had a smaller chance of being awarded the contract;

Notes with concern that the evaluation criteria for the abovementioned procedure were

not sufficiently specific to ensure full transparency and the equal treatment of bidders;

observes that the abovementioned weakness affected the efficiency and effectiveness of

this procurement procedure, as well as creating the risk of hindering the competition;

Acknowledges from the Centre that the relevant contract notice was published via the

information system for European public procurement, which imposes some restrictions on

the information that can be published; acknowledges furthermore that all tenderers were

treated equally and evaluated in accordance with the established and published award

criteria and method; calls on the Centre to nonetheless improve its procurement

processes and to report to the discharge authority on the measures taken.

In 2015, the EMCDDA pursued its effort to reduce, as much as possible, the need to

adjust technical specifications. Furthermore, it ensured a more effective communication

of information to all relevant actors whenever such adjustments were needed, namely via

the publication of more explicit notices on its website.

2. Prevention and management of conflicts of interest and transparency

Observation No 9 of the European Parliament discharge decision

Acknowledges from the Centre that it has reviewed its policy on the prevention and

management of conflicts of interests in line with the Commission’s guidelines; notes that

the revised policy was approved by the Centre’s Management Board at its meeting of 4

and 5 December 2014; awaits the publication of declarations of interests of the

Management Board, senior management and the Director.

Pursuant to the approved policy and the relevant templates, the declarations referred to

were published as required.

3. Other comments

Observation No 13 of the European Parliament discharge decision

Takes note that the ‘Cais do Sodre Relógio’ building remains mostly unused as only a few

expressions of interest for leasing the building materialised into concrete proposals;

acknowledges that negotiations for a short-term lease are currently ongoing with an offer

well below the renting costs endured by the Centre and that it is negotiating with the

building’s landlord for a possible reduction of the rent in order to neutralise rental costs as

much as possible; calls on the Centre to inform the discharge authority about future

developments once more information is available.

The EMCDDA continued to pursue its effort to find a suitable solution with regard to the

areas referred to. For this purpose, the Relógio building was visited by potentially

interested parties (mostly represented by the real estate agencies in charge of facilitating

the operation at stake). None of these parties have yet confirmed their interest or any

intention to conclude a sub-lease contract. The EMCDDA will inform the discharge

authority of any relevant developments in this situation.

2

92

In line with Article 23 of the EMCDDA’s recast Founding Regulation, the European

Commission initiates an external evaluation of the agency every six years and submits the

evaluation report to the European Parliament, the Council and the Management Board of

the EMCDDA.

The last external evaluation of the agency was completed in June 2012. The main findings

of this evaluation can be summarised as follows (49):

• As stated in the overall conclusions and recommendations, the EMCDDA performed

well, during the 2007–2012 period, in its mission to provide the EU and Member States

with factual, objective, reliable and comparable information at the European level on

drugs and drug addiction, and their consequences. This overall conclusion is supported

by evidence from a number of different sources, including survey work.

• In relation to the various tasks set out in the EMCDDA’s 2006 recast Founding

Regulation, the evaluation findings are generally positive. Firstly, in relation to its role of

providing ‘factual, objective, reliable and comparable information at the European level

concerning drugs and drugs addiction, and their consequences’, the EMCDDA

performed strongly. In addition to the demand side of the drugs problem, progress was

also made towards improving the understanding of supply.

• The EMCDDA also performed well in relation to the second task defined in the 2006

recast Founding Regulation, namely to ‘collect, register and analyse information on

emerging trends’. During the period under review, the upwards trend in NPS being

detected accelerated, but the EMCDDA kept pace with developments through its EWS

and related activities, and provided information to the Commission and Member States

that was used to shape policy responses. Feedback from the research on the

EMCDDA’s performance in relation to the third task set out in the recast Founding

Regulation, namely ‘identifying best practices in Member States and facilitating the

exchange of such practices between them’, is not as positive as it is for the other tasks.

The EMCDDA’s fourth task (‘to promote cooperation with other European and

international bodies and with third countries’) has been successfully promoted.

The final report contains 15 recommendations and the agency has prepared an action

plan to implement these. This action plan was adopted by the Management Board at its

meeting of 5–6 July 2012.

With a view to monitoring the implementation of the follow-up action plan, an annual

internal assessment exercise was put into place and the results were presented in the

General Report of Activities for 2013 and 2014 (50).

(49) The full result of the evaluation can be found online at: emcdda.europa.eu/html.cfm/index184823EN.html(50) Available at: emcdda.europa.eu/publications/searchresults?action=list&type=PUBLICATIONS&SERIES_

PUB=w8

CHAPTER 2External evaluations

Chapter 2 I External evaluations

93

Furthermore, in order to measure the progress achieved, a KPI (10.1.6: Degree of

implementation of the follow-up action plan to the third external evaluation of the

EMCDDA) was defined in the 2014 work programme and adopted by the Management

Board in July 2012.

At the end of 2014, total implementation (100 %) was shown for this KPI for all of the

actions that resulted from the 15 recommendations under the control of the EMCDDA.

The EMCDDA therefore concluded that all of these recommendations could be closed.

This was adopted by decision by the Management Board at its 51st meeting in

September 2015.

However, the agency maintains its commitment to ensuring that its future activities are

aligned with these recommendations. This commitment is fully reflected in the EMCDDA’s

2016–18 strategy and work programme, which was adopted by the Management Board at

its 52nd meeting in December 2015, as well as in the SPD for 2017–19.

The fourth external evaluation of the EMCDDA by the European Commission is likely to be

carried out during the period 2017–18. The exercise will evaluate the implementation of

the new three-year strategy and work programme for 2016–18, as well as the previous

strategy and work programme for 2013–15.

3

95

I Risk management and compliance with, and effectiveness of, the internal control standards

As in previous years, a comprehensive risk identification and assessment exercise aimed

at improving risk management in the EMCDDA was carried out in 2015. The central risk

register, as well as the sector risk register set up by the ICT unit, were kept updated. Risk

analysis was a continuous exercise at the EMCDDA during the year, although at the stage

of preparation of annual work programmes, more systematic reviews were conducted by

managers.

A comprehensive document that reviews and lays down the progress made in the

implementation of the EMCDDA internal control standards (ICS) was drawn up in early

2013, and has been reviewed regularly since then. As a result of these reviews, two main

areas in which implementation of the EMCDDA ICS should be improved have been

identified, namely (and by order of priority): ‘Business continuity’ (ICS 10) and

‘Governance in IT’, notably regarding ‘Projects’ management’ (one key feature under

ICS 7 — ‘Operational structures’). The EMCDDA has continued to take measures across

the agency to mitigate risks.

The adoption, in September 2013, of a fully fledged business continuity plan (BCP) for the

agency as a whole reflected a major improvement in the implementation of the

aforementioned ICS. Without prejudice to future improvements, this plan already appears

to be detailed and comprehensive enough to allow the EMCDDA to act swiftly and

operate recoveries in the event of an emergency or disaster. It is also worth mentioning

the continuous effort made in relation to governance and technical management of ICT

operations. In this area, business continuity was achieved without major incidents,

namely by ensuring sound procurement procedures, adequate licensing and proper

testing of applications. Furthermore, some mitigating measures were taken during 2015

in order to achieve nearly tolerable levels of risks inherent to the management of some

ICT-related investments and projects.

In combination with the IT sector risk register, an adequate risk management plan was set

up. This plan identifies, for each area, the estimated risk level, the controls that should be

put in place, and the list of the ongoing programmes and projects that will contribute to

the reduction of the risks at stake. As mentioned in the ‘Assessment by management’

section above, the IAS carried out an audit on ‘IT project management in the EMCDDA’ in

September 2015: the implementation of the resulting recommendations will allow the

agency to make further improvements in this area, including a better alignment of IT

projects with core business needs.

CHAPTER 3Assessment of the

effectiveness of the internal control systems

General Report of Activities 2015

96

The monitoring of performance supported by KPIs (ICS 5) was further developed in 2015.

This was the first year in which KPIs were established for all the main areas of work in the

annual work programme; therefore, the agency had to establish the necessary data

collection and reporting mechanism, pilot some of the new measurement tools, refine

working definitions and develop the internal monitoring and evaluation plan. The KPIs will

require further improvement, in light of the results of the first round of complete data

collection carried out at the end of the year and the lessons learnt from implementing the

new methodologies.

Moreover, the agency started to develop an IT tool to integrate the planning and

monitoring of activities (management information system). However, the progress

achieved in 2015 was slower than planned because of the need to prioritise work on the

SPD (top-level priority), from the perspective of the business owner (the planning

function), and the development of other level 1 priority projects, from the perspective of

the ICT team. The timeline for the completion of this tool hinges on the availability of the

necessary resources (in terms of both human resources and funding).

Internal EMCDDA coordination bodies (namely the Coordination Group) contributed to

strengthening risk management processes, by enhancing the capacity of managers and

other key staff to closely monitor all major issues related to the timely and effective

implementation of planned activities, the delivery of outputs and the achievement of

results.

The risks more directly associated with operational activities, particularly the lack of

proper funding for the Reitox NFPs, which was already apparent in 2014, were further

aggravated throughout 2015. Cuts in funding from national sources to certain NFPs

occurred once again in 2015, increasing the risk that all core monitoring activities of the

EMCDDA will be affected. In addition, these difficulties were compounded by the budget

constraints faced by the EMCDDA itself, which led to decreases in the amounts granted

to NFPs for properly complying with their reporting obligations to the agency.

As a consequence of these events, the rationalisation of the present NFP reporting

package had to be carried out and should probably continue; notably, this involves regular

assessments of core data needs on the basis of soundly defined priorities.

Furthermore, in 2015, there were reductions in the reporting capacities of Member

States, because core data of sufficiently high quality were either completely lacking or

available to only a limited extent. As a consequence, the timeliness and

comprehensiveness of the reporting by Member States on new threats and drug

developments were affected; moreover, some comparative data became unavailable,

which curtailed the possibility of carrying out useful analyses at European level. In

addition, the reporting of matters related to NPS was often missing or delayed.

Following the materialisation of this risk, a closer monitoring of and feedback to the

Member States on their reporting performance was envisaged and is currently ongoing.

This measure should allow corrective action to be taken by Member States, if required.

4

98

I Declaration of assurance by the Authorising Officer

I, the undersigned, Director of the European Monitoring Centre for Drugs and Drug

Addiction

In my capacity as Authorising Officer

• Declare that the information contained in this report gives a true and fair view (1).

• State that I have reasonable assurance that the resources assigned to the activities

described in this report have been used for their intended purpose and in accordance

with the principles of sound financial management, and that the control procedures

put in place give the necessary guarantees concerning the legality and regularity of the

underlying transactions.

• This reasonable assurance is based on my own judgement and on the information at

my disposal, such as the results of the self-assessment, the observations of the

Internal Audit Service and the lessons learnt from the reports of the Court of Auditors

for years prior to the year of this declaration.

• Confirm that I am not aware of anything not reported here which could harm the

interests of the institution.

Done in Lisbon on 23 May 2016

Alexis Goosdeel

Director

CHAPTER 4Management assurance

(1) ‘True and fair’ in this context means a reliable, complete and correct view on the state of affairs in the service.

Annexes

General Report of Activities 2015

100

ANNEX 1 Organisational chart

Unit Prevalence, data management and

content coordination

(EPI)

Sector Estimates, statistics and data management

Sector Contents coordination and trend analysis

Unit Consequences, responses and best practices

(IBS)

Sector Health consequencesand responses

Sector Best practices, knowledge exchange and economic issues

Unit Supply reduction

and new drugs (SAT)

Sector Action on new drugs

Sector Markets, crime and supply reduction

Unit Reitox and

international cooperation

(RTX)

Sector International cooperation

Scientific Division (SDI)

Unit Administration

(ADM)

Sector Infrastructure and logistics

Sector Human resources management

Sector Financial management

Director Wolfgang Götz

Data protection officer

Governance unit (GOV)

Unit Communication

(COM)

Sector Media relations and marketing

Unit Information and communication

technology (ICT)

Sector ICT project management

101

ANNEX 2 Staff details

A. Breakdown of EMCDDA staff as of 31 December 2015

EMCDDA contract agents (CA), temporary agents (TA) and officials

Category/ Grade Officials

GenderTA

Gender

Male Female Male Female

AD

15 0 1 1

14

13 1 1 3 2 1

12 3 3 6 5 1

11 5 2 3

10 3 2 1

9 1 1 3 2 1

8 1 1 8 2 6

7 8 2 6

6 4 2 2

5 1 1

Subtotal AD 6 6 0 42 21 21

AST

11

10 1 1

9 3 2 1

8 1 1 1 1

7 1 1 2 2

6 4 1 3

5 1 1 8 5 3

4 2 2

3 1 1

2 1 1

1

Subtotal AST 4 0 4 22 12 10

TOTAL 10 6 4 64 33 31

Function group

Gender Total EMCDDA

staff

Gender

Male Female Male Female

Contract Agents

IV 2 2 99 46 53

III 8 3 5 % 46.46 % 53.54 %

II 12 1 11

SNE 1I 3 3

Total CA 25 7 18Administrator = ADAssistant = ASTSeconded national expert = SNE

General Report of Activities 2015

102

B. Staff by nationality

United KingdomSweden

Finland

Slovakia

SloveniaRomania

Portugal

Poland

AustriaNetherlands

Malta

Hungary

LuxembourgLithuania

Latvia

Cyprus

Italy

FranceSpain

Greece

Ireland

EstoniaGermany

Denmark

Czech Republic

BulgariaBelgium

0 5 10 15 20 25 30 35

Number of sta�

O�cials Temporary agents Contract agents Seconded national expert

Annex 2

103

C. Results of the 2015 benchmarking exercise

Job type (sub-) category 2015 (%)

Administrative support and coordination 20.68

Administrative support 19.83

Coordination 0.85

Operational 68.56

Top level operational coordination 5.34

Programme management and implementation 49.49

Evaluation and impact assessment 0

General operational 13.73

Neutral 10.76

Finance/control 10.76

Linguistics 0

General Report of Activities 2015

104

ANNEX 3 Outputs and products

Annual reporting

European Drug Report 2015: Trends and developments, EMCDDA, Lisbon, June 2015

A yearly overview of the drug phenomenon in Europe.

Available in 24 languages — all EU official languages (except MT and GA), plus TR and NO.

http://www.emcdda.europa.eu/publications/edr/trends-developments/2015

Statistical bulletin (Data and statistics)

The epidemiological basis on which the EDR is based, with over 300 tables and 100

graphics collated by the EMCDDA from the information submitted by the network of

Reitox NFPs.

Available as a website in EN: http://www.emcdda.europa.eu/data/2015

Perspective on drugs (PODs)

Designed-for-the-web interactive analyses providing deeper insights into a selection of

important issues.

Drug consumption rooms: an overview of provision and evidence, EMCDDA, Lisbon, June

2015.

http://www.emcdda.europa.eu/topics/pods/drug-consumption-rooms

The misuse of benzodiazepines among high-risk opioid users in Europe, EMCDDA, Lisbon,

June 2015.

www.emcdda.europa.eu/topics/pods/benzodiazepines

Opioid trafficking routes from Asia to Europe, EMCDDA, Lisbon, June 2015.

http://www.emcdda.europa.eu/topics/pods/opioid-trafficking-routes

The role of psychosocial interventions in drug treatment, EMCDDA, Lisbon, June 2015.

http://www.emcdda.europa.eu/topics/pods/psychosocial-interventions

Country overviews

Summaries of the national drug situation showing the drug use prevalence position in

seven former Soviet Union countries: Belarus, Georgia, Moldova, Ukraine, Kazakhstan,

Kyrgyzstan and Uzbekistan.

Available online in EN (for all) and in RU (for Kazakhstan, Kyrgyzstan and Uzbekistan):

http://www.emcdda.europa.eu/publications/country-overviews

Country overviews (FSU)

Summaries of the national drug situation showing the drug use prevalence position in

seven former Soviet Union countries: Belarus, Georgia, Moldova, Ukraine, Kazakhstan,

Kyrgyzstan and Uzbekistan.

Annex 3

105

Available online in EN (for all) and in RU (for Kazakhstan, Kyrgyzstan and Uzbekistan):

http://www.emcdda.europa.eu/publications/country-overviews

National reports

Commissioned each year by the EMCDDA and produced by the Reitox NFPs, the national

reports provide an overall picture of the drugs phenomenon at the national level in each

EU Member State. Published on the EMCDDA website: http://www.emcdda.europa.eu/

publications/searchresults?action=list&type= PUBLICATIONS&SERIES_PUB=w203

Institutional publications

General Report of Activities 2014 including the annual activity report of the EMCDDA’s

authorising officer (for 2014), EMCDDA, Lisbon, June 2015.

http://www.emcdda.europa.eu/publications/gra/2014

A year in review. Highlights from the EMCDDA’s General Report of Activities 2014,

EMCDDA, Lisbon, June 2015.

http://www.emcdda.europa.eu/publications/gra/2014-highlights

Annual accounts 2014, EMCDDA, Lisbon, August 2015.

http://www.emcdda.europa.eu/publications/annual-account/2014

Budget 2015, EMCDDA, Lisbon, July 2015.

http://www.emcdda.europa.eu/publications/budget-2015

Work programme 2015, EMCDDA, Lisbon, February 2015.

http://www.emcdda.europa.eu/publications/work-programmes/2015

Outputs linked to the implementation of the Council Decision on new psychoactive substances (2005/387/JHA)

EMCDDA–Europol 2014 Annual Report on the implementation of Council Decision

2005/387/JHA (New drugs in Europe, 2013), EMCDDA, Lisbon, July 2015.

http://www.emcdda.europa.eu/publications/implementation-reports/2014

This report presents the results and outlines the key achievements for 2014 on the

information exchange, risk assessment and control with regard to NPS.

EMCDDA–Europol Joint Report on a new psychoactive substance: 1-phenyl-2-(1-

pyrrolidinyl)-1-pentanone (α-PVP), EMCDDA, Lisbon, September 2015.

http://www.emcdda.europa.eu/publications/joint-reports/alpha-pvp

Risk assessments

Report on the risk assessment of MT-45 in the framework of the Council Decision on new

psychoactive substances, EMCDDA, Lisbon, October 2015.

http://www.emcdda.europa.eu/publications/risk-assessments/mt-45

General Report of Activities 2015

106

Report on the risk assessment of 4,4′-DMAR in the framework of the Council Decision on

new psychoactive substances, EMCDDA, Lisbon, October 2015.

http://www.emcdda.europa.eu/publications/risk-assessment/44-dmar

EMCDDA Insights

Treatment of cannabis-related disorders in Europe, EMCDDA, Lisbon, April 2015.

http://www.emcdda.europa.eu/publications/insights/2015/

treatment-of-cannabis-related-disorders

Prevention of addictive behaviours, EMCDDA, Lisbon, September 2015.

http://www.emcdda.europa.eu/publications/insights/preventing-addictive-behaviours

Comorbidity of substance use and mental disorders in Europe, EMCDDA, Lisbon,

November 2015.

http://www.emcdda.europa.eu/publications/insights/

comorbidity-substance-use-mental-disorders-europe

Joint publications

Wound botulism in people who inject heroin in Norway and the United Kingdom, EMCDDA

and ECDC, Lisbon, February 2015.

http://www.emcdda.europa.eu/publications/joint-publications/

wound-botulism-norway-uk-2015

The ESPAD validity study in four countries in 2013, EMCDDA and ESPAD, Lisbon, July 2015.

http://www.emcdda.europa.eu/publications/joint-publications/espad-validity-study

EMCDDA Papers

Preventing fatal overdoses: a systematic review of the effectiveness of take-home

naloxone, EMCDDA, Lisbon, January 2015.

http://www.emcdda.europa.eu/publications/emcdda-papers/naloxone-effectiveness

Mortality among drug users in Europe: new and old challenges for public health,

EMCDDA, Lisbon, February 2015.

http://www.emcdda.europa.eu/publications/emcdda-papers/

mortality-among-drug-users-in-europe

Drugs policy and the city in Europe, EMCDDA, Lisbon, June 2015.

http://www.emcdda.europa.eu/publications/emcdda-papers/drug-policy-and-the-city

Alternatives to punishment for drug-using offenders, EMCDDA, Lisbon, July 2015.

http://www.emcdda.europa.eu/publications/emcdda-papers/alternatives-to-prison

Technical reports

The internet and drug markets — summary of results from an EMCDDA Trendspotter

study, EMCDDA, Lisbon, January 2015.

http://www.emcdda.europa.eu/publications/technical-reports/internet-drug-markets

Annex 3

107

Prevention of infectious diseases among people who inject drugs in some Western Balkan

countries: A report based on the Reitox Academy organised on 29–30 October 2013 in

Sarajevo, Bosnia and Herzegovina, EMCDDA, Lisbon, February 2015.

http://www.emcdda.europa.eu/publications/technical-reports/

prevention-infectious-diseases-western-balkan-countries

Drug law offences in the Western Balkan region: from definition to monitoring: A report

based on the Reitox Academy ‘Drug law offences in the Western Balkan region: from

definition to monitoring’, organised on 2 and 3 April 2014 in Podgorica, Montenegro,

EMCDDA, Lisbon, February 2015.

http://www.emcdda.europa.eu/publications/technical-reports/

drug-law-offences-western-balkan-countries

Estimating trends in injecting drug use in Europe using national data on drug treatment

admissions, EMCDDA, Lisbon, June 2015.

http://www.emcdda.europa.eu/publications/technical-reports/estimating-trends-inject-

ing-drug-use-europe-using-national-data-drug-treatment-admissions

Rapid communications

New psychoactive substances in Europe. An update from the EU Early Warning System

(March 2015), EMCDDA, Lisbon, March 2015.

http://www.emcdda.europa.eu/publications/2015/new-psychoactive-substances

New psychoactive substances in Europe: Innovative legal responses, EMCDDA, Lisbon,

July 2015.

http://www.emcdda.europa.eu/publications/ad-hoc-publication/

new-psychoactive-substances-europe-innovative-legal-responses

Drug-related infectious diseases in Europe. Update from the EMCDDA expert network,

EMCDDA, Lisbon, September 2015.

http://www.emcdda.europa.eu/publications/rapid/2015/

drug-related-infectious-diseases-in-europe

Estimating trends in injecting drug use in Europe using national data on drug treatment

admissions, EMCDDA, Lisbon, June 2015.

http://www.emcdda.europa.eu/publications/technical-reports/estimating-trends-inject-

ing-drug-use-europe-using-national-data-drug-treatment-admissions

Brochures

European Drug Report 2015: promotional brochure, EMCDDA, Lisbon, June 2015.

http://www.emcdda.europa.eu/publications/brochures/edr2015

20 years: Monitoring, communicating evidence, informing policy, EMCDDA, Lisbon,

September 2015.

http://www.emcdda.europa.eu/publications/brochures/20-years

General Report of Activities 2015

108

Drugnet Europe

The EMCDDA’s quarterly newsletter provides regular information on the agency’s

activities to a broad readership. There were four editions in 2015 (89, 90, 91 and 92).

These are available in EN.

http://www.emcdda.europa.eu/publications/drugnet

Other

Drug use and its consequences in the Western Balkans 2006–14, EMCDDA, Lisbon,

March 2015.

http://www.emcdda.europa.eu/publications/2015/western-balkans-report

EMCDDA internal statistics code of practice, EMCDDA, Lisbon, February 2015.

http://www.emcdda.europa.eu/publications/manuals/statistics-code-of-practice

Media products

News releases

Eleven news releases

No 11/2015: EMCDDA Management Board elects new Chair and Vice-Chair (4.12.2015)

EN/DE/FR/PT

No 10/2015: New EMCDDA report explores combined mental health and substance use

disorders (27.11.2015) EN

No 9/2015: 4,4’-DMAR and MT-45 to be placed under control across the EU (20.10.2015)

EN

No 8/2015: Annual award ceremony to celebrate excellence in scientific writing on illicit

drugs (22.9.2015) EN/DE/FR/PT

No 7/2015: EMCDDA conference: 20 years of monitoring and communicating evidence on

drugs (18.9.2015) EN/DE/FR/PT

No 6/2015: EMCDDA Management Board selects new Director (10.9.2015)

EN/DE/FR/PT

No 5/2015: Europe’s cities offer valuable observation window on new drug trends

(25.6.2015) EN/DE/FR/PT

No 4/2015: EMCDDA explores new dynamics and dimensions of Europe’s drugs problem

(4.6.2015) BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HR/HU/IT/LT/LV/NL/PL/PT/RO/SK/

SL/SV/NO/TU

No 3/2015: EMCDDA underlines growing importance of effective treatment for cannabis

use (21.4.2015) EN

Annex 3

109

No 2/2015: Coming soon: European Drug Report 2015 (15.4.2015) BG/CS/DA/DE/EL/

EN/ES/ET/FI/FR/HR/HU/IT/LT/LV/NL/PL/PT/RO/SK/SL/SV/NO/TU

No 1/2015: EMCDDA presents latest update on ‘new drugs’ from EU Early Warning

System (9.3.2015) EN/DE/FR/PT

Fact sheets

Ten fact sheets available only in EN

No 10/2015: Over 40 countries attend 2015 Reitox week in Lisbon (24.11.2015)

No 9/2015: EU drugs agency boosts cooperation with Georgian Ministry of Justice

(4.11.2015)

No 8/2015: EMCDDA co-hosts ‘Testing the waters 2015’ (9.10.2015)

No 7/2015: EMCDDA Director Wolfgang Götz receives award for services to the Republic

of Austria (8.9.2015)

No 6/2015: EU drugs agency steps up cooperation with National Security Council of

Armenia (28.7.2015)

No 5/2015: EMCDDA publishes first overview of the drug situation in the Western Balkans

(23.3.2015)

No 4/2015: New EMCDDA annual work programme published today (12.2.2015)

No 3/2015: New EMCDDA trendspotter study explores online supply of drugs (30.1.2015)

No 2/2015: New EMCDDA review studies the effectiveness of overdose antidote,

naloxone 19.1.2015)

No 1/2015: Registration opens for fourth European drugs summer school (15.1.2015)

News items are also published throughout the year. For a full listing, please see:

http://www.emcdda.europa.eu/news/2015

Videos

European Drug Report 2015 to be launched on 4 June (13.4.2015)

https://www.youtube.com/watch?v=vzzyp3k6pSk

Lisbon Addictions 2015: first European conference on addictive behaviours and

dependencies (13.4.2015)

https://www.youtube.com/watch?v=83bKhj3LQZc

Drug consumption rooms (28.5.2015)

https://www.youtube.com/watch?v=YhLoLbORzi0

European Drug Report 2015 — Get the facts (28.5.2015)

https://www.youtube.com/watch?v=zPrRlRWaIbk

General Report of Activities 2015

110

Misuse of benzodiazepines among high-risk opioid users (28.5.2015)

https://www.youtube.com/watch?v=hKnQ6-HLjws

What is decriminalisation of drugs? (3.6.2015)

https://www.youtube.com/watch?v=9NKhpujqOXc

Europäischer Drogenbericht 2015 — Die Hauptfakten (21.7.2015) DE

https://www.youtube.com/watch?v=CO-mBjG2tXc

Relatório Europeu sobre Drogas 2015 — Conheça os factos (21.7.2015) PT

https://www.youtube.com/watch?v=UCrZQbRNDdQ

Europejski raport narkotykowy 2015 — najnowsze fakty (19.8.2015) PL

https://www.youtube.com/watch?v=RA59mkvvdL0

Informe Europeo sobre Drogas 2015 — conoce las cifras (5.10.2015) ES

https://www.youtube.com/watch?v=X5Wy4JQZves

Rapport européen sur les drogues 2015 — Les principaux faits (11.11.2015) FR

https://www.youtube.com/watch?v=MeBGcvS8fEo

Online tools and web-based resources

EMCDDA public website

The gateway to drug information in Europe

http://www.emcdda.europa.eu

Prevention profiles

http://www.emcdda.europa.eu/countries/prevention-profiles

Action on new drugs

http://www.emcdda.europa.eu/activities/action-on-new-drugs

Drug-related research

http://www.emcdda.europa.eu/themes/research

Best practice portal: A resource for professionals, policymakers and researchers in the

areas of drug-related prevention, treatment, harm reduction and social reintegration.

http://www.emcdda.europa.eu/best-practice

ELDD (European Legal Database on Drugs)

http://www.emcdda.europa.eu/eldd

Treatment profiles

http://www.emcdda.europa.eu/responses/treatment-overviews

Annex 3

111

Articles and book chapters published in 2015 (bold indicates EMCDDA staff member(s))

1. Allara, E., Ferri, M., Bo, A., Gasparrini, A. and Faggiano, F. (2015), ‘Are mass-media

campaigns effective in preventing drug use? A Cochrane systematic review and

meta-analysis’, British Medical Journal.

2. Allara, E., Ferri, M., Bo, A., Gasparrini, A. and Faggioano, F. (2015), ‘Are mass-media

campaigns effective in preventing drug use? A Cochrane systematic review and

meta-analysis’, BMJ Open, 5:e007449. doi:10.1136/bmjopen-2014-007449.

3. Burkhart, G. and Simon, R. (2015), ‘Prevention strategies and basics’, in el-Guebaly, N.,

Carrà, G. and Galanter, M. (eds), Textbook of Addiction Treatment: International

Perspectives, Springer, Milan.

4. Burkhart, G. (2015), ‘¿Confiamos demasiado en el valor de la cognición y de la

educación en la prevención?’, Revista Española de Drogodependencias 40, pp. 61–70.

5. Burkhart, G. (2015), ‘International standards in prevention: how to influence prevention

systems by policy interventions?’, International Journal of Prevention and Treatment of

Substance Use Disorders 1, pp. 18–37.

6. Burkhart, G. (2015), ‘Is the Strengthening Families Programme feasible in Europe?’,

Journal of Children’s Services 10, pp. 133–150.

7. Cruciani, M., Wiessing, L., Serpelloni, G., Genetti, B., Andreotti, A., Iulia, C., Zermiani, M.

and Suligoi, B. (2015), ‘Increasing prevalence of HIV infection among first time clients

in Italian drug treatment services – is it sexual transmission?’, BMC Infectious

Diseases 15, p. 201.

8. Hedrich, D. and Hartnoll, R. (2015), ‘Harm reduction interventions’, in el-Guebaly, N.,

Carrà, G. and Galanter, M. (eds), Textbook of Addiction Treatment: International

Perspectives, Springer, Milan.

9. Dines, A. M., Wood, D. M., Galicia, M., Yates, C. M., Heyerdahl, F., Hovda, K. E.,

Giraudon, I. and Sedefov, R. (2015), ‘Presentations to the emergency department

following cannabis use — a multi-centre case series from ten European countries’,

Journal of Medical Toxicology 11, pp. 415–421.

10. Dines, A. M., Wood, D. M., Yates, C., Heyerdahl, F., Hovda, K. E., Giraudon, I.,

Sedefov, R., Dargan, P. I. and Euro-DEN Research Group (2015), ‘Acute recreational

drug and new psychoactive substance toxicity in Europe: 12 months data collection

from the European Drug Emergencies Network (Euro-DEN)’, Clinical Toxicology 53,

pp. 893–900.

11. Ferri, M. and Dias, S. (2015), ‘Time, consensus and implementation: challenges for

effective knowledge exchange’, Addiction 110, pp. 900–902.

12. Ferri, M., Ballotta, D., Carra, G. and Dias, S. (2015), ‘A review of regional drug

strategies across the world: How is prevention perceived and addressed?’, Drugs:

Education, Prevention and Policy 22, pp. 444–448.

General Report of Activities 2015

112

13. Griffiths, P. and Ferri M. (2015), ‘Systems, approaches, public policies, evaluation

and outcome of treatment’, in el-Guebaly, N., Carrà, G. and Galanter, M. (eds),

Textbook of Addiction Treatment: International Perspectives, Springer, Milan.

14. Hatzakis, A., Sypsa, V., Paraskevis, D., Nikolopoulos, G., Tsiara, C., Micha, K., Panopoulos,

A., Malliori, M., Psichogiou, M., Pharris, A., Wiessing, L., van de Laar, M., Donoghoe, M.,

Heckathorn, D. D., Friedman, S. R. and Des Jarlais, D. C. (2015), ‘Design and baseline

findings of a large-scale rapid response to an HIV outbreak in people who inject drugs

in Athens, Greece: the ARISTOTLE programme’, Addiction 110, pp. 1453–1467.

15. Mounteney, J., Griffiths, P., Sedefov, R., Noor, A., Vicente, J. and Simon R. (2015),

‘The drug situation in Europe: an overview of data available on illicit drugs and new

psychoactive substances from European monitoring in 2015’, Addiction 111,

pp. 34–48.

16. Mounteney, J., Gallegos, A., Sedefov, R. and Hughes, B. (2015), ‘Identifisering,

riskovurdering og regulering as NPS’, Nye psykoaktive stoffer: en rusmiddelrevolusjon?

Universitetsforlaget, Oslo, pp. 118–130.

17. Mounteney, J., Giraudon, I., Denissov, G. and Griffiths, P. (2015), ‘Fentanyls: are we

missing the signs? Highly potent and on the rise in Europe’, International Journal of

Drug Policy 26, pp. 626–631.

18. Hartnoll, R. and Hedrich, D. (2015), ‘Harm reduction policies, settings and challenges’,

in el-Guebaly, N., Carrà, G. and Galanter, M. (eds), Textbook of Addiction Treatment:

International Perspectives, Springer, Milan.

19. Rosińska, M., Sierosławski, J. and Wiessing, L. (2015), ‘High regional variability of HIV,

HCV and injecting risks among people who inject drugs in Poland: comparing

a cross-sectional bio-behavioural study with case-based surveillance’, BMC

Infectious Diseases 15, p. 83.

20. Simon, R. and Burkhart, G. (2015), ‘Regional and cultural aspects of prevention’, In

el-Guebaly, N., Carrà, G. and Galanter, M. (eds), Textbook of Addiction Treatment:

International Perspectives, Springer, Milan.

21. Simon, R. and West, R. (2015), ‘Models of addiction and types of interventions: An

integrative look’, The International Journal of Alcohol and Drug Research 4, pp. 13–20.

22. Simon, R. and Hughes, B. (2015), ‘Cannabis und Drogenrecht in Europa:

Gesetzeslage, Umsetzung und aktuelle Diskussionen zur Weiterentwicklung’, Sucht

Aktuell, Heft 2, pp. 18–26.

23. Strang, J., Groshkova, T., Uchtenhagen, A., van den Brink, W., Haasen, C., Schechter,

M., Lintzeris, N., Bell, J., Pirona, A., Oviedo-Joekes, E., Simon, R. and Metrebian, N.

(2015), ‘Heroin on trial: systematic review and meta-analysis of randomised trials of

diamorphine-prescribing as treatment for refractory heroin addiction’, British Journal

of Psychiatry 207, pp. 5–14 (doi: 10.1192/bjp.bp.114.149195).

24. Sypsa, V., Paraskevis, D., Malliori, M., Nikolopoulos, G., Panopoulos, A., Kantzanou, M.,

Katsoulidou, A., Psichogiou, M., Fotiou, A., Pharris, A., Van De Laar, M., Wiessing, L.,

Jarlais, D., Friedman, S. and Hatzakis, A. (2015) ‘Homelessness and other risk factors

for HIV infection in the current outbreak among injection drug users in Athens,

Greece’, American Journal of Public Health 105, p. 196.

Annexes 4, 5, 6

113

25. Wiessing, L., Hughes, B., Ferri, M. and Griffiths, P. (2015), ‘Cannabis: monitor policy

changes’, Nature 527, p. 305.

26. Wood, D., Sedefov, R., Cunningham, A. and Dargan, P. I. (2015), ‘Prevalence of use

and acute toxicity associated with the use of NBOMe drugs’, Clinical Toxicology, 53,

pp. 85–92.

27. Wood, D., Dines, A. M., Heyerdahl, F., Yates, C., Giraudon, I., Paasma, R., Hovda, K. N.

and Dargan, P.I. (2016), ‘Review of European-Drug Emergencies Network (Euro-DEN)

training package for non-specialist workers to assess acute recreational drug and new

psychoactive substance toxicity in night-time economy environments’, Drugs:

Education, Prevention and Policy 23, pp. 73–77. Published online: 24 September 2015

(http://www.tandfonline.com/doi/full/10.3109/09687637.2015.1081379).

ANNEX 4 Key external events, conferences and meetings, 2015

During 2015, EMCDDA staff participated in many external events, conferences and

technical meetings. Through this participation, they brought their knowledge and

expertise to international scientific discussions and the various political debates currently

active in the drugs field. For details of these events, see emcdda.europa.eu/publications/

gra/2015

ANNEX 5 Implementation of the 2015 work programme by objectives, activities and expected outputs/results

This annex presents, in detail, the activities contained within the work programme for

2015 and how these activities were carried out during the course of the year. It can be

found at emcdda.europa.eu/publications/gra/2015

ANNEX 6 Key performance indicators

Attaining good performance was a strategic goal for the EMCDDA in 2013–15, and the

agency made significant progress in this area during this three-year period. This included

establishing KPIs for all the main areas of work. In line with the two-step approach

endorsed by the Management Board, the process started with the definition of KPIs for

three areas in the 2014 work programme; in the second phase, which was completed

under the framework of the preparation of the 2015 work programme, KPIs were

developed for all areas of work (51 KPIs in total).

These KPIs were designed to measure the achievement of the specific objectives defined

in the 2015 work programme. As much as this was possible, annual targets were defined

in order to support the measurement of the KPIs. The results are presented in the online

annex at emcdda.europa.eu/publications/gra/2015

General Report of Activities 2015

114

ANNEX 7 Members of the EMCDDA’s statutory bodies

I Members of the Management Board

The Management Board consists of one representative from each Member State, two

representatives of the European Commission, two independent experts that are

particularly knowledgeable in the field of drugs, designated by the European Parliament,

and one representative from each country that has concluded an agreement with the

EMCDDA (i.e. Norway and Turkey). Non-voting observers, such as those from international

organisations with which the agency cooperates, may also be invited to Management

Board meetings.

Country/organisation Member Substitute

Belgium Claude GILLARD (Vice-Chairman) Vladimir MARTENS

Bulgaria Momtchil VASSILEV

Czech Republic Jindrich VOBOŘIL Lucia KISSOVA

Denmark Lars PETERSEN Dennis PIHL THOMSEN

Germany Marlene MORTLER Dirk LESSER

Estonia Anna-Liisa PÄÄSUKENE Ain PEIL

Ireland Susan SCALLY Marie McBRIDE

Greece Christina DIAMANTOPOULOU Gerasimos PAPANASTASATOS

Spain Francisco BABÍN VICH Maria Sofia ARAGÓN SÁNCHEZ

France Laura d’ARRIGO Danièle JOURDAIN MENNINGER

Croatia Željko PETKOVIĆ Sanja MIKULIĆ

Italy Patrizia DE ROSE Elisabetta SIMEONI

Cyprus Stelios SERGIDES Marios ADONIS

Latvia Dzintars MOZGIS

Lithuania Inga JUOZAPAVIČIENÉ Gražina BELIAN

Luxembourg Xavier POOS Alain ORIGER

Hungary Mónika SZÁSZIK Ibolya CSÁKÓ

Malta Richard MUSCAT Marilyn CLARK

Netherlands Wil DE ZWART

Austria Franz PIETSCH Christina SCHAFFER-KRAL

Poland Piotr JABŁOŃSKI Bogusława BUKOWSKA

Portugal JOÃO GOULÃO (Chairman) Manuel CARDOSO

Romania Sorin OPREA Cătălin NEGOI-NIŢĂ

Slovenia Vesna-Kerstin PETRIČ Jože HREN

Slovakia Mario MIKLOSI Dominika GREISIGEROVÁ

Finland Elina KOTOVIRTA Kari PAASO

Sweden Lina PASTOREK Bo PETTERSON

United Kingdom John McCRACKEN Sam WEBB

European Commission Matthias RUETE and Luigi SORECA Floriana SIPALA and Philippe ROUX

Annex 7

115

Country/organisation Member Substitute

European ParliamentBarbara DÜHRKOP DÜHRKOP and Carla ROSSI

Massimo CANU and Katalin FELVINCZI

Norwegian representatives Lilly Sofie OTTESEN Hege Christina BREDESEN

Turkish representatives Cengiz ERİŞİR Murat SARIKAMIŞLI

Observers

Scientific Committee Gerhard BÜHRINGER

Reitox spokesperson Tim PFEIFFER-GERSCHEL

UNODC Gilberto GERRA

Council of Europe Pompidou Group

Thomas KATTAU

WHO Lars MØLLER

I Members of the Executive Committee

The Management Board is assisted by an Executive Committee. The Executive Committee is made up of the

Chairperson and the Vice-Chairperson of the Management Board, two other members of the Management

Board representing the Member States and appointed by the Management Board, and two representatives of

DG HOME, as the EMCDDA’s partner DG, for the European Commission. The Executive Committee prepares

and follows up the decisions of the Management Board, and assists and advises the EMCDDA Director.

João GOULÃO Portugal (Chairman of the Management Board)

Claude GILLARDBelgium (Vice-Chairman of the Management Board and Chair of the Budget Committee)

Laura d’ARRIGO France

Franz PIETSCH Austria

Two representatives of the European Commission (DG HOME)

I Members of the Scientific Committee

The members of the Scientific Committee are selected for their independence and proven expertise in

a particular field/specialty, as indicated below.

Field/specialty Scientific Committee Member(s)

Basic biological, neurobiological and behavioural research Fernando RODRIGUEZ DE FONSECA

Rainer SPANAGEL

Drug policy Henri BERGERON

Anne Line BRETTEVILLE-JENSEN

Krzysztof KRAJEWSKI

Population-based research and epidemiology Catherine COMISKEY

Paul DARGAN

Dirk KORF

Matthew HICKMAN

Supply, supply reduction and crime Brice DE RUYVER

Letizia PAOLI

Demand reduction Gerhard BÜHRINGER

Marina DAVOLI

Gabriele FISCHER

Henk GARRETSEN

General Report of Activities 2015

116

EMCDDA 2015 budget execution by objectives and activities in the 2015 work programme

A. Monitoring and reporting on the drugs problem in Europe (vertical operations)

Objectives and activities of EMCDDA 2015 WP

Main organisational actors for

implementation

Assigned HR Initial allocation of budget resources — non assigned appropriation

Final allocation of budget resources — non assigned appropriation

Executed budget — non assigned appropriation

O TA CA SNE Total HRDirect cost

of operations

Indirect costs of

operationsTotal budget

Direct cost of

operations

Indirect costs of

operationsTotal budget

Direct cost of

operations

Indirect costs of

operations

Total budget execution

Data collection, analysis and quality assurance

EPI + RTX 0.5 3.0 3.5 0.0 7.0 596 433.00 545 130.62 1 141 563.62 793 012.73 347 720.70 1 140 733.43 568 822.47 754 458.40 1 323 280.87

Monitoring and understanding drug use and problems: key indicators and epidemiology

EPI 0.5 3.5 0.5 0.0 4.5 624 776.09 509 994.38 1 134 770.47 534 313.96 208 788.75 743 102.71 684 081.35 705 830.00 1 389 911.35

Monitoring demand reduction responses applied to drug-related problems

IBS 2.0 6.0 0.5 0.0 8.5 641 369.28 269 711.76 911 081.04 336 767.81 99 148.99 435 916.80 637 971.37 746 559.79 1 384 531.16

Monitoring drug supply and supply reduction interventions

SAT 1.0 4.0 2.0 1.0 8.0 488 383.04 360 604.36 848 987.40 360 382.53 104 497.24 464 879.77 471 259.41 499 074.86 970 334.28

Monitoring new trends and developments and assessing the risks of new substances

SAT 0.0 4.0 3.0 0.0 7.0 583 311.82 385 658.43 968 970.25 411 831.87 104 497.24 516 329.11 473 885.34 533 749.58 1 007 634.91

Improving Europe's capacity to monitor and evaluate policies

EPI + IBS + SAT 0.0 2.5 0.0 0.0 2.5 244 585.90 194 619.78 439 205.68 555 697.52 208 788.81 764 486.33 224 835.69 269 352.92 494 188.61

Scientific coordination, research and content support

SDI + EPI 0.5 4.0 2.5 0.0 7.0 780 054.65 482 379.56 1 262 434.21 433 395.28 123 072.16 556 467.44 768 591.70 936 964.12 1 705 555.82

TOTAL 4.5 27.0 12.0 1.0 44.5 3 958 913.78 2 748 098.89 6 707 012.67 3 425 401.70 1 196 513.89 4 621 915.59 3 829 447.34 4 445 989.66 8 275 437.00

B. Cooperation and collaboration with key external partners (transversal operations)

Objectives and activities of EMCDDA 2015 WP

Main organisational actors for

implementation

Assigned HR Initial allocation of budget resources — non assigned appropriation

Final allocation of budget resources — non assigned appropriation

Executed budget — non assigned appropriation

O TA CA SNE Total HRDirect cost

of operations

Indirect costs of

operations

Total budget

Direct cost of

operations

Indirect costs of

operations

Total budget

Direct cost of

operations

Indirect costs of

operations

Total budget

execution

Cooperation and collaboration with key partners

DIR + SDI + RTX 0.5 4.0 0.5 0.0 5.0 604 345.37 419 104.70 1 023 450.07 341 116.70 113 280.73 454 397.43 576 202.98 580 039.07 1 156 242.05

TOTAL 0.5 4.0 0.5 0.0 5.0 604 345.37 419 104.70 1 023 450.07 341 116.70 113 280.73 454 397.43 576 202.98 580 039.07 1 156 242.05

Note: Figures are in EUR.

ANNEX 8 Use of the available resources in 2015

Annex 8

117

EMCDDA 2015 budget execution by objectives and activities in the 2015 work programme

A. Monitoring and reporting on the drugs problem in Europe (vertical operations)

Objectives and activities of EMCDDA 2015 WP

Main organisational actors for

implementation

Assigned HR Initial allocation of budget resources — non assigned appropriation

Final allocation of budget resources — non assigned appropriation

Executed budget — non assigned appropriation

O TA CA SNE Total HRDirect cost

of operations

Indirect costs of

operationsTotal budget

Direct cost of

operations

Indirect costs of

operationsTotal budget

Direct cost of

operations

Indirect costs of

operations

Total budget execution

Data collection, analysis and quality assurance

EPI + RTX 0.5 3.0 3.5 0.0 7.0 596 433.00 545 130.62 1 141 563.62 793 012.73 347 720.70 1 140 733.43 568 822.47 754 458.40 1 323 280.87

Monitoring and understanding drug use and problems: key indicators and epidemiology

EPI 0.5 3.5 0.5 0.0 4.5 624 776.09 509 994.38 1 134 770.47 534 313.96 208 788.75 743 102.71 684 081.35 705 830.00 1 389 911.35

Monitoring demand reduction responses applied to drug-related problems

IBS 2.0 6.0 0.5 0.0 8.5 641 369.28 269 711.76 911 081.04 336 767.81 99 148.99 435 916.80 637 971.37 746 559.79 1 384 531.16

Monitoring drug supply and supply reduction interventions

SAT 1.0 4.0 2.0 1.0 8.0 488 383.04 360 604.36 848 987.40 360 382.53 104 497.24 464 879.77 471 259.41 499 074.86 970 334.28

Monitoring new trends and developments and assessing the risks of new substances

SAT 0.0 4.0 3.0 0.0 7.0 583 311.82 385 658.43 968 970.25 411 831.87 104 497.24 516 329.11 473 885.34 533 749.58 1 007 634.91

Improving Europe's capacity to monitor and evaluate policies

EPI + IBS + SAT 0.0 2.5 0.0 0.0 2.5 244 585.90 194 619.78 439 205.68 555 697.52 208 788.81 764 486.33 224 835.69 269 352.92 494 188.61

Scientific coordination, research and content support

SDI + EPI 0.5 4.0 2.5 0.0 7.0 780 054.65 482 379.56 1 262 434.21 433 395.28 123 072.16 556 467.44 768 591.70 936 964.12 1 705 555.82

TOTAL 4.5 27.0 12.0 1.0 44.5 3 958 913.78 2 748 098.89 6 707 012.67 3 425 401.70 1 196 513.89 4 621 915.59 3 829 447.34 4 445 989.66 8 275 437.00

B. Cooperation and collaboration with key external partners (transversal operations)

Objectives and activities of EMCDDA 2015 WP

Main organisational actors for

implementation

Assigned HR Initial allocation of budget resources — non assigned appropriation

Final allocation of budget resources — non assigned appropriation

Executed budget — non assigned appropriation

O TA CA SNE Total HRDirect cost

of operations

Indirect costs of

operations

Total budget

Direct cost of

operations

Indirect costs of

operations

Total budget

Direct cost of

operations

Indirect costs of

operations

Total budget

execution

Cooperation and collaboration with key partners

DIR + SDI + RTX 0.5 4.0 0.5 0.0 5.0 604 345.37 419 104.70 1 023 450.07 341 116.70 113 280.73 454 397.43 576 202.98 580 039.07 1 156 242.05

TOTAL 0.5 4.0 0.5 0.0 5.0 604 345.37 419 104.70 1 023 450.07 341 116.70 113 280.73 454 397.43 576 202.98 580 039.07 1 156 242.05

Note: Figures are in EUR.

General Report of Activities 2015

118

C. Supporting the achievement of results (transversal operations)

Objectives and activities of EMCDDA 2015 WP

Main organisational actors for

implementation=

Assigned HR Initial allocation of budget resources — non assigned appropriation

Final allocation of budget resources — non assigned appropriation

Executed budget — non assigned appropriation

O TA CA SNE Total HRDirect cost

of operations

Indirect costs of

operationsTotal budget

Direct cost of

operations

Indirect costs of

operationsTotal budget

Direct cost of

operations

Indirect costs of

operations

Total budget execution

Communicating the EMCDDA’s findings to external audiences (including translation)

COM 1.0 9.0 2.0 0.0 12.0 1 654 324.53 930 443.01 2 584 767.54 1 475 955.19 404 853.88 1 880 809.07 1 683 571.97 1 287 729.06 2 971 301.03

Governance, management and networks (executive and corporate management + governing bodies’ activities)

DIR + SDI 3.5 5.0 2.0 0.0 10.5 1 221 884.49 920 774.54 2 142 659.03 1 001 965.05 298 269.62 1 300 234.67 1 208 297.22 1 373 889.24 2 582 186.46

RTX + NFPs' co-financed activities

0.5 3.0 0.5 0.0 4.0 2 559 847.18 316 226.15 2 876 073.33 2 807 417.53 91 867.04 2 899 284.57 2 446 631.84 437 655.60 2 884 287.44

TOTAL 5.0 17.0 4.5 0.0 26.5 5 436 056.20 2 167 443.70 7 603 499.90 5 285 337.77 794 990.54 6 080 328.31 5 338 501.03 3 099 273.90 8 437 774.94

GRAND TOTAL FOR OPERATIONS 10.0 48.0 17.0 1.0 76.0 9 999 315.35 5 334 647.29 15 333 962.64 9 051 856.17 2 104 785.16 11 156 641.33 9 744 151.36 8 125 302.63 17 869 453.99

D. Support to operations under A, B and C above (overheads)

Objectives and activities of EMCDDA 2015 WP

Main organisational actors for

implementation

Assigned HR Initial allocation of budget resources for direct cost of supporting activities to be

distributed to operations

Final allocation of budget resources for direct cost of supporting activities to be

distributed to operations

Executed budget — non assigned appropriationO TA CA SNE Total HR

Administration: supporting core businessADM (administration

and resources/assets management)

3.0 11.0 7.5 0.0 21.5 2 954 104.75 6 835 912.08 6 835 912.08

Information and communication technologies

ICT (equipment and services)

0.0 8.0 2.5 0.0 10.5 1 073 216.56 1 320 500.96 1 289 390.55

TOTAL 3.0 19.0 10.0 0.0 32.0 4 027 321.31 8 156 413.04 8 125 302.63

E. Grand total for operations and support to operations

Objectives and activities of EMCDDA 2015 WP

Main organisational actors for

implementation

Assigned HR Allocated budget resources for direct costs of supporting activities to be

distributed to operations (see above) — non-assigned appropriations

O TA CA SNE Total HR

TOTAL 13.0 67.0 27.0 1.0 108.0 17 869 453.99

F. Special projects

Objectives and activities of EMCDDA 2015 WP

Main organisational actors for

implementation

Assigned HR Budget –assigned appropriations

O TA CA SNE Total HR Budget allocation — financing received in 2015

Carried over and carried forward from 2014 Total available in 2015 Budget execution

Preparation of IPA beneficiary countries for their participation in the EMCDDA (IPA 5 project — first year)

RTX 0.0 0.0 0.5 0.0 0.5 600 000.00 0.00 600 000.00 74 349.09

Project for technical assistance aimed at strengthening the capacity of the ENP partner countries to react to new challenges and developments in the drug situation (ENP 1 project — second year)

RTX 0.0 0.0 0.0 0.0 0.0 111 787.83 135 982.17 247 770.00 187 849.99

Note: Figures are in EUR.Remarks:Assigned HR = full-time time equivalent per year; O = officials; TA = temporary agents; CA = contract agents; SNE = seconded national experts.Appropriations for cost/expenditure for operational activities and staff that directly aim to implement the EMCDDA mission/task/WP.Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that are used indirectly to implement the EMCDDAmission/task/WP, as their immediate aim is to support operational activities and staff. These overheads are distributed to operational activities inproportion with the human resources assigned to the implementation of these activities.

Annex 8

119

C. Supporting the achievement of results (transversal operations)

Objectives and activities of EMCDDA 2015 WP

Main organisational actors for

implementation=

Assigned HR Initial allocation of budget resources — non assigned appropriation

Final allocation of budget resources — non assigned appropriation

Executed budget — non assigned appropriation

O TA CA SNE Total HRDirect cost

of operations

Indirect costs of

operationsTotal budget

Direct cost of

operations

Indirect costs of

operationsTotal budget

Direct cost of

operations

Indirect costs of

operations

Total budget execution

Communicating the EMCDDA’s findings to external audiences (including translation)

COM 1.0 9.0 2.0 0.0 12.0 1 654 324.53 930 443.01 2 584 767.54 1 475 955.19 404 853.88 1 880 809.07 1 683 571.97 1 287 729.06 2 971 301.03

Governance, management and networks (executive and corporate management + governing bodies’ activities)

DIR + SDI 3.5 5.0 2.0 0.0 10.5 1 221 884.49 920 774.54 2 142 659.03 1 001 965.05 298 269.62 1 300 234.67 1 208 297.22 1 373 889.24 2 582 186.46

RTX + NFPs' co-financed activities

0.5 3.0 0.5 0.0 4.0 2 559 847.18 316 226.15 2 876 073.33 2 807 417.53 91 867.04 2 899 284.57 2 446 631.84 437 655.60 2 884 287.44

TOTAL 5.0 17.0 4.5 0.0 26.5 5 436 056.20 2 167 443.70 7 603 499.90 5 285 337.77 794 990.54 6 080 328.31 5 338 501.03 3 099 273.90 8 437 774.94

GRAND TOTAL FOR OPERATIONS 10.0 48.0 17.0 1.0 76.0 9 999 315.35 5 334 647.29 15 333 962.64 9 051 856.17 2 104 785.16 11 156 641.33 9 744 151.36 8 125 302.63 17 869 453.99

D. Support to operations under A, B and C above (overheads)

Objectives and activities of EMCDDA 2015 WP

Main organisational actors for

implementation

Assigned HR Initial allocation of budget resources for direct cost of supporting activities to be

distributed to operations

Final allocation of budget resources for direct cost of supporting activities to be

distributed to operations

Executed budget — non assigned appropriationO TA CA SNE Total HR

Administration: supporting core businessADM (administration

and resources/assets management)

3.0 11.0 7.5 0.0 21.5 2 954 104.75 6 835 912.08 6 835 912.08

Information and communication technologies

ICT (equipment and services)

0.0 8.0 2.5 0.0 10.5 1 073 216.56 1 320 500.96 1 289 390.55

TOTAL 3.0 19.0 10.0 0.0 32.0 4 027 321.31 8 156 413.04 8 125 302.63

E. Grand total for operations and support to operations

Objectives and activities of EMCDDA 2015 WP

Main organisational actors for

implementation

Assigned HR Allocated budget resources for direct costs of supporting activities to be

distributed to operations (see above) — non-assigned appropriations

O TA CA SNE Total HR

TOTAL 13.0 67.0 27.0 1.0 108.0 17 869 453.99

F. Special projects

Objectives and activities of EMCDDA 2015 WP

Main organisational actors for

implementation

Assigned HR Budget –assigned appropriations

O TA CA SNE Total HR Budget allocation — financing received in 2015

Carried over and carried forward from 2014 Total available in 2015 Budget execution

Preparation of IPA beneficiary countries for their participation in the EMCDDA (IPA 5 project — first year)

RTX 0.0 0.0 0.5 0.0 0.5 600 000.00 0.00 600 000.00 74 349.09

Project for technical assistance aimed at strengthening the capacity of the ENP partner countries to react to new challenges and developments in the drug situation (ENP 1 project — second year)

RTX 0.0 0.0 0.0 0.0 0.0 111 787.83 135 982.17 247 770.00 187 849.99

Note: Figures are in EUR.Remarks:Assigned HR = full-time time equivalent per year; O = officials; TA = temporary agents; CA = contract agents; SNE = seconded national experts.Appropriations for cost/expenditure for operational activities and staff that directly aim to implement the EMCDDA mission/task/WP.Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that are used indirectly to implement the EMCDDAmission/task/WP, as their immediate aim is to support operational activities and staff. These overheads are distributed to operational activities inproportion with the human resources assigned to the implementation of these activities.

General Report of Activities 2015

120

Statement of financial performance

2015 2014 Variation

Contributions of EFTA countries belonging to the EEA 394 005.50 392 177.02 1 828.48

Recovery of expenses 41 614.00 27 910.85 13 703.15

Revenues from administrative operations 2 649 174.72 1 936.25 2 647 238.47

Other operating revenue 14 965 604.27 15 293 808.38 –328 204.11

TOTAL OPERATING REVENUE 18 050 398.49 15 715 832.50 2 334 565.99

Administrative expenses –13 589 506.36 –11 325 830.20 –2 263 676.16

All staff expenses –9 100 284.26 –8 654 377.38 –445 906.88

Fixed asset-related expenses –1 988 158.10 –256 302.53 –1 731 855.57

Other administrative expenses –2 501 064.00 –2 415 150.29 –85 913.71

Operational expenses –3 819 662.72 –4 223 010.71 403 347.99

Other operational expenses –3 819 662.72 –4 223 010.71 403 347.99

TOTAL OPERATING EXPENSES –17 409 169.08 –15 548 840.91 –1 860 328.17

SURPLUS/DEFICIT FROM OPERATING ACTIVITIES 641 229.41 166 991.59 474 237.82

Financial revenues 20 944.90 9 105.05 11 839.85

Financial expenses –3 102.80 –3 651.30 548.50

SURPLUS/DEFICIT FROM NON-OPERATING ACTIVITIES 17 842.10 5 453.75 12 388.35

SURPLUS/DEFICIT FROM ORDINARY ACTIVITIES 659 071.51 172 445.34 486 626.17

ECONOMIC OUTTURN FOR THE YEAR 659 071.51 172 445.34 486 626.17

Annex 8

121

EMCDDA 2015 budget appropriations and execution by nature of expenditure

Title Description EUR

1. Expenditure relating to persons working with the EMCDDA

Staff in active employment 9 026 729.19

Other staff-related expenditure (exchange of officials, etc.) 132 431.59

Total under Title 1 9 159 160.78

2. Expenditure for support activities

Investment in immovable property, rental of buildings and associated costs 4 018 349.82

Data processing 575 683.25

Movable property and associated costs 134 713.08

Current administrative expenditure + postal charges and telecommunications 104 986.38

Socio-medical infrastructure 22 049.52

Total under Title 2 4 855 782.05

3. Expenditure for operational activities

Statutory meetings 169 999.50

Expenditure on formal and others meetings + representative expenses 336 764.38

Studies, surveys, consultations 469 221.83

Publishing and translations 558 832.41

European Network on Drugs and Drug Addiction Reitox 2 069 945.41

Missions 249 747.63

Total under Title 3 – Section 1.01 3 854 511.16

Section 1.02 – Total core budget 17 869 453.99

Section 1.03

4. Expenditure relating to other subsidies

EU financing of specific projects

4a. IPA 5: financing for implementing pre-accession strategy 74 349.09

4b. ENP1: strengthening the capacity of the partner countries to react to new challenges and developments in the drug situation

187 849.99

5 Other expenses (reserve) 0.00

Total budget 18 131 653.07

Note: The amounts committed under 4a and 4b contain the commitment appropriations carried forward from the previous year.

Execution of the budget: Credit consumption, 2015 (commitments)

Title Description % consumption of available credits

1 Staff 100.00

2. Expenditure for support activities 100.00

3. Expenditure for operational activities 99.20

4a. Expenditure relating to IPA5 12.39

4b. Expenditure relating to ENP1 75.82

Total consumption of core budget (Titles 1, 2, 3 ) 99.62

General Report of Activities 2015

122

Balance sheet: ASSETS (in EUR)

31.12.2015 31.12.2014 Variation

ASSETS

A. NON-CURRENT ASSETS

Intangible assets 290 584.25 96 308.03 194 276.22

Property, plant and equipment 387 925.97 2 104 365.66 –1 716 439.69

Land and buildings 0.00 1 810 069.20 –1 810 069.20

Plant and equipment 83 809.05 93 654.67 –9 845.62

Computer hardware 211 191.35 137 275.28 73 916.07

Furniture and vehicles 92 925.57 63 366.51 29 559.06

Long-term pre-financing 1 966 664.00 0.00 1 966 664.00

Long-term pre-financing 1 966 664.00 0.00 1 966 664.00

TOTAL NON-CURRENT ASSETS 2 645 174.22 2 200 673.69 444 500.53

B. CURRENT ASSETS

Short-term pre-financing 546 199.38 0.00 546 199.38

Short-term pre-financing 546 199.38 0.00 546 199.38

Short-term receivables 913 418.65 767 915.59 145 503.06

Current receivables 737 782.43 398 410.97 339 371.46

Other 175 636.22 369 504.62 –193 868.40

Deferred charges 175 636.22 369 504.62 –193 868.40

Cash and cash equivalents 1 467 861.10 1 071 938.39 395 922.71

TOTAL CURRENT ASSETS 2 927 479.13 1 839 853.98 1 087 625.15

TOTAL 5 572 653.35 4 040 527.67 1 532 125.68

Annex 8

123

Balance sheet: LIABILITIES (in EUR)

31.12.2015 31.12.2014 Variation

LIABILITIES

A. Net assets 3 385 544.54 2 726 473.03 659 071.51

Accumulated surplus/deficit 2 726 473.03 2 554 027.69 172 445.34

Economic outturn for the year — profit +/ loss- 659 071.51 172 445.34 486 626.17

TOTAL NET ASSETS 3 385 544.54 2 726 473.03 659 071.51

D. Current liabilities 2 187 108.81 1 314 054.64 873 054.17

Accounts payable 2 187 108.81 1 314 054.64 873 054.17

Current payables 617 488.80 4 102.64 613 386.16

Sundry payables –256.00 0.00 –256.00

Other 866 469.68 1 110 134.23 –243 664.55

Accrued charges 863 815.15 946 780.70 –82 965.55

Deferred income 2 654.53 2 253.53 401.00

Deferred income with consolidated EU entities 0.00 161 100.00 –161 100.00

Accounts payable with consolidated EU entities 703 406.33 199 817.77 503 588.56

Pre-financing received from consolidated EU entities 699 240.03 199 817.77 499 422.26

Other accounts payable against consolidated EU entities

4 166.30 0.00 4 166.30

TOTAL D. CURRENT LIABILITIES 2 187 108.81 1 314 054.64 873 054.17

TOTAL 5 572 653.35 4 040 527.67 1 532 125.68

General Report of Activities 2015

124

Budget result account for the financial year 2015 (in EUR)

2015 2014

REVENUE

Balancing Commission subsidy + 14 794 000.00 14 793 959.00

Other subsidy from Commission (IPA, ENP, etc.) + 711 787.83 488 900.00

Own revenue (sale of building) + 2 500 000.00

Other income (Norway, Turkey, internal assigned revenue, bank interests, Translation Centre refund 2015)

+ 626 434.98 407 822.92

TOTAL REVENUE (a) 18 632 222.81 15 690 681.92

EXPENDITURE

Title I: Staff

Payments – 9 122 210.74 8 644 335.30

Appropriations carried over – 138 169.78 38 178.67

Title II: Administrative expenses

Payments – 4 458 390.98 1 932 659.31

Appropriations carried over – 443 069.65 701 335.34

Title III: Operating expenditure

Payments – 4 045 844.43 4 417 989.82

Appropriations carried over – 599 237.01 153 508.06

TOTAL EXPENDITURE (b) 18 806 922.59 15 888 006.50

RESULT FOR THE FINANCIAL YEAR (a–b) –174 699.78 –197 324.58

Cancellation of unused payment appropriations carried over from previous year + 38 712.08 8 622.14

Adjustment for carry-over from the previous year of appropriations available on 31 December arising from assigned revenue

+ 188 102.04 262 588.50

Exchange differences for the year (gain: +; loss: –) +/– 4 976.68 –1 272.22

Pro rata Norway 2015 –1 995.71–2 253.53

Pro rata Turkey 2015 –658.82

BALANCE OF THE RESULT ACCOUNT FOR THE FINANCIAL YEAR 54 436.49 70 360.31

Balance year n–1 +/– 70 360.31 151 386.27

Positive balance from year n–1 reimbursed in year n to the Commission – –70 360.31 –151 386.27

Result used for determining amounts in general accounting 54 436.49 70 360.31

Commission subsidy — agency registers accrued revenue and Commission accrued expense

14 739 563.51 14 723 598.69

Pre-financing remaining open to be reimbursed by agency to Commission in year n+1

54 436.49 70 360.31

125

ANNEX 9 List of acronyms and abbreviations

ABAC The EMCDDA’s electronic management and accounting system

AIDS Acquired immune deficiency syndrome

ALICE-RAPAddiction and Lifestyles in Contemporary Europe — Reframing Addictions Project

BCP Business continuity plan

BPP Best practice portal

CEPOL European Police College

CICAD Inter-American Drug Abuse Control Commission

CLEN Customs Laboratories European Network

CND Commission on Narcotic Drugs

COPOLAD Cooperation Programme between Latin America and the EU on Drugs Policies

COSIThe Council of the European Union’s Standing Committee on Operational Cooperation on Internal Security

DEA Drug Enforcement Agency

DG Directorate-General

DG HOME Directorate-General for Migration and Home Affairs

DG HR Directorate-General for Human Resources and Security

DG NEAR Directorate-General for Neighbourhood and Enlargement Negotiations

DG SANTE Directorate-General for Health and Food Safety

DG TAXUD Directorate-General for Taxation and Customs Union

4,4′-DMAR 4,4′-Dimethylaminorex

DRID drug-related infectious diseases (indicator)

EASO European Asylum Support Office

Eawag Swiss Federal Institute of Aquatic Science and Technology

EC European Commission

ECA European Court of Auditors

ECDC European Centre for Disease Prevention and Control

EDMR EU Drug Markets Report

EDND European Database on New Drugs

EDR European Drug Report

EEAS European External Action Service

EFSA European Food Safety Authority

EFSQ European Facility Survey Questionnaire

ELDD European Legal Database on Drugs

EMA European Medicines Agency

EMCDDA European Monitoring Centre for Drugs and Drug Addiction

EMPACT European Multidisciplinary Platform Against Criminal Threats

EMQ European Model Questionnaire

EMSA European Maritime Safety Agency

General Report of Activities 2015

126

ENFSI European Network of Forensic Science Institutes

ENP European Neighbourhood Policy

ERANID European Research Area Network on Illicit Drugs

ERICES European Reporting Instrument for Cocaine Extraction Sites

ERICP European Reporting Tool for Cannabis Production

ERISSP European Reporting on Illicit Synthetic Substances Production Sites

ESPAD European School Survey Project on Alcohol and Other Drugs

EU European Union

EU-ANSA EU Agencies Network of Scientific Advisors

Euro-DEN European Drug Emergencies Network

Eurojust the European Union’s Judicial Cooperation Unit

Europol European Police Office

EUSPR European Society for Prevention Research

EWS Early Warning System

FP7 Seventh Framework Programme for Research and Development

FRA Fundamental Rights Agency

Frontex The European External Border Agency

GPS General population survey

HCIN Heads of Communication and Information network

HCV Hepatitis C virus

HDG Horizontal Drugs Group

HFP Head of national focal point

HIPP Health in Prisons Programme

HIV Human immunodeficiency virus

IALN Inter-Agency Legal Network

IAS Internal Audit Service of the European Commission

ICS Internal Control Standard

ICT Information and communication technology

ICTAC Inter-Agency ICT Managers’ Network

INCB International Narcotics Control Board

IPA Instrument for Pre-Accession Assistance

ISAJE International Society of Addiction Journal Editors

ISCTE-IUL ISCTE — University Institute of Lisbon

JHA Justice and Home Affairs

KI Key epidemiological indicator

KPI Key performance indicator

LIBE CommitteeCivil Liberties, Justice and Home Affairs Committee of the European Parliament

MAOC-N Maritime Analysis and Operations Centre — Narcotics

MDMA Methylenedioxyphenethylamine

MEP Member of the European Parliament

Annex 9

127

MILDECA French Interministerial Mission for Combating Drugs and Addictive Behaviours

MoU Memorandum of Understanding

NAPO Network of Agencies Procurement Officers

NFP National focal point

NIDA US National Institute on Drug Abuse

NPS New psychoactive substance(s)

NRP National reporting package

NSC National Security Council of Armenia

OAP Operational action plan

OAS Organization of American States

ONDA Moroccan National Observatory on Drugs and Addictions

OSI Open source information

POD Perspectives on drugs

α-PVP α-Pyrrolidinovalerophenone

PWID People who inject drugs

RARHA Joint action on reducing alcohol-related harm

Reitox European Information Network on Drugs and Drug Addiction

SEWPROF Sewage profiling project

SICADPortuguese General-Directorate for Intervention on Addictive behaviours and Dependencies (Serviço de Intervenção nos Comportamentos Aditivos e nas Dependências)

SPD Single multi-annual programming document

TAIEXTechnical Assistance and Information Exchange Instrument managed by DG NEAR of the European Commission

TDI Treatment demand indicator

UMMCDAUkrainian Monitoring and Medical Centre on Drugs and Alcohol of the Ministry of Health of Ukraine

UNGASS United Nations General Assembly Special Session on Drug Policy

UNODC United Nations Office on Drugs and Crime

WHO World Health Organization

HOW TO OBTAIN EU PUBLICATIONS

Free publications

one copy:

via EU Bookshop (http://bookshop.europa.eu)

more than one copy or posters/maps:

from the European Union’s representations

(http://ec.europa.eu/represent_en.htm);

from the delegations in non-EU countries

(http://eeas.europa.eu/delegations/index_en.htm);

by contacting the Europe Direct service

(http://europa.eu/europedirect/index_en.htm) or

calling 00 800 6 7 8 9 10 11

(freephone number from anywhere in the EU) (*).

(*) The information given is free, as are most calls (though

some operators, phone boxes or hotels may charge you).

Priced publications

via EU Bookshop (http://bookshop.europa.eu)

TD

-AB

-16

-001-E

N-N

GE

NE

RA

L RE

PO

RT

OF

AC

TIV

ITIE

S 2

01

5 K

ey achievem

ents an

d govern

ance: a year in

review

About this report

The General Report of Activities is an annual

publication providing a detailed progress report of the

EMCDDA’s activities over a 12-month period. Published

every spring, it catalogues the agency’s achievements

in each area of its annual work programme. The report

is a useful information source for all those seeking

comprehensive information on the agency and its work.

About the EMCDDA

The European Monitoring Centre for Drugs and Drug

Addiction (EMCDDA) is the central source and

confirmed authority on drug-related issues in Europe.

For over 20 years, it has been collecting, analysing and

disseminating scientifically sound information on drugs

and drug addiction and their consequences, providing

its audiences with an evidence-based picture of the

drug phenomenon at European level.

The EMCDDA’s publications are a prime source of

information for a wide range of audiences including:

policymakers and their advisors; professionals and

researchers working in the drugs field; and, more

broadly, the media and general public. Based in Lisbon,

the EMCDDA is one of the decentralised agencies of

the European Union.

ISBN 978-92-9168-914-9 doi:10.2810/15377

1

Annex 4General Report of Activities 2015

I ANNEX 4 Key external events, conferences and meetings, 2015

In 2015, EMCDDA staff participated in many external events, conferences and technical meetings. Through this participation, they brought their knowledge and expertise to

international scientific discussions and the various political debates currently active in the drugs field. The events are presented here according to their order in the work

programme. For acronyms and abbreviations used, please refer to Annex 9 of the full report available at: emcdda.europa.eu/publications/gra/2015

Date Place Event Title of the presentation

2. Monitoring and understanding drug use and problems: key indicators and epidemiology

23 January UK, Gatwick Euro-DEN steering group meeting

28–29 January SE, Stockholm ESPAD steering committee meetingDrug-related deaths: update on the situation and some prevention interventions developed in Europe

13–14 March EL, Athens Meeting of RARHA/SMART survey initiative(1) Is data on drug-related mortality comparable between countries? (2) Trends in drug-related mortality in Europe — an EU level perspective

28–29 April BE, BrusselsMeeting of the Committee on National Alcohol Policy and Action (CNAPA)

1 October AT, GasteinWorkshop on ‘Health information — Creating evidence for EU health policy making’, European Health Forum Gastein

An example of an indicator on health information: drug use in Europe

15–17 November CY, Larnaca ESPAD project meeting

11–12 December IT, Rome Board of Directors and working groups meeting, HWBTreatment demand indicator: implementation and results in the European countries

3. Monitoring demand reduction responses applied to drug‑related problems

4–6 February SE, StockholmUnderstanding the impact of smart phone apps on men who have sex with men, sexual health and HIV prevention in EU

9–11 February DE, Dresden European graduate school in addiction research (ESADD) Prevention research

10–11 February LU, LuxembourgMeeting on the quality review of joint action on harm reduction applications

16–18 February SE, Stockholm Third hepatitis B and C network meetingChanging patterns in drug use, harm reduction and the burden of hepatitis amongst people who inject drugs

25–26 February DE, Berlin Druck Studie, Robert Koch-Institut

Nach der DRUCK Studie: welche Daten sollten regelmaessig erholten werden? Informationen zur EU Datensammlung zu drogenbezogenen Infektionskrankheiten

2

Annex 4General Report of Activities 2015

Date Place Event Title of the presentation

27 February–3 March ES, Granada Master University of Granada

Epidemiología, tratamiento, reducción de daños y aspectos legalesLa prevención en la Unión EuropeaProgramación y evaluación en la prevención

12–14 March SI, LjubljanaSeventh SEEA net conference and sixth Slovene conference on hepatitis C in people who use drugs

26–27 March DE, Tübingen Tübinger Suchtterapietage 2015Amerikanische Präventionsprogramme in Europa: wirksam?

7 April ES, Madrid Jornada consumo de alcohol en jovenes¿Son efectivas las campañas de prevención? El efecto de las campañas sobre el consumo

13–15 April ES, Cordoba RIOD seminario BCT en intervenciones preventivas

27 April–7 May USA, MiamiTraining of master trainers for Western Hemisphere on the universal prevention curriculum for substance use, The Colombo Plan

7 May DE, St. Ingbert 10. Europäisches Expertentreffen Drogenerkennung Drogenkonsum in Europa: Legal, illegal?

18–19 May ES, Barcelona European Prison Observatory Drugs and prison in Europe: state of play

19–20 May IT, RomeSyva drug testing diagnostics conference: ‘The Ever-changing World of Drug Abuse’

Drug use in Europe: long term trends and recent developments

28–29 May DK, Copenhagen Steering group meeting on prison health

1–5 June DE, Munich

41st annual alcohol epidemiology symposium of the Kettil Bruun Society (KBS) and Institut für Therapieforschung (IFT), and Ludwig-Maximilians-Universität, Department of Psychiatry and Psychotherapy

Harm reduction for cannabis and alcohol in the EU: where similarities start and were they end

3–4 June IT, Cagliari‘Health without barriers’. Third Board of Directors meeting and first Annual General Meeting: good practice in prison health

Drugs and prison in Europe: state of play

8 June DE, Berlin Cannabisfachtagung: 30 Jahre TherapieladenCannabiskonsum in Deutschland und in Europa: Verbreitung, Gesetzeslage und Behandlungsnachfrage

10 June DE, Münster ‘Click for Support’ final conference

17–19 June PT, LisbonClub Health Lisbon 2015 — 9th international conference on nightlife, substance use and related health issues

Handling emergent topics without solid evidence: the case of NPS

14–16 July AT, Vienna XXXIVth International congress on law and mental health Drug use and related health services in European prisons: achievements and challenges

3

Annex 4General Report of Activities 2015

Date Place Event Title of the presentation

16 July DE, StuttgartLandestagung zum Thema ‘Cannabis’, Landesstelle für Suchtfragen der Liga der freien Wohlfahrtspflege in Baden-Württemberg e.V.

Andere Laender — andere Sitten? Cannabisrecht in der Discussion (Cannabis legal state under debate)

27–28 August FR, ParisExpert group meeting on the project ‘TDOLEG’, Centre Hospitalier Universitaire Vaudois

Monitoring opioid substitution treatment — determining minimal versus ideal indicators

31 August–1 September NO, Bergen National conference on overdose prevention, SERAFViewpoints on future dissemination of take-home naloxone: opportunities and challenges

16–18 September DE, Hamburg Deutscher Suchtkongress ’15

EU Trends in Konsum, Behandlungsnachfrage und drogenbezogener KriminalitätNeue Psychoaktive Substanzen (NPS) und die Folgen: Neue Anforderungen an Prävention, Harm Reduction und Therapie

23–24 September SE, Stockholm14th Nordic workshop on ‘New aspects in drugs of abuse screening, therapeutic drug monitoring and immunosuppressive drug testing’, Thermo Scientific

28–30 September UK, Edinburgh2015 REWARD/EQUATOR conference on increasing value and reducing waste in biomedical research

Avoiding waste in research on treatment of drug dependence: a systematic approach by the EMCDDA and the European Commission

29 September–2 October TR, IstanbulInternational expert meeting on education sector responses to substance use among young children and young people

EDPQS in 10 minutes

15 October FR, ParisCollège Scientifique de l’OFDT et concernant l’utilisation des indicateurs d’urgence (Euro-DEN et autres)

22–24 October SI, Ljubljana Sixth EUSPR conference and members’ meetingQuality standards in drug demand reduction: prevention gave the example

27–29 October KG, BishkekHealth and justice annual conference 2015, Public Health England (PHE) and WHO HIPP

Substance use and specific needs of drug users living in the European prisons. What do we know?

5 November IT, Rome‘Prevenzione nel nulla chimico... e se la chiamassimo educazione e promozione della connettività sociale?’, FICT

Le linee guida internazionali in materia di prevenzione efficace delle diverse forme di dipendenze (International guidelines for effective prevention interventions)

6 November HU, Budapest Jubilee, Federation of Hungarian Drug Therapeutic InstitutesThe long term therapeutic institutions in Europe: therapeutic communities in perspective

11–13 November SE, Stockholm ESCAIDE 2015

23–24 November DE, BerlinCTC-EU-Project ‘Making CTC work at the European level’, Representation of Lower Saxony at the Federal Government

Provide and roll-out evidence-based interventions for the prevention of problem behaviours to policy makers and professionals in Europe

4

Annex 4General Report of Activities 2015

Date Place Event Title of the presentation

7 December AT, Vienna Universal prevention curriculum meeting

4. Monitoring drug supply and supply reduction interventions

22–23 January NL, The Hague EMPACT 2015/505, Europol

2–3 February NL, The Hague Kick-off meeting EMPACT heroin

24–25 March LU, Luxembourg Working group on statistics on crime and criminal justice

30–31 March FR, Paris Meeting of the task force on charting illicit trade

13 April FR, ParisUniversity of Cergy-Pontoise, conference on European drug markets and drug squads

Marchés des drogues et «brigades de stups» en Europe

21–22 April SE, Stockholm Consultative Swedish liaison meeting

21–22 April NL, UtrechtEuropean Chemical Emergency Network Project (ECHEMNET) workshop

21–22 April NL, The Hague EMPACT-Cocaine strategic meetingEuropean Reporting on Illicit Cocaine Extraction-Conversion Sites (ERICES): update and way forward

21–24 April TH, BangkokInternational conference ‘Precursor chemicals and new psychoactive substances’

The European Union Early Warning System on NPS

19 May NL, The Hague EMPACT Heroin

21–22 May NL, The Hague FP cannabis analysis group meeting

The European Reporting tool on Illicit Cannabis Production sites (ERICP): a starting point for data collection on sites related to illicit cannabis production in the European Union

9–10 June NL, The Hague EMPACT internet and darknet, synthetic drugs/cocaine/heroin Online anonymous drug marketplaces

11 June PL, Legionowo — Jachranka Advanced training course on dismantling illicit drug laboratoriesEarly Warning System: emerging trends in new drugs in Europe

22–25 June BE, BrusselsEleventh meeting of Heads of National Drug Law Enforcement Agencies (HONLEA)

24–26 June NL, Rotterdam Seminar on cocaine smugglingStrategic picture of drug markets in Europe — way forward

31 August NL, The Hague SOCTA customer requirements meeting, Europol

01 September NL, The Hague SOCTA methodology meeting, Europol

5

Annex 4General Report of Activities 2015

Date Place Event Title of the presentation

14–15 September PL, Warsaw EMPACT — OAP synthetic drugs annual meeting, Europol Overview of the NPS situation in Europe in 2014–2015

29 September–1 October LT, Vilnius CEPOL course on synthetic drugs

Synthetic drug use in Europe; Understanding new psychoactive substances — the EU response PROCESS;Understanding new psychoactive substances — the EU response FINDINGS

6–7 October NL, The Hague EMPACT 2015/541 — Heroin OAP drafting, Europol

8–9 October NL, The Hague EMPACT 2015/534 — Synthetic drugs OAP drafting, Europol

20–21 October NL, The Hague EMPACT cocaine, cannabis working group meeting, EuropolThe European reporting tool on illicit cannabis production sites (ERICP)

4 November BE, Brussels Cocaine route programme steering committee, CORMS Project Recent developments in drug market monitoring

18–20 November AT, Bad ErlachConference ‘Joint investigation to combat drug trafficking via the virtual market (darknet) within and also into the EU’

23–24 November BE, BrusselsCLEN project group on designer drugs and other illicit products, DG TAXUD

25–26 November NL, ApeldoornCEPOL course: Heroin smuggling — by using TOR networks and darknet

Strategic picture of drug markets in Europe, with a special focus on heroin

5. Monitoring new trends and developments and assessing the risks of new substances

5–6 February NL, Breda Local Pass ConferenceNew drugs, new trends and new responses? A European backdrop for local interventions

5–6 February PT, Lisbon2nd meeting of the CLEN project group on designer drugs and other illicit products

10–11 March UK, London EU-MADNESS first annual meeting

17 March AT, Vienna Global SMART advisory board meeting

28 April ES, Castellón SEWPROF supervisory board

5–8 May IE, DublinEuropean Network of Forensic Science Institutes (ENFSI) DWG annual meeting

New psychoactive substances in Europe — diversity and changes

9 May PT, Caparica‘O Futuro do Cientista Forense na Sociedade Contemporânea’, Instituto Superior de Ciências da Saúde Egas Moniz

New psychoactive substances in Europe — challenges and responses

27 May LT, Vilnius ‘Psychoactive substances: new tendencies and political decisions’ Monitoring and responding to NPS in Europe

6

Annex 4General Report of Activities 2015

Date Place Event Title of the presentation

25–26 June FR, Paris EUROMEDLAB Paris 2015 The European response to new psychoactive substances

2–3 July BA, SarajevoRegional workshop on new psychoactive substances for South Eastern Europe, OSCE and UNODC

New psychoactive substances in Europe — an update on diversity and trends from the EU Early Warning System

12–16 September PT, Porto Eurotox 2015

11–15 November CH, Ascona2nd International Conference on ‘Wastewater-based drug epidemiology’, EMCDDA, SCORE, SEWPROF and Eawag

20 October BE, BrusselsAbendveranstaltung zum Thema Designerdrogen und die Herausforderungen, Saxony Liaison Office in Brussels

5 November SI, Ljubljana National conference on prevention and expert meeting on EWS The EU Early Warning System — new psychoactive substances in Europe

17–19 November NL, Nunspeet 7th synthetic drugs enforcement conference (SYNDEC 7)Key synthetic drugs in Europe — should we be concerned?

6. Improving Europe’s capacity to monitor and evaluate policies

2 March ES, ValenciaPolicies on drug addiction from a national and transnational perspective, Sociedad Española de Toxicomanías

4 March CZ, PragueMedical cannabis and cannabinoids: policy, science and medical practice

10–11 March ES, BarcelonaComo identificar, evaluar y resumir la evidencia sobre el impacto economico de las intervenciones

23–24 March SI, Ljubljana

2015 executive training for drug policy managers on ‘Conducting a review of global drug policies and instruments with a view to national and European drug policy priorities — a contribution to the preparation for the 2016 UNGASS’

Presentation on UNGASS 2016

20–22 May BE, Ghent ISSDP annual conference City level drug policies in Europe

8 June FI, Helsinki Drug policy seminar and launch of EDR 2015 EDR 2015 and road to UNGASS 2016

8–9 June NO, OsloExpert group on ‘Possible adverse effects and associated cost of drug control policies’

15 June IT, Bari

2015 executive training for drug policy managers on ‘Conducting a review of global drug policies and instruments with a view to national and European drug policy priorities — a contribution to the preparation for the 2016 UNGASS’

Evidence based policies on drugs

13–14 July HU, BudapestWorkshop ‘Developing and advocating for a progressive European position for UNGASS’, School of Public Policy, Central European University, Budapest

UNGASS and the EU evidence based approach

7

Annex 4General Report of Activities 2015

Date Place Event Title of the presentation

29 October BE, BrusselsExpert workshop in relation to our ongoing research study into alternatives to coercive sanctions as response to drug law offences and drug-related crimes, RAND

2 November IE, DublinLSE event ‘Policy planning workshop regarding drug strategy in Ireland’

4–6 November UK, SussexRoundtable meeting ‘Responding to the evolving drugs challenge: towards UNGASS 2016’

8 December IE, Dublin Irish drug strategy review steering group meeting

7. Scientific coordination, research and content support

29 January UK, LondonACMD (Advisory Council on the Misuse of Drugs) meeting on social harms and decision making

14–15 May PT, Aveiro 4° Encontro ‘práticas expiradas, transpiradas e inspiradas’

12–15 June USA, Phoenix AZInternational forum at the annual conference of the college on problems of drug dependence

31 August–2 September HU, Budapest ISAJE annual meeting

13–15 September PT, Porto51st congress of the European Societies of Toxicology (Eurotox),

‘Bridging sciences for safety’

5–8 October UK, DundeeInternational Society of Addiction Medicine (ISAM) annual congress

New trends in drug use in the EU

8. Cooperation and collaboration with key partners

7 January PT, Lisbon Presentation of EDR 2014 to the Portuguese National Parliament A droga na União Europeia: situação e tendências 2014

13–14 January BE, Brussels Meeting of the horizontal working party on drugs (HDG) Intervention on Minimum Quality Standards

15 January BE, Brussels EU-CELAC technical committee meeting

20–21 January BE, Brussels LIBE Committee meeting on new psychoactive substances

27 January BE, Brussels

Shadows meeting on new psychoactive substances regulation (Boni) and Definition of drug directive (Jimenez) proposals — exchange of views with the Global Commission on Drug Policy, LIBE Committee

Speech by EMCDDA Director

27 January BE, Brussels Meeting with DG NEAR

29 January BE, Brussels266th CPQS meeting (Comité de Préparation pour les Questions Statutaires)

8

Annex 4General Report of Activities 2015

Date Place Event Title of the presentation

7 January PT, Lisbon Presentation of EDR 2014 to the Portuguese National Parliament A droga na União Europeia: situação e tendências 2014

13–14 January BE, Brussels Meeting of the horizontal working party on drugs (HDG) Intervention on Minimum Quality Standards

15 January BE, Brussels EU-CELAC technical committee meeting

20–21 January BE, Brussels LIBE Committee meeting on new psychoactive substances

27 January BE, Brussels

Shadows meeting on new psychoactive substances regulation (Boni) and Definition of drug directive (Jimenez) proposals — exchange of views with the Global Commission on Drug Policy, LIBE Committee

Speech by EMCDDA Director

27 January BE, Brussels Meeting with DG NEAR

29 January BE, Brussels266th CPQS meeting (Comité de Préparation pour les Questions Statutaires)

6–7 February BE, Brussels HDG Meeting and EU–Western Balkans meeting

12 February BE, Brussels Heads of administration meeting

2–3 March MA, RabatRoundtable ‘Vers une institutionnalisation du rapport annuel de l’ONDA’

4 March EE, Tallinn JHA Agencies’ network meeting

5 March BE, Brussels 267th CPQS meeting

9–17 March AT, Vienna 58th Session of the Commission on Narcotic Drugs (CND)

Speech for panel: ‘Supply reduction and related measures; responses to drugs-related crime; countering money-laundering and promoting judicial cooperation’. Presentation side event: Developing a comprehensive response to the challenge of drug-impaired driving

17–18 March UK, London EMA’s 20th Anniversary conference and reception

18 March BE, Brussels Brazil–EU dialogue on drugsEDR;The European Union Early Warning System on new psychoactive substances

23–24 March AE, Abu DhabiWorkshop ‘Building a national drug observatory’, National Rehabilitation Centre

Monitoring the EU drug situation: main concepts and instrumentsMonitoring the EU drug situation: key indicators

23–24 March LU, Luxembourg 44th meeting of the Translation Centre’s Management Board

24–26 March HR, Zagreb TAIEX expert mission study on the drug marketRecent developments in drug market analysis at the EU level

(*) This designation is without prejudice to positions on status, and is in line with UNSCR 1244 and the ICJ Opinion on the Kosovo declaration of independence.

9

Annex 4General Report of Activities 2015

Date Place Event Title of the presentation

26–27 March CR, San JoséTaller regional de capacitación sobre elaboración de informes nacionales de drogas

5 April–5 May USA Mission to OAS–CICADPublic health approach as a base for drug policy: the Portuguese experienceCannabis laws around Europe: what really happens?

7–8 April BE, Brussels Standing working party meeting and DG HR meeting

16 April LT, Riga National drug coordinators meeting Presentation on cannabis

16–17 April GE, TbilisiReitox Regional Academy on new psychoactive substances for ENP Eastern partnership beneficiaries

The European Union Early Warning System

16–17 April IT, Parma IALN (Inter agency legal network) annual meeting

20–21 April IE, Dublin Meeting of the performance development network

21–22 April DZ, Algiers MedNet opioid substitution therapy and risk reduction seminarCurrent trends in opioid substitution treatment in the European Union

21–23 April SE, StockholmScientific meeting on the harms to health due to cannabis use, HO Department of Mental Health & Substance Abuse

23 April BE, Brussels 268th CPQS meeting

23–24 April ES, Bilbao Informal agencies network on international cooperation Presentation on illicit drug markets

27–30 April AM, Yerevan Visit to ArmeniaPresentation on EMCDDA mandate and activities and cooperation with ENP countries

28–29 April BE, Brussels HDG meeting Measuring implementation of EU minimum quality standards

29 April BE, Brussels EU-Eastern Partnership countries dialogue on drugsEU Drug situation and relations EMCDDA Eastern partnership countries

30 April–1 May GE, Tbilisi GPS meeting, Addiction Research Centre, Alternative Georgia

6–8 May AT, ViennaEMCDDA–UNODC coordination meeting and meeting with FRA (Fundamental Rights Agency)

7 May BE, Brussels 269th CPQS meeting

19 May TN, Tunis MedNET meeting

19–20 May LU, Luxembourg Meeting of the expert group on health information, DG SANTE EMCDDA — update on recent activities

10

Annex 4General Report of Activities 2015

Date Place Event Title of the presentation

20–21 May TN, TunisRoundtable on the setting up of a national drug monitoring centre in Tunisia

Presentation on NFP building

21–22 May EL, Thessaloniki Eurolib general assembly

21–22 May RS, BelgradeMeeting with the Minister of Health and the authorities of the Ministry of Health and meeting with representatives of the National Monitoring Centre

21–22 May BE, Brussels EU–US dialogue on drugs and HDGPresentation on the EU drug situation; Presentation on the use of prescribed medicines in the EU

27 May BE, Brussels Heads of Administration meeting

27–28 May FR, Strasbourg 76th meeting permanent correspondents, Pompidou Group

28 May BE, Brussels Heads of Agencies meeting

1–2 June BE, Brussels EU-ANSA meetings

8–9 June DE, Frankfurt 20. Deutscher PräventionstagBCTs and principles of crime-prevention and drug-prevention

8–9 June NO, OsloPompidou Group’s expert group on ‘Possible adverse effects and associated cost of drug control policies’

10 June BE, BrusselsPresentation EDR 2015 at the inter-services meeting of the European Commission

Presentation EDR

11 June EE, Tallinn JHA Agencies’ network meeting

16 June BE, Brussels HDG meeting EDR 2015; SR indicators; monitoring medicines

17 June BE, Brussels Presentation EDR 2015 at the LIBE Committee

17 June BE, Brussels EU–Central Asia dialogue on drugs

18 June ES, BilbaoLas jornadas de la Cátedra ‘Drogas y regulación: diálogos entre Latino américa y Europa’

The EU position on the regulation of cannabis

23–26 June DK, CopenhagenWHO regional consultation on the global health sector strategies for HIV and viral hepatitis ‘Towards universal health coverage’

Implementation of GHSS in the European Region

24–25 June EL, Thessaloniki IALN working group on EU case-law Implications of Art. 55 SR

2 July LU, Luxembourg 271st CPQS meeting

2 July FR, Strasbourg JHA Agencies network ICT expert meeting, EU-LISA

11

Annex 4General Report of Activities 2015

Date Place Event Title of the presentation

6 July AT, Vienna EMCDDA–UNODC coordination meetingOral presentation on the comparisons of the UNODC data with EMCDDA data

6–9 July TH, BangkokExpert advisory group meeting on universal prevention curriculum for substance use (UPC)

International cooperation in prevention standards

7–8 July LU, Luxembourg Think tank meeting, DG SANTE and Civil Society Forum HIV/AIDS Think tank meeting: EMCDDA report

7–8 July AT, Vienna Scientific advisory group for World Drugs Report, UNODC

9 July BE, Brussels HDG meeting, LU presidency Presentation on monitoring of medicines

13 July BE, BrusselsConference ‘EU policies on the fight against drugs trafficking and organised crime: assessing a new approach for soft drugs’, European Parliament

Cannabis in the EU context

16–17 July RO, Bucharest

International workshop on combating heroin trafficking in Black Sea region, DCCO — Serviciul Cooperare Operativa & Directorate for Countering Organized Criminality — International Police Cooperation

Heroin in Europe: a strategic picture

3 September HU, Budapest Stakeholder meeting, CEPOL

3–4 September BE, Brussels HDG meeting

3–4 September EG, Cairo MedNet roundtable and national conference, Pompidou Group

4 September BE, Brussels Dialogue Western Balkans, LU presidency

9–11 September IR, Tehran 9th Annual international congress on addiction scienceCurrent trends in opioid substitution treatment in the European Union

10–11 September AT, Vienna OSCE-wide drugs conference, OSCEBest practice and evidence-based interventions for prevention of drug use among young people: the holistic approach

16–18 September CZ, PraguePompidou Group 2015 annual meeting of the international network on precursor control

Situation with regard to precursors for methamphetamine production in Europe

17 September BE, Brussels 272nd CPQS meeting and WG IV

23 September BE, BrusselsUnited Nations General Assembly Special Session on Drug Policy: European Parliament event

EU role in the UNGASS process

28–29 September LU, Luxembourg National Drug Coordinators meetingNew, old and cross-cutting approaches in prevention of drug use and associated harm

29–30 September BE, BrusselsConference on the Home Affairs funds ‘Investing in an open and secure Europe’

Europol, CEPOL and EMCDDA: enhancing security (conversation table)

12

Annex 4General Report of Activities 2015

Date Place Event Title of the presentation

30 September LU, LuxembourgConsensus meeting of third EU health programme — Call for project proposals 2015, Consumers, Health, Agriculture and Food Executive Agency

1–2 October ES, Alicante Interagency accountants’ network meetingWork programme — working group on External Audit survey

1–2 October IE, Dublin Interagency web managers’ network meeting

1–2 October LU, Luxembourg 45th meeting of the Translation Centre’s Management Board

6 October EE, Tallinn JHA Agencies’ network meeting

6 October BE, Brussels Civil Society Forum on Drugs — Session with HDG members

7–8 October BE, Brussels HDG meeting Presentation on monitoring of medicines

8 October BE, Brussels EU–Russia expert meetingPresentation on EU drugs situation; presentation on successful demand reduction; on supply indicators

7–8 October IE, Dublin HCIN meeting

8–9 October IE, DublinAnnual meeting of the performance development network, Eurofound

12–14 October ME, PodgoricaMeeting with the assistant Minister of Health of Montenegro, Ms Pesalj, and discuss the establishment of a NFP

Presentation of the EMCDDA mandate and activities and Montenegrin progress through Roadmap

15 October BE, Brussels 273rd CPQS meeting

15–16 October SE, Stockholm Dublin Declaration advisory group meeting, ECDCMaking better use of existing data and improving the process for monitoring the HIV response in the region: EMCDDA data

16 October UK, London Eurolib SHECA meeting, EMA Journal content alerting services outside British Library

19–20 October NL, The Hague Europol’s third partners strategic cooperation meeting, Europol

21 October IE, Dublin Heads of Administration meeting, Eurofound

22–23 October IE, Dublin Heads of Agencies meeting, Eurofound

2–4 November DE, Berlin5th steering group, second advisory group and IQ HIV meeting, HIV Quality Action

3–4 November EE, Tallinn Heads of JHA Agencies meeting

3–4 November BE, Brussels HDG meeting

13

Annex 4General Report of Activities 2015

Date Place Event Title of the presentation

3–4 November FR, Strasbourg2015 annual meeting of the expert group on ‘Drug related cybercrime’, Pompidou Group

EMCDDA trendspotter study on internet and drug markets

5–6 November IE, Dublin EU-ANSA meetings, Eurofound

9 November BE, BrusselsThe European Union Agency for Network and Information Security (ENISA) 2015 high level event (HLE)

9–10 November SE, Stockholm Hepatitis B and C coordination committee meeting, ECDC

10–11 November IL, JerusalemReitox Academy seminar ‘Building the treatment demand indicator: the challenge for monitoring and evaluation systems to support coherent national policies

Monitoring treatment in Europe: EMCDDA treatment monitoring strategy, system based approach and tools; Characterising treatment facilities; system based approach and tools;The treatment demand indicator; Total treatment population; Data quality issues;Dissemination and use of data: the EU perspective

12 November BE, Brussels 274th CPQS meeting

12 November LU, Luxembourg Expert Group on Health Information (EGHI) meeting, DG SANTE EMCDDA — update on recent activities

16–20 November CH, Geneva WHO 37th expert committee on drug dependence, WHO

17–19 November NO, OsloPompidou Group symposium on experience with new evolutions in drug policy, 77th meeting of the Permanent Correspondents

18 November BE, BrusselsDG HOME — Conference on the investments of organised crime in the EU

20 November SE, StockholmGuidance on prevention of communicable diseases in penal institutions kick-off meeting, ECDC

EMCDDA update; HIV/HCV among people who inject drugs: situation and response. Focus on access to HCV treatment for PWID

23–24 November LU, Luxembourg Meeting of the HIV/AIDS Civil Society Forum, DG SANTEEMCDDA update; HIV/HCV among people who inject drugs: situation and response. Focus on Hepatitis C

23–25 November CH, GenevaMeeting of WHO technical advisory group on alcohol and drug epidemiology, WHO

EMCDDA treatment monitoring strategy — A systems based approach

23–27 November DE, FrankfurtFirst training session on ‘Drugs prevention and treatment’ for professionals coming from Tbilisi and Sukhumi to Frankfurt (Germany), Pompidou Group

24 November LU, LuxembourgSecond meeting of the Translation Contact Network, Translation Centre for the Bodies of the European Union

24–25 November LU, Luxembourg Think tank meeting, DG SANTEEMCDDA — update HIV/HCV among people who inject drugs: situation and response

14

Annex 4General Report of Activities 2015

Date Place Event Title of the presentation

26 November AT, ViennaSteering committee of the UNODC Regional Programme for South Eastern Europe and the launch of the new Regional Programme for the period 2016–2019, UNODC

1–2 December BE, Brussels HDG meeting

2 December BE, Brussels EU–US dialogue on drugs

3 December BE, Brussels Meeting of the Dublin Group Presentation on the EU drugs situation

7 December AT, Vienna Meeting of the G7+ expert group on new psychoactive substances

8 December AT, Vienna 8th intersessional meeting of the CND, UNODC EU drug policy/evidence based approach

8–9 December MA, Rabat ENP National Reitox Academy ‘Best practice in drug prevention’

9–10 December AL, TiranaMeeting with Minister of Health and Deputy Minister of Interior of Albania and launch of the IPA project in Albania

9–11 December AT, Vienna Reconvened 58th session of the CND Presentation at EU side event

10 December BE, Brussels 275th CPQS meeting

10–11 December AT, Vienna

Scientific consultation on prevention of drug use and treatment of drug use disorders (10 December) and second expert meeting ‘Building international standards on treatment of drug use disorders’ (11 December), UNODC

Treatment effectiveness — why and how do evidence based approaches matter in the treatment of drug use disorders?

15–16 December FR, Paris 18th MedNet meeting, Pompidou Group

16–17 December ES, Mallorca Second technical consultation on drug use and road safety, WHO

17 December RS, BelgradeReitox Academy national seminar in Serbia ‘Establishing a national EWS in Serbia’

EU Council decision on the information exchange, risk assessment and control of new psychoactive substances and its implementation in the EU Member States

9. Communicating the EMCDDA´s findings to external audiences

17 December CZ, Prague Launch of European Drug Report (EDR) 2015 European Drug Report: trends and developments

4 June SK, Bratislava Launch of EDR 2015

4 June EL, Athens Launch of EDR 2015

4 June SE, Stockholm Launch of EDR 2015

10–11 June PL, WarsawLaunch of EDR 2015 and international conference on EU minimum quality standards in drug demand reduction

Drug treatment in Europe: trends and developments;European Drug Report: trends and developments

15

Annex 4General Report of Activities 2015

Date Place Event Title of the presentation

11 June HR, Zagreb Launch of EDR 2015

18 June NO, Oslo Regional Norwegian conference EDR — Trends and developments

19 June PT, Porto Sixth Infectious disease courseHIV and viral hepatitis among people who inject drugs — European level epidemiology

2–5 September PT, Porto Eurocrim 2015, 19th annual conference of the ESC The internet and drug markets

16 September LU, Luxembourg Innovative cooperation and cooperation tools

16 September PT, Coimbra ‘Click for Support’ Seminário

17 September BE, BrusselsWorkshop on internal communications (Internal Communications Community of Practice (ICCP))

15–16 October IT, Florence National thematic conference FeDerSerDMisuse of benzodiazepines among high risk drug users in Europe

10. Governance, management and networks

19–20 January ES, Vigo Data protection audit of EFCA’s video-surveillance policy

31 March SI, LjubljanaMeeting with the Governmental Commission on Drugs, Slovenian Ministry of Health

7–8 May LU, Luxembourg Data protection officers (DPO) network meeting

26 June CY, Nicosia International day against drug abuse and illicit trafficking event

30 June BE, BrusselsAnti-fraud strategies for EU decentralised agencies/‘Train the trainer’ course

2–3 September PL, KracowReitox Regional Academy for Baltic countries ‘Monitoring and responses to NPS’

NPS in Europe: Update from the EU Early Warning System

4–5 November EL, Athens DPO Network meeting and meeting with EDPS, ENISA

11. Administration — supporting core business

22 January BE, Brussels ABAC coordination board meeting

4 March BE, Brussels 273ème Collège des Chefs d’administration

17 April BE, Brussels Collège Medical

21 April PL, Warsaw First interagency Mission Officers meeting

27–28 April ES, Barcelona 29th AASC meeting

16

Annex 4General Report of Activities 2015

Date Place Event Title of the presentation

28 May BE, Brussels ABAC coordination board

17–18 September IT, Rome 9th greening network meeting, EFSA Guidelines on writing an environmental policy

1–2 October ES, Alicante NAPO meeting

20 October BE, BrusselsMeeting for accounting officers of institutions, agencies and joint undertakings

21 October BE, Brussels 274ème Collège des Chefs d’administration

26–27 October BE, Brussels 30th meeting of the Assembly of Agency Staff Committees (AASC)

3 November BE, Brussels EC Security and Safety Symposium, DG HR

19–20 November BE, Brussels IALN training meeting, ERCEA

20 November BE, Brussels SWP meeting

12. Information and communications technology

25–26 March BE, Brussels Infosecurity and storage expo

26 March LU, Luxembourg ITS14 Kick-off Meeting

28–29 April BE, Brussels CERT_EU on cyber threat intelligence workshop

28–30 April NL, Amsterdam CPX — Check point experience, IDW

7 May UK, London Graph Connect 2015 conference

21–22 May IE, Dublin ICTAC 25th meeting

3–4 June UK, London Service desk and IT support show

1–2 July FR, Strasbourg First industry roundtable and study visit to eu-LISA operations site

29–30 September BE, Brussels CERT-EU Conference

14–16 October RU, Rostov-on-Don2015 international conference on application of information and communication technologies

1

Annex 5General Report of Activities 2015

I ANNEX 5 Implementation of the 2015 work programme by objectives, activities and expected outputs/results

This annex presents, in detail, the implementation of the EMCDDA’s work programme by objectives, activities and expected results, in order to provide a clear picture of the work

carried out by the agency in 2015.

The EMCDDA fully achieved 82 % of the applicable results (1) in the 2015 work programme (i.e. 204 out of 250). A further 14 % of the results were partially achieved (most of

these were delayed and were in progress at the end of 2015) and only 4 % of the results were not achieved (either postponed or cancelled).

A further analysis of results by priority levels shows that the agency fully achieved 92 % of the applicable level 1 priority (L1) results, 77 % of the L2 results and 75 % of the L3

results. This gradually decreasing degree of achievement with decreasing priority reflects that the work carried out in 2015 was correctly focused on the activities which had the

highest priority level.

In terms of the annual targets (2), these were slightly underachieved with regard to the L1 priority results, but overachieved for L2 and L3 priority results (see also section ‘KPI

10.2.1: Degree of implementation of the 2015 WP’ in Annex 6). However, it is important to highlight the fact that these targets measure only the proportion of the results fully

achieved; they do not consider the results that were partially achieved and, therefore, do not provide a complete picture of the progress made with regard to the implementation

of the 2015 work programme.

As regards the L1 results, the 8 % of results (i.e. 6 results) that were not fully achieved were all partially achieved and work is under way to fulfil them in the framework of the 2016

work programme.

Several factors had a major impact on the implementation of the 2015 work programme, and it is important to mention them in order to place the work of the EMCDDA into the

right context and gain a useful insight into the complexity of the implementation conditions.

In terms of the L1 priority results, two major projects were in progress in 2015. Although a significant amount of work was invested in both of these projects, the results were not

fully achieved by the end of the year. These projects were the development of the new EDND (see Main Area 5) and the new content management system (the Drupal project)

(see Main Area 9).

With regard to the EDND, this is an extremely complex project, which requires significant investment, not only in terms of money, but also in terms of human resources (business

owners, scientific analysts and ICT staff). From the business perspective, these resources were fully deployed to implement other L1 priorities throughout the year (particularly

the management of the EU EWS); therefore, planned progress in the development of the EDND was difficult to achieve. In addition, again because of EDND project complexity,

difficulties were encountered by the internal business owners with regard to working with the deliverables provided by contractors.

(1) Four results, which were not applicable, were excluded from the analysis.(2) Annual targets: 100 % for L1 results, 70 % for L2 results and 40 % for L3 results.

2

Annex 5General Report of Activities 2015

The situation was very similar for the Drupal project: business owners were fully involved in delivering other high priority results (related to the EMCDDA’s online presence, which

has become increasingly dynamic and also requires proper resources to develop and maintain over a year). Capacity was also limited on the ICT side, and, in addition, the

deliverables provided by contractors had to be substantially adapted by the internal team to satisfy EMCDDA needs.

Another factor which influenced the capacity to implement the work programme was staff absence (permanent or temporary leave). Two staff members who worked in the same

area (Main Area 2) left the agency in 2015; although recruitment was carried out in order to replace them, the time involved in this could not be recovered by using existing

resources. There were also staff members on maternity leave. Because of the highly specialised nature of their tasks, and the heavy workload in the corresponding areas, their

projects could not be fully covered by other colleagues.

Other factors, mainly external and, therefore, outside the agency’s control, also influenced the results obtained in 2015. This mainly affected the activities implemented in

cooperation with third countries (IPA and ENP partners) (see Main Area 8).

Finally, objective implementation conditions made revision of initial planning necessary. This is a normal development in the work of any organisation and needs to be

acknowledged. Such shifts occurred in most of the main areas of work, as indicated in the table below.

Despite all the challenges encountered during the year, the EMCDDA managed to fulfil all of its legal obligations and achieve a very good level of implementation of its work

programme. The deviations from the planned targets were minimal and work on residual activities will continue in 2016, in line with the available resources.

This annex presents the activities undertaken by the EMCDDA in 2015 in brief. For details about the achievements during the year, please see the full report and Annexes 3, 4 and 6.

For acronyms and abbreviations used, please refer to Annex 9 of the full report, available at: emcdda.europa.eu/publications/gra/2015

3

Annex 5General Report of Activities 2015

Main Area 1: Data collection, analysis and quality assurance

Activities Expected outputs/results Implemented Comments

Specific objective 1.1. Improve data collection instruments and processes

1.1.1. Ensure the coherence, efficiency and quality of reporting tools and processes

1.1.1.1. Review and revise reporting package to ensure efficiency, and match priorities and resources (in coordination with NFPs) (L1)

Streamlined reporting package developed and implemented

Yes All 30 countries completed the five workbooks which were minimally required for the 2015 reporting; 25 countries exceeded the minimal requirements — they completed all 10 workbooks

Work plan and tools adopted for 2016 Yes Guidelines for 2016 national reporting, including the revised structured questionnaire on prevention, were adopted at the HFPs meeting in November

1.1.2. Annual data collection exercise

1.1.2.1. Implement annual reporting cycle (L1) NFPs supported in data submission (guidelines and tools)

Yes

2014–15 data cycle implemented Yes

2015–16 data cycle launched Yes

1.1.2.2. Fonte maintenance and update: revise templates (as required) (L1)

Templates and processes adjusted as required Yes

1.1.3. Maintain Fonte reporting system and data warehouse

1.1.3.1. Maintain databases and tools (L1) Systems for drug data collection operational Yes

Review and cleaning of the database Yes

1.1.3.2. Improve automatic data submission tools and data extraction tools (L2)

Improved functionality for NFPs Yes

Data sets that can more easily be queried or analysed in house

Yes

1.1.3.3. Review and reconcile historical data sets in supply area (L2)

Ongoing validation and update of historical data series (resource dependent)

Yes, ongoing

4

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

Specific objective 1.2. Strengthen the quality assurance framework to support data collection, analysis and reporting

1.2.1. Implement a cross‑indicator method for validation and analysis

1.2.1.1. Implement coherence checks and combined analysis (L3)

Improved multi‑indicator analysis Yes

1.2.2. Review, rationalise and improve quality assurance measures for data collection

1.2.2.1. Monitor the quality of the data reported by NFPs and provide feedback (L2)

Quality feedback provided to NFPs (in line with the developments concerning the revision of the national reporting system)

Yes

1.2.2.2. Implement cross‑checking of data between the different data collection tools (L2)

Improved validity and reliability of the data received Yes

1.2.2.3. Carry out, where possible, coherence checks with external data sources (L3)

Coherence problems identified and rectified Yes Data coherence check with UNODC: validations processes rationalised and improved

1.2.3. Develop a statistical quality framework for the analysis, manipulation and reporting of data within the EMCDDA

1.2.3.1. Produce the 2015 European Drug Report: Data and statistics (Statistical bulletin) (L1)

2015 European Drug Report: Data and statistics (Statistical bulletin) published online (new structure implemented)

Yes Published on 4 June, as part of the 2015 EDR 2015 package (emcdda.europa.eu/data/2015)Improvements made on methods and definitions

1.2.3.2. Implement framework for statistical quality assurance (L2)

Statistics code of practice implemented Yes The document was published in February (emcdda.europa.eu/publications/manuals/statistics‑code‑of‑practice) Training for implementation was held in July, with Eurostat experts

Framework for expert ratings implemented Yes

5

Annex 5General Report of Activities 2015

Main Area 2: Monitoring and understanding drug use and problems — key indicators and epidemiology

Activities Expected outputs/results Implemented Comments

Specific objective 2.1. Ensure progress in the methodological development of the KIs

2.1.1. Ensure key indicator methods and tools remain fit for purpose

2.1.1.1. Revise tools for data collection on treatment prevalence based on TDI data collection (L2)

Treatment prevalence module — tool for data collection developed, for implementation in 2016

Yes Treatment Prevalence Guidelines finalised

2.1.1.2. Revise the EMQ on alcohol and medicines variables (in the context of polydrug use) (L2)

EMQ module for alcohol revised Postponed Staff member in charge of this activity left the agency in April; recruitment process organised and position filled in November 2015

Draft EMQ module on medicines items prepared Postponed Staff member in charge of this activity left the agency in April; recruitment process organised and position filled in November 2015

2.1.1.3. Audit national survey data collected on new psychoactive drugs (L2)

Analysis presented at the GPS annual expert meeting Postponed Staff member in charge of this activity left the agency in April; recruitment process organised and position filled in November 2015

2.1.2. Scale up cooperation with ESPAD project

2.1.2.1. Contribute to the launch of the 2015 ESPAD study and ensure ESPAD coordination and the preparatory work for the 2016 ESPAD report (L2)

EMCDDA support provided to coordination tasks, ESPAD data collection and preliminary analysis

Yes This included participation of the EMCDDA in the two Steering Committee meetings (28–29 January in Stockholm, and 15–17 November in Larnaca)

Preparatory work for the 2016 ESPAD report undertaken

Yes Agreement reached with ESPAD on the layout and timeline for the publication of the report in 2016

2.1.2.2. Support analysis and dissemination (L2) Preparatory work for the ESPAD web presence (to be launched in 2016)

Partially Preliminary work carried out (clarifications regarding the data format, implications for the website development, resources estimate)

Specific objective 2.2. Support the implementation of the key indicators through ongoing monitoring and provision of technical guidance and training

2.2.1. Actively monitor implementation of KIs and identify implementation needs

2.2.1.1. Monitor the implementation status of KIs in all countries (L2)

Triennial review conducted and follow‑up implemented as needed

Yes Review completed and report presented to the Management Board at its December meeting

2.2.2. Support KI implementation through expert advice and training, as needed

2.2.2.1. Support countries in implementation of KIs (L2) Training and assistance provided based on identified needs and availability of resources

Yes Expert advice provided ongoing; training provided as required and in line with available resources

6

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

2.2.3. Support KI implementation in third countries and international efforts to improve reporting capacity (see also specific objectives 8.4. and 8.5.)

2.2.3.1. Provide training and support (where appropriate and based on available resources) (L3)

Training and advice provided (see also activity 8.5.3.1.)

Yes Expert advice provided ongoing; training provided as required and in line with available resources

Specific objective 2.3. Maximise the value of key indicator information through analysis to provide a comprehensive, relevant and multi‑source understanding of contemporary patterns of drug use, trends and related health and social consequences, and responses

2.3.1. Develop analytical capacity, maintain KI expert networks, and introduce more integrated and efficient working practices

2.3.1.1. Carry out analysis of the European drug situation by using KI data and maintain expert networks through meetings, networking and capacity building activities (L2)

Annual European expert meetings organised and results disseminated

Yes Two events were held in 2015: the DRID annual meeting (Lisbon, 15–16 June) and the ‘20 years of monitoring’ event (Lisbon, 21–22 September) — all KIs

Quality assurance guidelines for meetings implemented

Partially Final report from the ‘20 years of monitoring’ event could not be completed on time because of competing priorities (see also Annex 6 — KPI 2.3.1.)

Cross‑indicator analysis and networking supported (technical collaboration and online resources)

Yes

2.3.2. Improve exploitation of data through standalone, cross‑indicator, and cross‑area analysis

2.3.2.1. Identify priority questions requiring analysis and task internal work group(s) (L1)

Core analysis completed to inform EMCDDA outputs Yes In the context of the preparation of the EDR and the PODs

2.3.2.2. Conduct selected cross‑indicator analysis in different domains (L2)

Analysis sheets in the European Drug Report: Data and statistics (Statistical bulletin) web area

Yes One factsheet produced; three other factsheets under development

2.3.2.3. Carry out stand‑alone analysis of KI data (L2) Analysis of harmonised GPS data Postponed Staff member in charge of this activity left the agency in April; recruitment process organised and position filled in November 2015

Improved harmonisation of problem drug use estimates

Partially Staff member in charge of this activity was on maternity leave, after which she left the agency; recruitment process organised and position filled by 1 March 2016

Analysis of polydrug use based on TDI data Yes

7

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

2.3.2.4. Explore potential of wastewater analysis as an indicator to estimate population drug consumption (L2)

Technical proposal for wastewater monitoring Yes Technical guidelines were published in 2014; the more elaborated version of the technical proposal is presented in Chapter 1 of the EMCDDA Insights on wastewater prepared in 2015 (published in March 2016)

In‑depth topic review on wastewater published (EMCDDA Insights series)

Delayed The publication was drafted in 2015, however, the launch will be possible only in March 2016

2.3.2.5. Publish in‑depth topical review on psychiatric co‑morbidities (EMCDDA Insights series) (L2)

EMCDDA Insights on psychiatric comorbidities published

Yes Published in November: emcdda.europa.eu/publications/insights/comorbidity‑substance‑use‑mental‑disorders‑europe

2.3.2.6. Improve understanding of market size (L2) Multi‑indicator model of market size developed Yes

2.3.2.7. Improve timeliness and access to information on drug injecting, health consequences and service development (with input from partners) (L3)

Annual update on trends and developments (web based)

Yes The report Drug‑related infectious diseases in Europe. Update from the EMCDDA expert network was published in September: emcdda.europa.eu/publications/rapid/2015/drug‑related‑infectious‑diseases‑in‑europe

2.3.2.8. Improve reporting capacity for non‑fatal health consequences of drug use (L3)

Analysis on emergencies related to cannabis published (dependent on outcome of the pilot study carried out in 2014)

Yes

2.3.3. Rationalise and improve web‑based information on the drug situation

2.3.3.1. Further develop website content on key themes, methods and national data profiles in context of the integrated EMCDDA website framework (L2)

National profiles Delayed In the context of the delays related to the new content management system (see Main Area 9 — 9.3.1.1.)

Expert users’ area(s) in place Yes

8

Annex 5General Report of Activities 2015

Main Area 3: Monitoring demand reduction responses applied to drug‑related problems

Activities Expected outputs/results Implemented Comments

Specific objective 3.1. To monitor prevention provision, implementation and outcomes, and to improve reporting on important areas in which information resources are lacking

3.1.1. Provide an ongoing overview of drug prevention provision

3.1.1.1. Analyse and report findings from drug prevention area and develop thematic area within context of the integrated website framework (L2)

Key analysis conducted and improved web resources available, including prevention profiles

Yes

3.1.2. Develop analysis on environmental prevention

3.1.2.1. Carry out new analyses and disseminate results (L3)

Analysis and prevention profiles extended in the areas of parenting, school climate and alcohol

Cancelled A BPP module on interventions for the general population was created to host new evidence on environmental strategies: emcdda.europa.eu/best‑practice#view‑answer

3.1.3. Develop information on coordinated programming

3.1.3.1. Review multidimensional programmes and strategies across behavioural domains (L3)

Technical review on programmes with multiple outcomes

Yes A systematic review of the effectiveness of community was drafted (in collaboration with the Cochrane Group), for publication in 2016

Specific objective 3.2. To improve the monitoring and analysis of treatment, harm reduction and social reintegration interventions, and provide an integrated model for understanding service provision in Europe

3.2.1. Provide an ongoing overview of drug treatment, harm reduction and social reintegration

3.2.1.1. Analyse and report findings from responses area and develop thematic area within context of the integrated website framework (L2)

Key analysis conducted and improved web resources available, including online products on treatment, harm reduction and social reintegration

Yes Examples: 2015 EDR and statistical tables; harm and social reintegration profiles; treatment profiles; harm reduction overviews; EU treatment systems map (EDR 2015)

New POD analysis Drug consumption rooms: an overview of provision and evidence (emcdda.europa.eu/topics/pods/drug‑consumption‑rooms)

3.2.1.2. Improve understanding of responses to NPS (L2)

Expert meeting Yes Lisbon, 28–29 October

3.2.2. Implement the new treatment data collection and analysis strategy

3.2.2.1. Support countries to implement the EFSQ (L2) Increased number of countries that report national EFSQ results in Structured Questionnaire 27 (SQ 27)

Yes No countries had reported EFSQ results by the beginning of 2015; in 2015, two countries (Greece and Hungary) reported national EFSQ results in the framework of the Treatment Workbook

9

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

3.2.2.2. Support countries in improving estimates of the total number of people in treatment (L2)

Increased number of countries that are able to provide estimates on the total number of people in treatment

Yes 23 countries were able to provide estimates on the total number of people in treatment in 2015, as compared with 19 in 2014 (see also Annex 6 — KPI 3.2.1.)

3.2.3. Conduct comparative analysis of drug treatment systems in Europe

3.2.3.1. Develop a conceptual framework for analysis of national treatment systems (L3)

Technical paper Comparative analysis of national treatment systems in the EU prepared

Yes

3.2.4. Develop and test health and social responses and target‑and‑indicator frameworks

3.2.4.1. Develop and test model for a target‑and‑indicator framework in the treatment field, as policy tool, based on multiple‑indicator set (L3)

Target‑and‑indicator conceptual framework developed and model tested

Cancelled Multi‑indicator risk assessments have become an integrated component of DRID expert meetings. Furthermore, developing this framework would bring risks of duplication with the work carried out by the Joint action on reducing alcohol‑related harm run by the European Commission

Specific objective 3.3. To identify and support dissemination and knowledge exchange on best practices

3.3.1. Conduct state‑of‑the‑art and evidence reviews

3.3.1.1. Publish in‑depth topical review on hepatitis C treatment (L2)

In‑depth topical review on hepatitis C treatment published (EMCDDA Insights series)

Delayed Drafting ongoing in 2015, but publication will not be possible until 2016

3.3.1.2. Prepare in‑depth topical review on naloxone, to reduce drug‑related deaths (L2)

In‑depth topical review on naloxone prepared (EMCDDA Insights series)

Yes Draft prepared, for publication in 2016, as planned

3.3.1.3. Carry out a review of evidence on effectiveness of treatment approaches using contingency management interventions (L3)

Technical paper prepared Yes Ongoing

3.3.1.4. Conduct a meta‑analysis of long‑term observational studies to analyse survival rate and recovery rate of drug users (L3)

Technical paper prepared Yes

3.3.2. Disseminate knowledge on best practice and improve functionality and usability of online tools

3.3.2.1. Revise the BPP website and improve usability (L2)

Redesigned and more interactive BPP Yes See emcdda.europa.eu/best‑practice

Maps on the quality assurance approaches that were adopted at national level published

Yes Published in December

3.3.2.2. Update synthesis of evidence resources for demand reduction interventions in the BPP (L2)

Modules updated Yes Three new modules, on NPS, the misuse of prescription medicines and interventions in prison, were released; existing modules were updated

10

Annex 5General Report of Activities 2015

Main Area 4: Monitoring drug supply and supply reduction interventions

Activities Expected outputs/results Implemented Comments

Specific objective 4.1. Develop European key indicators and complementary information resources for understanding drug markets, drug‑related crime and drug supply reduction

4.1.1. Improve the quality and comparability of data on drug supply (drug markets, drug‑related crime and drug supply reduction)

4.1.1.1. Improve tools for reporting drug seizures (L1) Revised reporting instrument piloted, and endorsed by the Member States (Reitox NFPs) for routine implementation

Yes See Annex 6 — KPI 4.1.1.

4.1.1.2. Improve tools and concepts for reporting on drug production facilities, through pilot work on cocaine secondary extraction labs and on cannabis cultivation sites (L2)

Draft reporting instrument available for piloting by Europol

Yes See Annex 6 — KPI 4.1.1.

4.1.1.3. Improve tools for reporting on drug production facilities, through pilot work on synthetic drugs production sites (L1)

Analysis of data collected by Europol Yes Joint training was organised by EMCDDA and Europol (24 March, Lisbon) on the use of ERISSP (22 participants from 21 Member States). Based on the feedback collected from participants, the tool was revised and used for the data collection exercise — 14 Member States provided their data, which were analysed and used for the production of the second EDMR

4.1.1.4. Improve tools and concepts for reporting on drug prices (L2)

Mapping exercise launched Delayed A contractor was appointed; however, as a result of unforeseen delays (due to the personal circumstances of the contractor), the mapping exercise was not launched at the end of 2015. The study was prepared and will be launched in February 2016

4.1.1.5. Improve tools and concepts for reporting on drug purity and content (L2)

Pilot study launched Yes

Technical background paper including a comparative analysis of reporting practices in Member States

Delayed Work in progress; however, the contractor will not deliver the technical background paper until 2016

4.1.1.6. Pilot implementation of the reporting tool on drug‑law offences, in coordination with Eurostat (L1)

Pilot data collection implemented Yes

4.1.2. Improve understanding of drug supply reduction activities

4.1.2.1. Update and report on drug squads at EU level (L3)

Relevant parts of the database updated Yes

11

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

4.1.3. Develop cooperation with external partners on drug supply indicators

4.1.3.1. Cooperate with European Commission on drug precursors monitoring (L1)

Analysis of drug precursors production and trafficking in the EU

Yes Further to a close cooperation with DG TAXUD, data for the last three years have been provided to the EMCDDA and included in the EDR 2015. A representative from DG TAXUD attended the Reference Group on Drug Supply Issues and contributed actively to the EDMR 2016

Specific objective 4.2. Establish networks in the area of drug supply and supply reduction

4.2.1. Consolidate and further operationalise the EMCDDA European Expert Reference Group on Drug Supply Issues

4.2.1.1. Organise the third meeting of national correspondents (L1)

Third meeting of national correspondents, including consultation on reporting tools

Yes Lisbon, 5–6 November. See also Annex 6 – KPI 4.2.1.

4.2.2. Provide training for the law‑enforcement community and promote information exchange

4.2.2.1. Provide evidence‑based training on drug problems in Europe to senior law‑enforcement officers in cooperation with CEPOL (L3)

Training activities delivered Yes See Annex 6 — KPI 4.4.1.

Specific objective 4.3. Produce a strategic analysis of drug supply and supply reduction in Europe

4.3.1. Improve strategic understanding of drug markets through developing strategic analysis of drug supply and supply reduction in Europe

4.3.1.1. Produce the second edition of the EDMR with Europol (L1)

Draft report prepared (for publication in 2016) Yes This important joint project involved an efficient collaboration between the EMCDDA and Europol, which brought together important resources. Good cooperation was also ensured with external contributors to the report (e.g. Eurojust, CEPOL, Frontex and MAOC‑N), and consultations with stakeholders, such as the Commission, the EMCDDA Reference Group on Drug Supply Issues and Europol NFPs, were held throughout the yearThe report will be launched in Brussels (5 April 2016) by the EU Commissioner in charge of Migration, Home Affairs and Citizenship, and the EMCDDA and Europol Directors

4.3.1.2. Assess current developments/trends in the importation of heroin into the EU (L2)

Analysis conducted to support relevant outputs Yes

4.3.1.3. Develop a conceptual framework of the business structures of criminal groups including their activities in legitimate and illegitimate markets to inform the EDMR (L2)

Short report prepared Yes

12

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

4.3.2. Provide accessible and high‑quality online information on drug supply issues

4.3.2.1. Further develop thematic area within context of the integrated website framework (L2)

Updated web resources available Partially New online resources were produced (e.g. the POD Opioid trafficking routes from Asia to Europe —emcdda.europa.eu/topics/pods/opioid‑trafficking‑routes); however, the delays in the implementation of the new content management system (see Main Area 9 (KPI 9.3.1.1.) had an impact on this activity

Specific objective 4.4. Support the Internal Security Strategy of the EU (COSI)

4.4.1. Support the EU policy cycle development and relevant actions

4.4.1.1. Fulfil the tasks assigned to the EMCDDA in the OAPs on heroin/cocaine trafficking and synthetic drugs (L2)

Support provided to Europol on reporting of synthetic drugs production sites (see also activity 4.1.1.3.)

Yes See Annex 6 — KPI 4.4.1.

Support provided to Europol on reporting on cocaine production sites

Yes See Annex 6 — KPI 4.4.1.

Support provided in other areas (as defined by the 2015 OAPs)

Yes See Annex 6 — KPI 4.4.1.

Main Area 5: Monitoring new trends and developments, and assessing the risks associated with new substances

Activities Expected outputs/results Implemented Comments

Specific objective 5.1. To ensure that the information exchange and risk assessment mechanism on new psychoactive substances is of high quality and implemented in a timely and efficient manner

5.1.1. Ensure the implementation of an EWS on NPS and required risk assessment procedure

5.1.1.1. Implement the provisions of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of NPS or of the new legal instrument replacing it (L1)

Operational EWS and information exchange mechanism

Yes See Annex 6 — KPI 5.1.1.

13

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

Strengthened toxicovigilance component of the EWS Yes Among others:– reporting tool to monitor serious adverse events

associated with NPS was developed;– more than 30 reporting forms on serious adverse

events associated with NPS were received, reviewed, validated and analysed, and the resulting data and information prioritised;

– 17 public health alerts (including updates) were produced based on information received, reviewed, validated and analysed from the EU EWS network and from searches and reviews of OSI;

– Toxicovigilance System Framework under development including draft standard operating procedures for the signal management system

EMCDDA–Europol Annual report on the implementation results submitted to the EU institutions and Member States, and published

Yes Report prepared by the two agencies, submitted to the EU institutions in June and published in July (emcdda.europa.eu/publications/implementation‑reports/2014)

EMCDDA–Europol joint reports on NPS (as required) Yes – Joint report on α‑PVP was submitted to the EMA, the Council and the Commission in August, by the legal deadline stipulated by Council Decision 2005/387/JHA (data collection launched in May)

– Joint report on acetylfentanyl was submitted to the EMA, the Council and the Commission in December, by the legal deadline stipulated by Council Decision 2005/387/JHA (data collection launched in September)

Multidisciplinary, scientifically sound risk assessment procedure implemented (if requested)

Yes Risk assessment on α‑PVP carried out in November by the extended Scientific Committee of the EMCDDA, at the request of the Council. The risk assessment report was subsequently submitted to the Council and the Commission within the timeline stipulated in Article 6 of Council Decision 2005/387/JHA

5.1.1.2. Adapt tools and processes necessary for the implementation of new legal and institutional requirements (L1)

Guidelines, procedures, processes and tools adapted and implemented (dependent on the timing of entering into force and the requirements of the new legislative framework)

Not applicable The new legislative framework did not enter into force in 2015

14

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

5.1.1.3. Maintain and strengthen the EWS network (L1) Annual meeting of the Reitox EWS network, with participation of Europol, the EMA, the European Commission and EU‑funded projects

Yes The 15th Annual Meeting of the Reitox Early Warning System Network took place on 8 and 9 June

Technical assistance to the network Yes Ongoing

5.1.1.4. Update the EDND to improve functionality, access and capacity (L1)

EDND with improved functionalities implemented and operational (level of operationality conditional upon resources)

Delayed Slower progress than planned. The activity is resource intensive and implemented in parallel with other, already very demanding, tasks related to ensuring the functioning of the EU EWSA prototype system was designed and produced which focuses on the reporting and review of event‑based data. This was then tested by the EMCDDA. The prototype will be used to inform the development of the work on the EDND as outlined in the 2016 work programmeFurthermore, a three‑year plan of action was developed by the internal stakeholders (business owners and ICT) and close follow‑up will be ensured and reported directly to the EMCDDA Director

5.1.1.5. Further develop the online resources on new drugs within the context of the integrated EMCDDA website framework (L2)

Thematic (‘Action on new drugs’) web pages further developed and updated

Yes Thematic web pages were regularly updated with new informationFurther development of the web pages within the context of the new integrated EMCDDA website framework began in 2015 and will be completed in 2016 after the phased introduction of the new content management system (Drupal) by the EMCDDA (see action 9.3.3.)

5.1.1.6. Participate in relevant international and European forums, explore the feasibility of (co‑)organising the 5th International Multidisciplinary Forum on New Drugs and the 4th International Conference on Novel Psychoactive Substances (L3)

Increased understanding of the NPS phenomenon and the visibility of EU actions in this area

Yes The EMCDDA delivered presentations and keynote speeches at more than 15 important drug‑related conferences and technical meetings, which helped increase the understanding of the NPS phenomenon and the visibility of EU actions in this area (for details, see Annex 4)

5.1.2. Implement the provisions of Article 28c of the EU pharmacovigilance legislation

5.1.2.1. Implement the provisions of Article 28c of the EU pharmacovigilance legislation (L1)

Information exchanged with the EMA and the EU pharmacovigilance system

Yes

15

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

5.1.3. Support capacity development in the forensic science and toxicology area

5.1.3.1. Support the formation of an informal forensic science and toxicology network (in line with OAP on synthetic drugs for 2014–15 of the new policy cycle 2014–17 within COSI) (see also priority intervention 4.4.1.) (L3)

Informal network of selected forensic, toxicology and law enforcement experts supported

Yes Ongoing exchange with international leading forensic, toxicology and law enforcement experts in the field of NPS

Cooperation between the EMCDDA and the European Network of Forensic Science Institutes (ENFSI) strengthened

Yes Presentations at the 2015 annual meeting of the European network of Forensic Science Institutes (5–8 May, Dublin)

Expert meeting on new drugs and on sub‑indicator ‘Drug purity and contents’ (see also 4.1.1.5.)

Not applicable The meeting was no longer necessary

5.1.3.2. Support the organisation of the expert meeting of CLEN (L2)

Strengthened cooperation with customs laboratories network

Yes The EMCDDA co‑hosted the meeting of the CLEN project group (5–6 February)

5.1.4. Consolidate and improve the methodology for monitoring the internet

5.1.4.1. Monitoring OSI, including structured monitoring of the internet (L3)

Methodology reviewed, updated and implemented (conditional upon tools available to automate the methodology)

Yes

5.1.5. Maintain the EMCDDA’s online Drug profiles series

5.1.5.1. Maintain and update the online Drug profiles (new drugs and old drugs) (L3)

Drug profiles consolidated and updated (as required) Postponed The resources in this area had to be prioritised to the L1 activities

16

Annex 5General Report of Activities 2015

Main Area 6: Improving Europe’s capacity to monitor and evaluate policies

Activities Expected outputs/results Implemented Comments

Specific objective 6.1. Develop European and global drug policy monitoring and analysis

6.1.1. Increase awareness of national and EU‑level policy developments

6.1.1.1. Review case studies of policy at the EU, national and local level (L2)

EMCDDA Paper on the evolution of the drug strategy in the EU prepared

Cancelled Work was ongoing on the development of a tool for the evaluation of national strategies

EMCDDA Paper on drug policies of large cities prepared

Yes Paper Drugs policy and the city in Europe published in June (emcdda.europa.eu/publications/emcdda‑papers/drug‑policy‑and‑the‑city)

Overview on drug supply and external security Yes The review will be part of the second EDMR strategic analysis

Follow‑up on key policy issues (as required) Yes Ongoing

Report on cannabis legislation in Europe prepared Yes

6.1.2. Monitor economic issues relevant to drug policy

6.1.2.1. Maintain reporting tools and carry out analysis of the developments in drug‑related public expenditure (L2)

EMCDDA web resources on drug‑related public expenditure updated

Yes

6.1.3. Support the EU drug strategy and action plan(s)

6.1.3.1. Contribute to the EU drugs strategy (2013–20) and the action plan (2013–16) (L1)

Follow‑up of EMCDDA indicated actions and reporting obligations

Yes On request from the European Commission, the EMCDDA contributed a detailed report to the biennial progress review of the European Commission

Input to the first bi‑annual progress assessment of the action plan (2013–16)

Yes

6.1.4. Support Member States in developing and evaluating their national drug policies

6.1.4.1. Provide information available on: evaluation approaches, methods to estimate public expenditure and legal developments (on request) (L2)

Technical support provided on request (resource dependent)

Yes Input and/or technical support was provided to policymakers and professionals from EU Member States such as Germany, Ireland and Luxembourg

6.1.5. Provide online resources on drug policy

6.1.5.1. Update web content for policy areas (L2) Web resources updated Yes

17

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

Specific objective 6.2. Strengthen European networks in drug law and drug policy analysis

6.2.1. Maintain network of legal and policy correspondents

6.2.1.1. Organise the legal and policy correspondents’ meeting (L2)

Meeting report and thematic analysis Yes The 16th Meeting of the Legal Correspondents of the European Legal Database on Drugs was organised in Lisbon, on 8–9 September

6.2.1.2. Maintain and revise the European Legal Database on Drugs (ELDD) (L2)

Web resources updated Yes

Main Area 7: Scientific coordination, research and content support

Activities Expected outputs/results Implemented Comments

Specific objective 7.1. Ensure the coordination of scientific activities so that resources are efficiently used, objectives are achieved and quality control of outputs is maintained

7.1.1. Improve handling of requests for scientific advice and opinion

7.1.1.1. Finalise concepts paper on procedure for handling requests for scientific advice (L3)

Guidelines operational Partially Guidelines ready; piloting to take place in 2016

7.1.2. Develop EMCDDA strategy on training for external audiences and coordinate training activities

7.1.2.1. Organise the 2015 summer school ‘Drugs in Europe: supply, demand and public policies’ (L2)

2015 summer school organised and training material available (subject to demand)

Yes The two‑week course, which took place from 29 June to 10 July, brought to Lisbon a record of 37 academics and professionals from Asia, Europe, Latin America and North America

7.1.2.2. Finalise options paper on integrated training strategy (including academic training) (L3)

Integrated training strategy operational Postponed The EMCDDA approach in this area will be redefined in the context of the new long‑term EMCDDA strategy to 2025

7.1.2.3. Collaborate with EU and academic training initiatives (if appropriate and within resources) (L3)

EMCDDA contributions to European Masters in Drug and Alcohol Studies (EMDAS), EUSPR, Initial Training Network (ITN‑SEWPROF), etc.

Yes

18

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

7.1.3. Support the production of high‑quality scientific content

7.1.3.1. Coordinate scientific activities to ensure that resources are managed efficiently, that objectives are achieved and that quality control of outputs is assured (L1)

Internal scientific coordination meeting organised and communication tools maintained

Yes Regular meetings organised, minutes uploaded on the intranet page, action points followed up

Improved coordination and planning of outputs (products database)

Yes Products database kept up to date; regular Editorial Board Meetings organised, minutes uploaded and action points followed up; monthly Follow‑up Meeting on Products organised, minutes uploaded on the intranet and actions points followed up

7.1.3.2. Implement the EMCDDA overall quality control framework for scientific publications (L1)

Scientific content of key EMCDDA publications checked and quality controlled

Yes

Support provided for content production (pre‑editing), and provision of scientific writing for EMCDDA publications

Yes

External scientific writing support operational Yes

Peer‑review system operational (in consultation with the Scientific Committee); key publications peer reviewed

Yes Guidelines developed by the EMCDDA were discussed with and endorsed by the Scientific Committee

7.1.3.3. Publish scientific articles in high‑impact scientific journals (L2)

Small number of articles published in high‑impact scientific journals

Yes 27 scientific articles and book chapters published (see also Annex 3 and Annex 6, KPI 7.1.2.)

7.1.3.4. Disseminate key results and technically support European debate on drug issues (L2)

Presentations and technical contribution delivered at relevant scientific and institutional meetings (resources dependent)

Yes Over 300 events attended by EMCDDA staff (see Annex 4 for details)

7.1.4. Coordinate internal information exchange on new developmental areas and/or transversal projects

7.1.4.1. Ensure the coherence of the overall reporting system, ensure efficiency of data collection requests and adjust requirements in context of changes in resource availability and institutional needs (L1)

Mechanism(s) for coherence, oversight and quality control operational (Data Coherence Group)

Yes

Revised NRP implemented in collaboration with NFPs Yes See Main Area 1 (1.1.1.1.)

7.1.4.2. CUP (cross‑unit project) Quality Assurance: develop a model and implementation strategy for data quality assurance management (L2)

Final report available recommending a model for data quality assurance management at the EMCDDA

Yes

19

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

7.1.4.3. CUP New Trends: coordination group to improve awareness on new developments and timeliness of reporting (L2)

Online discussion forum developed Yes

Strategy in place Delayed Work in progress, to be completed in 2016 in the context of the priorities set up by the 2016–18 strategy and work programme

Rapid assessment and response on key issue(s) conducted, including a Trendspotter study and ad hoc rapid assessments (when required)

Yes A ‘Trendspotter’ study on critical new developments within Europe’s MDMA/ecstasy market launched: data collection and a literature review undertaken, followed by an expert meeting in Lisbon on 22–23 October

In‑depth topical review on the internet and drug markets published (as part of the EMCDDA Insights series)

Delayed Slight delay — the product was launched in February 2016

7.1.4.4. CUP Treatment: internal coordination to ensure coherence and dialogue across treatment area (L2)

Improved communication channels and integrated outputs (see also Main Area 3)

Yes

7.1.4.5. CUP Medicines (in the context of polydrug use): develop conceptual framework, thematic web resources and expertise (L2)

Conceptual framework including options for monitoring finalised

Delayed Work in progress with support from external contractor; because the staff member in charge was on maternity leave in the second half of the year, the framework will not be finalised until 2016

Thematic web page updated Yes POD on benzodiazepine misuse among high‑risk opioid users released in June (emcdda.europa.eu/topics/pods/benzodiazepines)

Database of articles and grey literature Yes

7.1.4.6. CUP Key Epidemiological Indicators: ensure coordination and oversight of activities and monitor progress (L2)

Improved communication channels, meetings planning and integrated analysis (see also Main Area 2)

No The CUP was not fully operational but the activities related to the implementation of the KIs were carried out as planned (see Main Area 2)

Specific objective 7.2. Support drug‑related research, audit key developments and promote the use of research findings

7.2.1. Monitor and disseminate developments in drugs research

7.2.1.1. Update and improve public website and intranet research page (L2)

Updated research area on public website and intranet Yes

Input provided to Reitox Research Forum Yes

7.2.1.2. Maintain research country profiles within context of integrated website framework (L2)

Web‑based profiles available Yes

20

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

7.2.2. Support the development of the European Commission research agenda

7.2.2.1. Provide input on research priorities at EU level (L1)

Report submitted to the HDG for the Annual Dialogue on Research (in collaboration with the Scientific Committee)

Yes

7.2.2.2. Provide input on research priorities at Member State level (L3)

Support provided to national initiatives (on request) Yes Input provided (on request) during the preparation of the ‘Federal Research Programme Drugs: Call for Proposals 2015’; input provided (on request) to a Reitox NFP to assist, on request from the UNODC Informal International Scientific Network

EMCDDA input to ERANID provided Yes

7.2.3. Further develop collaboration with the scientific community through dissemination of findings and increased contribution to relevant events

7.2.3.1. Promote dissemination of significant research findings (L2)

Increased input, visibility and standing of EMCDDA outputs

Yes Presentations delivered throughout the year at different events (see Annex 4 for details)

7.2.3.2. Increase collaboration with projects and initiatives developed by the scientific community (L2)

EMCDDA participation and input provided to relevant scientific meetings (resource dependent)

Yes See Annex 4 for external events and Annex 6 – KPI 9.4.1. – for meetings organised at the EMCDDA

Support to the Lisbon Addictions Conference 2015 Yes The first European conference on addictive behaviours and dependencies — Lisbon Addictions 2015 — was held in Lisbon from 23 to 25 September. Hosted by SICAD, the event was held in collaboration with the scientific journal Addiction, the ISAJE and the EMCDDA

Participation in EU‑ANSA Yes Input provided to EU‑ANSA as requested on topics such as peer review; open access to data; and research needs. The EMCDDA also participated in the two EU‑ANSA meetings held in 2015 (1–2 June and 5–6 November)

21

Annex 5General Report of Activities 2015

Main Area 8: Cooperation and collaboration with key partners

Activities Expected outputs/results Implemented Comments

Specific objective 8.1. Coordinate, cooperate and provide technical support at EU level

8.1.1. Provide technical support to EU policy dialogue and deliberations

8.1.1.1. Provide expertise and technical information to the EU institutions and in institutional drugs meetings and policy documents and initiatives (as requested) (L1)

Support for EU institutions Yes Ongoing — for details see the main report and Annexes 4 and 6 (KPI 8.1.1.)

Contribution to policy debate, technical reports, reviews and presentations

Yes

8.1.2. Provide ad hoc technical and scientific support to European Commission regional programmes

8.1.2.1. Provide input for the European Commission regional projects (in line with the EMCDDA mandate and priorities in area of international cooperation, subject to resources) (L2)

Support provided to COPOLAD, CADAP, etc. Yes Feedback provided to European Commission services on the evaluation report for the COPOLAD 1 projectPresentations as part of the EU’s political dialogue with Central Asia on EDR 2015 and cooperation (past and future) with Central Asian countries (CADAP)The EMCDDA contributed information to the preparation of the Heroin Route and Cocaine Route Programmes

8.1.3. Ensure effective collaboration with other EU agencies

8.1.3.1. Cooperate with EU agencies to define and/or implement common positions, policies and working methods and tools (L2)

Participation in the Heads of Agencies meetings, in inter‑agency networks and in the JHA agencies cluster

Yes See the main report and Annex 4

Work programmes and cooperation agreements endorsed and implemented

Yes See the main report, Annex 4 and Annex 6 (KPI 8.1.2.)

Specific objective 8.2. Improve dialogue with policy audience, civil society and relevant technical and scientific bodies

8.2.1. Further develop information exchange with civil society partners and with technical and scientific bodies working in the drugs field

8.2.1.1. Engage in dialogue with civil society and technical and scientific organisations operating in the field covered by the EMCDDA mandate (resource dependent) (L3)

Dissemination of the EMCDDA’s expertise, findings and products

Yes See the main report and Annex 4

Dissemination of the EMCDDA’s expertise, findings and products

Yes

22

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

8.2.2. Improve understanding of information needs and identify effective communication channels with national policy bodies

8.2.2.1. Further strengthen relations with Member States, particularly with their key national policymaking bodies, and with the Portuguese authorities (L2)

Further improved communication channels with Member States (see also Main Area 9)

Yes Among others, this involved visits to the EMCDDA by representatives of the Member States and country visits from the EMCDDA. See details in the main report and Annex 4

Collaboration with the hosting country authorities, namely with the Portuguese Parliament, Government and Presidency of the Republic

Yes Ongoing

Specific objective 8.3: Coordinate, cooperate and provide appropriate technical input to work conducted by international bodies in the drugs field

8.3.1. Provide technical input and information to international activities (in line with mandate and strategy)

8.3.1.1. Contribute to reports, expert meetings, international projects, training and seminars, and exchange information with international partners and regional bodies (L2)

Existing arrangements and work programmes implemented

Yes See the main report, Annex 4 and Annex 6 (KPI 8.1.2.)

Input to reports, meetings, expert groups, projects, training activities and seminars

Yes

Specific objective 8.4. To support capacity development and enhance the scientific value of drug monitoring activities within candidate and potential candidate countries

8.4.1. Consolidate institutionalisation of NFPs within candidate and potential candidate countries

8.4.1.1. Launch and implement IPA 5 project (L2) Level of achievement of the project expected results. Target for 2015: 95 % of the results planned for the year achieved

Yes The launch of the project was delayed as the European Commission did not send us the grant contract for countersignature until 30 June. This influenced the implementation in 2015, as the activities could only start after the summer break. The project planning for 2015 was adjusted accordingly and all the expected results (applicable within this revised planning) were achieved. For details, see Annex 6 (KPI 8.4.1.)

Budget execution rate. Target for 2015: minimum 80 % of the total commitment appropriations for the first year

Partially See Annex 6 (KPI 8.4.2.)

Project activity reports Yes The IPA 5 inception report was drafted; however, because of the revision of the reporting template and the fact that additional months of activities have been added to the report, to ensure the necessary coherence with the final financial report, the inception report could not be sent to the European Commission before the end of 2015

23

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

8.4.2. Foster scientific cooperation in relation to data collection, interpretation and analysis, and accrue added value from cooperation activities

8.4.2.1. Enhance participation of candidate and potential candidate countries in EMCDDA work, and support candidate and potential candidate countries in producing new information on drugs in their country and disseminating the data (L2)

Reitox Academies organised at regional and national levels

Yes The seminar ‘Establishing national EWS in Serbia’ took place on 17 December in Belgrade at the request of the Drug Monitoring Centre within the Serbian Ministry of Health (45 participants)

Data collection increasingly aligned with EU standards and better analysis of available data

Not applicable Because of significant delays in the signature of the European Commission grant contract in 2015, the EMCDDA did not receive the funds necesary to initiate the activities under the project until August; therefore, there was not time for enough implementation and result assessment. Nevertheless, the EMCDDA closely monitored and supported the implementation of ESPAD 2015 studies (Albania, the former Yugoslav Republic of Macedonia and Montenegro), and kept in contact with Bosnia and Herzegovina and Serbia with regard to the progress of TDI 3.0 implementation throughout the year

8.4.2.2. Provide European Commission services with regular information on the progress made by countries (L2)

European Commission progress reports on candidate and potential candidate countries informed by EMCDDA IPA 5 activities

Yes

8.4.2.3. Disseminate information on the drugs situation in the Balkan region (L3)

Updated national information and country overviews Partially Three publications based on data from the Western Balkans were released in 2015 and the country overviews were updated. However, publication on the EMCDDA website will not take place until 2016

Specific objective 8.5. Support capacity development, information availability and exchange with interested ENP and other non‑EU countries

8.5.1. Implement the EMCDDA technical cooperation with interested ENP partner countries and Russia to improve knowledge base

8.5.1.1. Perform ENP project coordination and implementation activities (L1)

Training provided Yes Three Reitox Academies were organised, in Georgia, Morocco and Israel, for 88 participants

Country overviews for the seven participating countries prepared or updated on the EMCDDA website

Partially Work was in progress to update the country overviews for three countries. The remaining four countries did not provide any input for this activity. The result will be highly dependent on the cooperation of partner countries — not under the control of the EMCDDA

Project reports Yes

8.5.1.2. Provide European Commission services with regular information on the progress made by countries, and on obstacles to project implementation (L2)

European Commission progress reports on ENP countries informed by EMCDDA project activities

Yes

24

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

8.5.1.3. Strengthen the institutional relations and working arrangements with ENP countries (L2)

Working programmes/frameworks for cooperation adopted/updated

Yes Two MoUs signed in 2015: one with the NSC (16 July) and one with the Ministry of Justice of Georgia (4 November)

8.5.2. Exchange information, working practices and methodology on the identification of NPS with other interested regional and national monitoring systems

8.5.2.1. Capacity building and information exchange on NPS with ENP countries (L2)

Participation of ENP experts in EWS annual meeting Partially Only one expert, from Israel, attended the meeting. However, the Reitox Academy ‘Monitoring and control of New Psychoactive Substances’ took place on 16–17 April in Tbilisi, for 27 participants, representing national monitoring bodies, national law enforcement agencies and national forensic laboratories from six ENP countries

8.5.2.2. Extend functionality of EDND to disseminate appropriate information to ENP countries (L2)

EDND communication functionality implemented (in line with resources available for the EDND project)

No The development of the new EDND was delayed (see Main Areas 5 and 12) and the implementation plan had to be revised, including the ENP component

8.5.3. Support technical capacity development for drug monitoring systems

8.5.3.1. Prepare training materials and guidelines based on the European model to support capacity development work (L2)

Online training modules Partially Work in progress, to be completed in 2016

8.5.4. Promote EU model for National Drug Observatories and National Drug Information Systems

8.5.4.1. Disseminate EMCDDA knowledge in third countries (L2)

Fourth Reitox Week organised with participation of third countries

Yes The Fourth Reitox Week took place on 22–26 November in Lisbon

Presentations and technical contribution at conferences and events (based on resources)

Yes See Annex 4

Main Area 9: Communicating the EMCDDA’s findings to external audiences

Activities Expected outputs/results Implemented Comments

Specific objective 9.1. Implement the integrated communication strategy and action plan

9.1.1. Develop procedures to integrate communication perspective at product conception

9.1.1.1. Implement practices and workflows with scientific units to ensure an integrated approach to product conception and development (L2)

Improved planning and shaping of products upstream (see also priority intervention 9.2.1.)

Yes

25

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

9.1.2. Continue to develop product range to reflect EMCDDA priorities and changing patterns of communication

9.1.2.1. Develop new products in line with audience needs and developments in the field (L2)

A rationalised and balanced products mix with cost savings and efficiency gains

Yes The online‑only EMCDDA Papers series has been implemented, leading to a reduction in printed products and shorter and timelier ones. The risk assessments have also been converted to an online‑only series. Output price has fallen from around EUR 5 000 to EUR 300–500 per product. Online Rapid communications are also a favoured means of disseminating results online in a more timely manner

9.1.3. Implement revised linguistic policy

9.1.3.1. Translate selected products (L2) Multilingual products available, in line with audience needs and availability of resources

Partially Because of the budget constraints, in addition to the multilingual edition of the EDR 2015 (Trends and Developments report), a limited number of other translations were ordered, which were particularly relevant for the certain Member States

9.1.3.2. Continue to work with NFPs on the terminology/glossary project (L2)

New terms with agreed and translated definitions uploaded to IATE (the EU’s multilingual term base: InterActive Terminology for Europe)

Yes

9.1.4. Engaging better with audiences

9.1.4.1. Implement the new EMCDDA audience engagement strategy (L2)

2015 action plan implemented (see also priority intervention 8.2.2.)

Yes

Specific objective 9.2. Publish high‑quality and timely products in line with targets committed to in the 2013–15 work programme

9.2.1. Assure publication, launch and dissemination of EMCDDA products

9.2.1.1. Deliver timely editing, production, dissemination and promotion services (L2)

Planned products published, launched and disseminated (see list of key outputs)

Partially See Annex 6 (KPI 9.2.2.)

9.2.1.2. Improve quality control in the production process of EMCDDA products (L2)

Clear procedures and workflows for content production and publication in place

Yes

9.2.2. Produce the EDR package

9.2.2.1. Fine‑tune the EDR package based on feedback from 2014 (L1)

Improved, streamlined and electronically integrated EDR package

Yes The EDR package was fine‑tuned; in particular, the graphics were overhauled. A fully responsive HTML version of the report was developed for integration into the website as well as an e‑book version for use on handheld devices. A motion graphic video was produced to summarise the key findings

9.2.2.2. Draft, edit and produce Trends and developments, part of the EDR package (L1)

Report successfully produced, promoted and disseminated

Yes EDR 2015 package launched on 4 June, in Lisbon (emcdda.europa.eu/edr2015)

26

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

9.2.2.3. Conceive and develop new set of PODs with interactive features, and update existing ones (L1)

New and updated set of PODs online, showcasing topical content

Yes Four new PODs launched as part of the EDR 2015 package; in addition, nine previously produced PODs were updated

9.2.2.4. Fine‑tune and publish the 2015 European Drug Report: Data and statistics (Statistical bulletin) web area (see also Main Area 1) (L1)

More accessible and interactive European Drug Report: Data and statistics (Statistical bulletin) published online, as part of the EDR package

Yes The new method and process for displaying data tables (introduced in 2014) was further developed. The methods and definitions section was overhauled. The key graphics from the EDR were added to the Statistical bulletin to provide the visualisation element

9.2.2.5. Prepare country overviews in consultation with NFPs (L2)

30 country overviews published online, as part of the EDR package

Yes Available at: emcdda.europa.eu/countries

Specific objective 9.3. Increase the relevance and impact of the EMCDDA’s online presence

9.3.1. Develop web content in line with integrated communication strategy

9.3.1.1. Further develop integrated web resources in collaboration with the Scientific Division (see Main Areas 1–7 for details) (L1)

Web resources updated and further developed for each area

Partially completed, partially delayed

In 2015, all the available resources were deployed to the development of Drupal, the content management system of the EMCDDA website. The Drupal project is complex and the implementation faced important technical difficulties and consequent delays. The launch of the new website had therefore to be postponed to early 2016, which delayed all content‑related activities

9.3.2. Increase interactivity and targeted approach of the website

9.3.2.1. Continue to develop interactive products and improve findability of information (L1)

Increased number of interactive products launched Yes Important improvements were made to the presentation of the EDR package (see action 9.2.2.). A significant step forward has been the interactive development of methods for displaying the data collected under the EU EWS (see Main Area 5). Other examples include the BPP, the Harm Reduction and Social Responses profiles and the Prevalence profiles, all of which have high levels of interactivity

More possibilities for users to interact with information

Yes Among others, the HTML version of the EDR with its interactive graphics enables users to focus in on the information they are interested in. The exploratory data visualisation for the wastewater POD is another example

27

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

9.3.3. Continue to implement new content management tool, work flows and quality content

9.3.3.1. Implement web governance strategy (L1) Further improved governance of EMCDDA web resources

Partially completed, partially delayed

The delays in the implementation of the Drupal project (see 9.3.1.1. above) led to delays in all other related activities, including the development of the web governance strategy. Progress in 2015: the workflows were tested in Drupal; and the arrival of Piwik and reliable statistics (web metrics), which are useful monitoring instruments

9.3.3.2. Implement quality assurance measures (L2) Online resources comply with the defined web publishing quality standards

Partially completed, partially delayed

Electronic workflows for the creation of web content have been defined in the context of the Drupal project. Further steps in 2016 in line with the progress in the implementation of Drupal

Specific objective 9.4. Enhance the EMCDDA’s reputation and recognition as the European central reference point for drugs information

9.4.1. Ensure visibility of EMCDDA across multiple communication platforms

9.4.1.1. Ensure coordinated communication on key events and products (L2)

Constant feed of news on EMCDDA activities and results

Yes In order to enhance their visibility and increase uptake by audiences, during the year all the EMCDDA products were launched via news releases, fact sheets, news items, newsletters, website and social media. A total of 23 campaigns were sent out in 2016 via ‘Mailchimps’ including ‘Just published’, Best practice updates, summer school updates and information about the Lisbon Addictions 2015 conference

9.4.1.2. Organise events/product launches and support EMCDDA’s presence at conferences and technical meetings (as appropriate) (L2)

Awareness raising and positioning of EMCDDA’s work results and scientific expertise

Yes

9.4.1.3. Organise EDR launch (L2) Report successfully launched across multiple communication platforms

Yes The full EDR 2015 package was launched to the media on 4 June at a press conference in Lisbon in the presence of Dimitris Avramopoulos, European Commissioner responsible for Migration, Home Affairs and Citizenship. In addition to the visiting journalists, a further 27 journalists from the Portuguese media and foreign press in Portugal attended the press conference, bringing the total to 51, which is the highest number of journalists that have attended an EDR launch since the EMCDDA began launching the report in Lisbon in 2010. In terms of media coverage, there were 2 871 items of coverage in 2015, up 40 % on 2014

9.4.1.4. Organise visits of external partners to EMCDDA (L2)

Dissemination of knowledge and experience, increased visibility of EMCDDA among academic, policy and professional audiences

Yes 50 visits from external parties, involving 468 visitors (up by 15 % as compared with 2014 – 407 visitors), which reflects a growing interest in the agency’s activities

28

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

9.4.1.5. Contribute to the organisation and delivery of major conferences and technical meetings in the EMCDDA’s area of competence (if appropriate and resource dependent) (L3)

Increased visibility and engagement with scientific community

Yes The presence of staff at scientific conferences and events was supported by tailor‑made leaflets, publications dispatch and social media postings

Wider dissemination and uptake of EMCDDA outputs Yes Tailored HTML newsletters and thematic flyers helped reach and retain audience interest on specific topics. Structure and metadata of website adjusted to improve findability of information. We had approximately 990 000 unique visitors to our website throughout the year and 1.23 million unique page views

9.4.1.6. Continue to develop EMCDDA presence in the areas of social media, audio‑visual channels and mobile devices (L2)

Increased visibility for EMCDDA activities and products across social media, audio‑visual channels and mobile devices

Yes Social media activities were particularly dynamic in 2015. There were 4 220 followers on Facebook (4 000 ‘likes’ reached in November) and 960 on LinkedIn by the end of 2015EMCDDA videos were viewed nearly 25 000 times in 2015. For the first time, multilingual content was offered on YouTubeA ‘Live’ Twitter account was established to cover two high‑profile meetings. At the end of 2015, we had 6 800 followers on Twitter

9.4.2. Continue to build sound contacts and relations with journalists and provide media‑friendly information with clearly defined messages

9.4.2.1. Further develop contacts and relations with journalists and provide media‑friendly information (L2)

Interviews set up, catalogue of journalist groups further developed

Yes In 2015, 339 requests were received by the press office, up 94 requests on the previous year, which shows constant and important annual growth (245 in 2014, 194 in 2013 and 166 in 2012). Timely responses were ensured to all these requests

High‑quality press products in accessible formats Yes To mark major events, 11 news releases, 10 fact sheets, 14 web news and 1 feature article item were released. In total, there were 36 items issued in 2015, almost 10 % more than in 2014 (33 items in total)

9.4.2.2. Assess impact through monitoring and press reviews (L2)

Clear view of return on investment from media activities through press reviews and analyses

Yes For budgetary reasons, the EMCDDA media monitoring contract in 2015 covered the European Drug Report launch only. Among others, it assessed the return on investment (ROI) of inviting journalists to the event in Lisbon. In 2015, the EMCDDA invested EUR 15 168 in bringing 23 journalists from the Member States to the launch. This exercise led to 75 items of coverage and 81 syndicated items, giving a grand total of 156 items. The approximate total reach of articles or ’Opportunities To See’ (OTS) by visiting journalists was 8 million. The total advertising value equivalent (AVE) was EUR 105 051, suggesting a sound ROI.

29

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

9.4.3. Public information service

9.4.3.1. Operate enquiry‑answering service, produce website FAQs and other information (L2)

Efficient public information desk operates in line with guidelines set by the European Ombudsman

Yes In 2015, 149 enquiries made to enquiries@emcdda.europa.eu were answered promptly

9.4.4. Library and documentation services

9.4.4.1. Provide reliable and efficient information, library and documentation services supporting the research needs of scientific staff (L2)

Information bulletins published at regular intervals; ad hoc alerts distributed on an individual basis; literature searching; reference database construction and maintenance; management of library services

Yes

Main Area 10: Governance, management and networks

Activities Expected outputs/results Implemented Comments

Specific objective 10.1. Ensure good governance to provide the strategic guidance and direction for the work of the EMCDDA

10.1.1. Implement strategic decision‑making process at the level of the Management Board

10.1.1.1. Coordinate, prepare and organise follow‑ups of the meetings and decisions of the Management Board, the Executive Committee and the Budget Committee (L1)

Management Board, Executive Committee and Budget Committee meetings organised and statutory decisions adopted

Yes 9–11 September, Lisbon: 51st meeting of the Board3–4 December, Lisbon: 52nd meeting of the Board13 May, 9 September and 2 December: Executive Committee meetings

10.1.2. Provision of support and guidance by the Scientific Committee to further enhance the scientific quality of the EMCDDA’s work

10.1.2.1. Coordinate, prepare and organise meetings of the Scientific Committee and follow up on the conclusions and recommendations (L1)

Scientific Committee meetings organised Yes 28–30 April 2015, Lisbon: 42nd EMCDDA Scientific Committee meeting18–20 November, Lisbon: 43rd EMCDDA Scientific Committee meeting

Selected outputs peer reviewed by the Scientific Committee

Yes Six publications peer reviewed by the Scientific Committee

Specific objective 10.2. Ensure efficient management and leadership to support achievement of results and efficient use of resources

10.2.1. Implement sound management organisation and practices

10.2.1.1. Optimise internal processes to ensure that the agency’s resources are used in the most efficient, effective and economical manner (L2)

Further measures to rationalise use of resources and improve organisational performance

Yes

30

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

10.2.1.2. Ensure compliance with the data protection rules applicable to EU bodies, Regulation (EC) 45/2001 (L1)

Data protection rules applicable to EU bodies (Regulation (EC) 45/2001) observed in all EMCDDA activities

Yes Ongoing

Specific objective 10.3. Improve and implement the agency’s strategic planning and programming cycle processes, to support timely delivery of results and sound decision‑making with regard to the allocation of resources and actions to be taken to enhance performance

10.3.1. Design and put in place an integrated performance measurement system to allow the EMCDDA to better track progress of its achievements and detect implementation challenges in a timely way

10.3.1.1. Complete the development of the performance measurement system (L2)

Performance indicators in place for all main areas Yes

Development of the management information system completed and implementation phase started (resource dependent)

Delayed Priority was given to L1 activities and to the preparation of the SPD 2017–19 (new project, which had not been planned in the 2015 work programme)

Mid‑year monitoring report prepared and used to support internal decision‑making and planning

Yes

10.3.2. Prepare the documents required by the strategic planning and programming cycle

10.3.2.1. Prepare the strategic planning and programming cycle documents (L1)

General Report of Activities 2014 published online by 15 June

Yes The General Report of Activities 2014 — Key achievements and governance: a year in review was published online on 12 June (emcdda.europa.eu/publications/gra/2014) and sent, on the same day, to the European Parliament, the Council, the European Commission and the ECA, as required by the EMCDDA’s recast Founding Regulation. The content and format of the report were fully aligned with the template for the Consolidated Annual Activity Report for decentralised agencies, as provided by the communication from the European Commission (C(2014) 9641) issued in December 2014

2016–18 strategy and work programme and 2016 annual work programme submitted to the Management Board for adoption

Yes The document was adopted by the Management Board on 3 December

Specific objective 10.4. Ensure effective internal control and risk management system

10.4.1. Implement sound internal control system, in accordance with the relevant regulatory requirements, including sound financial management

10.4.1.1. Verify thoroughly the financial transactions, notably as regards legality and regularity of operations (L2)

Ex ante verification of all financial operations and corrections made if necessary

Yes Ongoing

31

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

10.4.1.2. Monitor the state of implementation of the 16 EMCDDA ICSs for effective management and control (L2)

Regular assessment of the quality of the EMCDDA internal control systems carried out and repository updated

Yes Ongoing

10.4.1.3. Update the central and sector risk registers as required under ICS 6 (L2)

Identification and assessment of risks posed to EMCDDA activities and timely setting up of action plans to mitigate those risks

Yes Ongoing

10.4.1.4. Liaise effectively with the EMCDDA Internal Auditor (the IAS) with a view to taking stock of recommendations arising from audits in areas of strategic importance (L2)

Proper implementation of recommendations addressed by the IAS in accordance with suitably designed action plans, leading to improvements in internal controls

Partially Ongoing

Reitox network

Specific objective 10.5. Ensure that the Reitox network is efficiently managed and structured to meet future needs and requirements

10.5.1. Agree the annual reporting package and necessary developments to the overall reporting framework

10.5.1.1. Implement the revised national reporting system (L1)

First phase of the action plan implemented Yes See Main Area 1 (1.1.1.1.)

National summaries submitted to the EMCDDA in the new format

Yes

10.5.1.2. Prepare and organise the Reitox HFP meetings (L1)

Fifth Reitox Week, 54th and 55th HFPs meetings organised

Yes 16–18 June, Lisbon: 52nd Reitox meeting of HFPs24–26 November, Lisbon: 53rd Reitox meeting of HFPs

New guidelines for national reporting adopted Yes

10.5.1.3. Carry out consultation of NFPs for guidelines and tools (L2)

Reitox technical meeting organised for analysis and discussion of proposed instruments

Not applicable The meeting was not necessary

10.5.2. Strengthen the Reitox network at national level as a high‑quality provider of information

10.5.2.1. Provide institutional and technical support, in line with needs and available resources (L2)

Institutional visits organised to the countries Yes

National or regional Reitox Academies organised for Member States, upon request

Yes Two Reitox Academies were organised in Poland (regional event) and Austria (national event)

10.5.3. Strengthen the management and organisational processes and procedures

10.5.3.1. Support NFPs in the management and implementation of their yearly grant agreement (L1)

28 grant agreements signed and implemented Yes

On‑site audit visits and training support (as needed and in line with available resources)

Yes

10.5.3.2. Implement the management information system HERMES (L2)

HERMES reports used to track the progress of implementation of the work programme

Yes

32

Annex 5General Report of Activities 2015

Main Area 11: Administration — supporting core business

Activities Expected outputs/results Implemented Comments

Financial and budget management and accounting

Specific objective 11.1. Enhance effectiveness and efficiency in the execution of the budget and in the management and accounting of financial resources

11.1.1. Align the EMCDDA’s financial rules with the revised EU financial regulation and ensure their implementation

11.1.1.1. Implement the EMCDDA’s financial rules (L1) Financial rules, and updated procedures, manuals and templates applied

Yes Ongoing

11.1.2. Further improve effectiveness and efficiency of financial transactions (payment process) and procurement processes

11.1.2.1. Carry out procurement activities and implement measures to rationalise and optimise tendering and financial processes for the execution of the budget and work programme (L1)

2015 annual procurement plan in place and successfully executed

Yes

11.1.3. Ensure effective and timely preparation and use of budget planning and management and reporting tools in line with EMCDDA priorities and constraints and in accordance with activity‑based management/activity‑based budgeting principles

11.1.3.1. Prepare and submit for approval the budget‑planning instruments in a timely manner (L1)

EMCDDA 2016 draft budget and 2017 preliminary draft budget

Yes The budget instruments were adopted by the Management Board on 3 December

11.1.3.2. Facilitate effective implementation of the 2015 budget (L1)

High rate of budget execution (over 97 % in commitment appropriations and over 93 % in payment appropriations)

Yes The EMCDDA once again achieved an outstandingly efficient management of its budget (execution rate) in 2015, as follows: 99.83 % for commitment appropriations and 97.4%.for payment appropriations (99.8 % for Title 3 payment appropriations)

11.1.3.3. Effective and timely reporting on budget execution (L2)

Regular and customised reports according to established schedule

Yes

11.1.4. Improve the accounting of EMCDDA assets, and further define the conditions and requirements for the function of accounting officer at the EMCDDA in accordance with applicable financial rules

11.1.4.1. Review of relevant processes and tools (L2) Full alignment of relevant processes and tools to new financial rules

Yes

Human resources management

Specific objective 11.2. Maximise efficiency and effectiveness of human resources management at the EMCDDA

11.2.1. Align EMCDDA human resources processes and policies to the revised EU staff regulations

11.2.1.1. Implement human resources processes and policies in line with the new EU staff regulations (L1)

Implementing rules to the staff regulations in place Yes

33

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

11.2.2. Further develop EMCDDA working and production capacity by maximising training opportunities for EMCDDA staff

11.2.2.1. Develop/update and implement the training plan as required to match working priorities and needs, and the available resources (L2)

Training plan developed and implemented in line with EMCDDA working priorities

Yes

11.2.3. Implement recruitment processes, where necessary, in line with the EMCDDA establishment plan and within the adopted budget

11.2.3.1. Carry out the necessary procedures for the recruitment, establishment and departure of statutory and non‑statutory staff as requested to fulfil the establishment plan and the organisational needs (L1)

Vacant positions are filled in accordance with the budget available and organisational needs

Yes

Infrastructure and logistics

Specific objective 11.3. Ensure a healthy working environment and further reduce utility costs by optimising the use of the available facilities, equipment and infrastructure

11.3.1. Ensure safety at work, sound environmental management and security in buildings, including reducing utility costs and promoting use of renewable energy

11.3.1.1. Review annual security risk assessment of the EMCDDA to identify and evaluate risks, foresee new developments and propose mitigation measures to reduce impact and likelihood (L2)

BCP implemented Yes

Risk assessment prepared Yes

11.3.1.2. Develop, put in place and promote an environmental management system within the agency (L3)

Environmental management system in place Yes

Contribution to the Greening Network meeting Yes The 9th meeting of the Greening Network was organised by EFSA (Parma, 17–18 September) with technical input from the EMCDDA

11.3.1.3. Implement appropriate management of the premises, to provide optimal working conditions for EMCDDA staff (L2)

Health and safety risks identified and addressed Yes No work accidents in 2015

Wardens trained and evacuation exercise carried out successfully

11.3.1.4. Implement measures to rationalise cost of utilities and service contracts (L2)

Maintain stable utility costs Yes Out of the three relevant parameters (electricity, gas and water) a reduction in cost was achieved for all buildings for electricity and gas. The water consumption was reduced in the EMCDDA main building but increased, in proportion to the increase in customers at the restaurant, in the separate ‘Palacete’ building (mainly because of participants at meetings organised by the neighbour agency EMSA, which shares the restaurant with the EMCDDA). This was outside EMCDDA control and based on the successful reduction of water costs in the main building — the implementation status of this output is considered as achieved

34

Annex 5General Report of Activities 2015

Main Area 12: Information and communications technology

Activities Expected outputs/results Implemented Comments

Specific objective 12.1. Develop and maintain ICT solutions and tools to support the EMCDDA’s work processes, while applying best practices and standards of ICT governance, planning and service management

12.1.1. Develop and maintain instruments for supporting business

12.1.1.1. Develop and maintain infrastructure for the annual drugs data collection and analysis, reflecting the evolution of the drugs data set and its protocols (L1)

Fonte online data collection system and analytical drugs database set up for annual run; Fonte updates performed during the year, as required

Yes

Drugs data warehouse phase II developed Yes

12.1.1.2. Support web content management and visualisation platform development (L1)

Development and migration to new platform finalised (phase II)

Delayed See Main Area 9 (9.3.1.1.)

12.1.1.3. Develop EDND (L1) New data collection procedure designed; new software and web interface further developed; different access levels for different audiences established

Delayed See Main Area 5 (5.1.1.4.)

12.1.1.4. Implementation of networking tools and extranets support (L2)

Concept study to support extranets and expert networks

Postponed No available resources to implement this activity

12.1.1.5. Develop a management information system to support the performance measurement system (see also 10.3.1.1.) (L2)

Development completed and implementation started (resource dependent)

Delayed System set up, adaptation and configuration for pilot use contracted out (start of work foreseen for early 2016). Lack of resources to advance more with this project — see also Main Area 10 (10.3.1.1.)

12.1.1.6. Further develop a tool for electronic management of EMCDDA staff’s working time (L2)

Application requirements document completed Delayed No available resources to ensure progress as planned

Partial analysis and design aimed at better estimating the investment required conducted

Delayed

12.1.1.7. Implement other business projects as indicated by ICT Steering Committee (L3)

Additional projects’ products, as needed and based on resources

Delayed No available resources to ensure progress as planned

Review and follow up as necessary on the ICT needs derived from the revision of the national reporting system

Yes

12.1.2. Implement business and information architecture management programme

12.1.2.1. Business architecture programme (L2) Definition or review of baselines and strategies for business and information/data architecture and security and privacy, and for electronic identity and access management

Yes

35

Annex 5General Report of Activities 2015

Activities Expected outputs/results Implemented Comments

12.1.3. Implement the technical services management programme

12.1.3.1. ICT services provision (L1) ICT service catalogue further developed Yes

Availability and stability of the technical infrastructure supporting services delivery

Yes

12.1.3.2. Implement ICT governance, ensuring correct planning and management of ICT resources (L2)

Project portfolio concept and project management principles developed, in coordination with the ICT Steering Committee, in line with IAS recommendations

Yes

12.1.3.3. Run projects to renew the technical infrastructure (L2)

Investments to maintain the technical infrastructure at the correct level of functionality and quality, minimising risks

Yes

1

Annex 6General Report of Activities 2015

I ANNEX 6 Key performance indicators

Attaining good performance was a strategic goal for the EMCDDA in 2013–15, and the agency made significant progress in this area during this three-year period. This included

establishing key performance indicators (KPIs) for all the main areas of work. In line with the two-step approach endorsed by the Management Board, the process started with the

definition of KPIs for three areas in the 2014 work programme; in the second phase, which was completed under the framework of the preparation of the 2015 work programme,

KPIs were developed for all areas of work (51 KPIs in total).

These KPIs were designed to measure the achievement of the specific objectives defined in the 2015 work programme. As much as this was possible, annual targets were defined

in order to support the measurement of the KPIs.

The results achieved are presented below. Data were retrieved from the internal monitoring documents, which are part of the corporate monitoring and evaluation (M&E) plan.

These data show that the EMCDDA had a good performance overall: of the 58 annual targets corresponding to the 51 KPIs, 83 % were either ‘overachieved’ or ‘achieved’, as

follows:

– 11 (19 %) targets were overachieved;

– 37 (64 %) targets were achieved;

– 9 (16 %) targets were underachieved;

– 1 target could not be assessed because of methodological limitations.

Methodological constraints/limitations

It should be noted that because 2015 was the first year of KPI implementation for all the main areas, it served as a test year, during which the methodologies for measuring the

indicators were developed and consolidated. While for most of the KPIs the data collection and analysis mechanisms were set up without any major difficulties, there were a few

cases in which a critical review was necessary. For instance, one of the KPIs proved not to be feasible because of the difficulty of obtaining reliable data (i.e. KPI 9.4.1: good

estimates for audience reached via participations in missions); hence, the data collection mechanism for this KPI is now being revised and, in the meantime, this KPI will be

discontinued. In addition, the developments in the work of the agency and the introduction of new tools made comparison with data from previous years impossible, which had an

impact on the definition of sound annual targets (e.g. in relation to web metrics (see KPI 9.3.1 and KPI 3.3.1)). These cases are duly identified in the document. Furthermore, this is

a natural development in the life of the performance measuring system of the agency, and the lessons learnt will be used to further improve the definition of the KPIs, to set up

targets and to build sound methodologies.

For acronyms and abbreviations used, please refer to Annex 9 of the full report available at: emcdda.europa.eu/publications/gra/2015

2

Annex 6General Report of Activities 2015

Main Area 1: Data collection, analysis and quality assurance

Specific objective 1.1. Improve data collection instruments and processes

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 1.1.1. Degree of implementation of the revised national reporting package

Phase 1 implemented Overachieved Reitox reporting All 30 countries completed the five workbooks which were minimally required for the 2015 reporting; 25 countries exceeded the minimal requirements — they completed all 10 workbooks (see Annex 5, 1.1.1.1)

Specific objective 1.2. Strengthen the quality assurance framework to support data collection, analysis and reporting

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 1.2.1. Level of progress in the development of the statistical quality framework at the EMCDDA

EMCDDA’s Statistics Code of Practice (SCP) implemented

Achieved Internal records

Main Area 2: Monitoring and understanding drug use and problems — key indicators and methodology

Specific objective 2.1. Ensure progress in the methodological development of the KIs

Specific objective 2.2. Support the implementation of the key indicators through ongoing monitoring and provision of technical guidance and training

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 2.1.1. Effective monitoring of the implementation of the key epidemiological indicators (KIs) in the EMCDDA reporting countries (28 Member States, Norway and Turkey)

Triennial review carried out and the 30 EMCDDA reporting countries provided with feedback to support further improvement of KIs’ implementation at the national level

Achieved Internal records

3

Annex 6General Report of Activities 2015

Specific objective 2.3. Maximise the value of key indicator information through analysis to provide a comprehensive, relevant and multi-source understanding of contemporary patterns of drug use, trends and related health and social consequences

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 2.3.1. Compliance of the key epidemiological indicators annual expert meetings with the quality standards (guidelines) in place at the EMCDDA

100 % Partially achieved

Internal records There were two KI expert meetings organised in 2015 (details in the main report):– the DRID meeting (15–16 June), for

which there was full compliance with all the applicable internal quality criteria (processes and outputs);

– the ‘20 years of monitoring’ meeting (21–22 September), for which there was full compliance for processes and partial compliance for outputs (one of the two outputs was delayed because of competing priorities)

Main Area 3: Monitoring demand reduction responses applied to drug-related problems

Specific objective 3.1. To monitor prevention provision, implementation and outcomes and to improve reporting on important areas where information resources are lacking

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 3.1.1. Improvement of the online resources in the prevention area

Web resources updated Achieved EMCDDA website

4

Annex 6General Report of Activities 2015

Specific objective 3.2. Improve the monitoring and analysis of treatment, harm reduction and social reintegration interventions and provide an integrated model for understanding service provision in Europe

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 3.2.1. Availability of estimates of the total number of people in treatment at the national level

50 % of the countries reporting to the EMCDDA provide an estimate of the total number of people in treatment at the national level (i.e. 15 countries)

Overachieved Reitox reporting In 2015, 23 countries (i.e. 77 % of the 30 reporting countries) were able to provide estimates on the total number of people in treatment

Specific objective 3.3. To identify and support dissemination and knowledge exchange on best practices

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 3.3.1. Number of visitors/visits to the Best practice portal (BPP)

To be defined based on the 2014 baseline data – please see comments for details

47 115 unique visits to the BPP. On track

Web statistics obtained through the dedicated tool (Piwik)

The number of unique visits to the BPP was estimated based on an internal methodology. Estimation was necessary because a new tool (Piwik) was introduced in May 2015, after the introduction of the new content management system Drupal (see also KPI 9.3.1.). The introduction of this new tool improved measurements, but comparisons with the data from 2014 are no longer relevant; therefore, setting up a target based on these data proved to be unfeasible. Although a clear target for this KPI could not be defined, the results achieved, in absolute numbers, are positive; therefore, we can consider this KPI as on track

5

Annex 6General Report of Activities 2015

Main Area 4: Monitoring drug supply and supply reduction interventions

Specific objective 4.1. Develop European key indicators and complementary information resources for understanding drug markets, drug-related crime and drug supply reduction

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 4.1.1. Availability of tools to improve data collection mechanisms

Revised reporting instrument on drug seizures endorsed and ready for routine implementation

Achieved Internal records; documents of the HFP meetings and the annual meeting of the EMCDDA Reference Group on Drug Supply Issues

Draft reporting instruments on drug production facilities agreed with Europol and ready to be implemented

Achieved Internal records

Specific objective 4.2. Establish networks in the area of drug supply and supply reduction

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 4.2.1. Level of operationality (effectiveness) of the EMCDDA Reference Group on drug supply

Reference group fully operational: agreement on the revised reporting instruments on drug seizures and on drug law offences; and consultation for the draft reporting instruments on drug production facilities (dismantled synthetic drugs, cocaine secondary extraction labs and cannabis cultivation)

Achieved Documents of the third annual meeting of the EMCDDA Reference Group on Drug Supply Issues

Specific objective 4.3. Produce a strategic analysis of drug supply and supply reduction in Europe

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 4.3.1. Number of strategic analyses produced jointly with Europol (cumulative 2013–15)

Two analyses (the first EU drug markets report: a strategic analysis, published in 2013; the second report in preparation in 2015, for publication in 2016)

Achieved EDMR (first edition published in 2013; second edition launched on 5 April 2016)

6

Annex 6General Report of Activities 2015

Specific objective 4.4. Support the EU Internal Security Strategy (COSI)

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 4.4.1. Degree of implementation of the activities assigned to the EMCDDA (cumulative 2014–15)

The tasks assigned to the EMCDDA in the Operational Action Plan (OAP) 2014–15 implemented

Achieved Internal records; CEPOL training records; correspondence with partners (Eurojust, CEPOL, Europol)

The EMCDDA fulfilled the tasks assigned in the OAP on synthetic drugs; cocaine; and heroin

Main Area 5: Monitoring new trends and developments and assessing the risks of new substances

Specific objective 5.1. To ensure that the information exchange and risk assessment mechanism on new psychoactive substances is of high quality and implemented in a timely and efficient manner

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 5.1.1. Timely implementation of the information exchange and risk assessment mechanism on new psychoactive substances (NPS)

Timely issue of formal notifications on NPS and public health related warnings to the EWS network, EDND regularly updated, annual implementation report submitted to the European Parliament, the Council and the EC and published

Achieved EWS records; EDND; EMCDDA–Europol 2014 annual report on the implementation of Council Decision 2005/387/JHA

A total of 100 reporting forms on NPS that were identified for the first time within Europe during 2015 were received, reviewed, validated and analysed in a timely mannerA total of 17 public health alerts (including updates) were produced based on information received from the EU EWS network and from searches and reviews of OSI, and reviewed, validated and analysed. These were then issued to the EU EWS networkEDND substance profiles were prepared/updated: 101 new substance profiles were prepared and included in the EDND for each of the NPS that were detected for the first time in 2015; in addition, 328 existing EDND substance profiles were reviewed/updated with new informationThe EMCDDA–Europol 2014 annual report on the implementation of Council Decision 2005/387/JHA was submitted to the relevant institutions on 5 June 2015

7

Annex 6General Report of Activities 2015

Key performance indicators (KPIs) Target 2015 Status Data source Comments

EMCDDA–Europol Joint Reports on NPS submitted to the EC, the Council and the EMA within four weeks of the date the information is received from the EWS partners (as appropriate)

Achieved A Joint Report on α-PVP was drafted, formally approved by the Directors of the EMCDDA and Europol, and submitted to the European Commission, the Council and the EMA on 3 August 2015 by the legal deadline stipulated by Council Decision 2005/387/JHAA joint report on acetylfentanyl was drafted, formally approved by the Directors of the EMCDDA and Europol, and submitted to the Commission, the Council and the EMA on 1 December 2015 by the legal deadline stipulated by Council Decision 2005/387/JHA

Risk Assessment reports submitted to the Council and the EC within twelve weeks of the date the request is received from the Council (as appropriate)

Achieved Documents from the Scientific Committee’s risk assessment meeting; a risk assessment report on α-PVP; and correspondence

A Scientific Committee meeting on the risk assessment of α-PVP was organised and held on 18 November 2015, in accordance with Article 6 of Council Decision 2005/387/JHA; the risk assessment report on α-PVP was submitted to the Commission and the Council within the timeline stipulated in Article 6 of Council Decision 2005/387/JHA

Corporate supporting infrastructure availability (websites, web applications, Fonte, databases, email, security): systems run on a 24/7 basis with an overall availability annual target of 99 % minimum availability (maximum of 88 hours of annual accumulated downtime)

Overachieved (99.4 %)

ICT unit monitoring reports

Main Area 6: Improving Europe’s capacity to monitor and evaluate policies

Specific objective 6.1. Develop European and global drug policy monitoring and analysis

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 6.1.1. Number of policy analyses published by the EMCDDA (cumulative 2013–15)

A minimum of six policy analyses (cumulative) Overachieved EMCDDA publications available on the public website

In total, 10 policy papers were published during the 2013–15 period

8

Annex 6General Report of Activities 2015

Specific objective 6.2. Strengthen European networks in drug law and drug policy analysis

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 6.2.1. Compliance of the legal correspondents meeting with the quality standards (guidelines) in place at the EMCDDA

15th meeting of the legal correspondents fulfils the quality standards

Achieved Meeting documents; internal records

The annual legal correspondents meeting took place on 8–9 September

Main Area 7: Scientific coordination, research and content support

Specific objective 7.1. Ensure the coordination of scientific activities so that resources are efficiently used, objectives are achieved and quality control of outputs is maintained

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 7.1.1. Implementation of quality mechanisms to support the scientific activities

Quality standards and guidelines in place for key scientific processes

Achieved Internal records A set of quality mechanisms was set up internally and the progress made in their implementation was monitored in the context of this composite KPI

KPI 7.1.2. Publishing of scientific articles in peer-reviewed journals

Impact score 10 or higher (impact score = the journal impact factor × the number of scientific articles published in 2015)

Overachieved; total impact score of 72 226

The list of scientific articles published in 2015 is presented in Annex 3

Specific objective 7.2. Support drug-related research, audit key developments and promote the use of research findings

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 7.2.1. Contribution to the development of the EU drug research agenda

Report with recommendations on research priorities at EU level submitted to the HDG for the Annual Dialogue of Research (in collaboration with the Scientific Committee)

Achieved Report submitted by the Scientific Committee; formal correspondence

The report was adopted by the Scientific Committee in October and submitted to the HDG’s Annual Dialogue of Research on 3 November by the Chair of the Scientific Committee

9

Annex 6General Report of Activities 2015

Main Area 8: Cooperation and collaboration with key partners

Specific objective 8.1. Coordinate, cooperate and provide technical support at EU level

Specific objective 8.2. Improve dialogue with policy audience, civil society and relevant technical and scientific bodies

Specific objective 8.3. Coordinate, cooperate and provide appropriate technical input to work conducted by international bodies in the drugs field

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 8.1.1. Percentage of requests from EU institutions (broken down by initiator) addressed by the EMCDDA

100 % Achieved Internal records; correspondence with stakeholders

KPI 8.1.2. Number of joint initiatives/actions implemented with key partners (EU agencies, international organisations, civil society, other partners, broken down by type of partners)

Based on needs Achieved; 75 joint initiatives implemented

Internal records; joint projects records; correspondence with partners

For the purpose of this KPI, we tracked the joint initiatives implemented with EU agencies and international organisations. In order to do that, an internal definition was first discussed and adopted. The scope was limited to activities carried out with different agencies and international organisations bilaterally, as well as joint actions in the context of the JHA cluster of agencies. Initiatives implemented within the Coordination of Agencies, including its different sub-networks, are not part of the definitionJoint initiatives include work on products or other projects, and participation in training, conferences and meetings. These categories were identified as the most appropriate to describe the type of joint work with partners in a structured way

10

Annex 6General Report of Activities 2015

Specific objective 8.4. To support capacity development and enhance the scientific value of drug monitoring activities within candidate and potential candidate countries

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 8.4.1. Level of achievement of the IPA 5 project results

95 % of results achieved (out of the total number of results planned by the end of 2015)

Achieved; 100 % of the applicable results (9 of the 12 results defined in the project matrix)

IPA 5 project records The percentage was calculated based on the level of achievement of the applicable results. The remaining three results are outcome level and they could not be assessed by the end of 2015 because of the very short implementation period

KPI 8.4.2. Budget execution rate (commitment appropriations) (IPA 5)

Minimum 80 % of the total commitment appropriations for year 1

Underachieved (50 %) IPA 5 project records The project started later than expected (the grant agreement was not received from the European Commission for countersignature until 30 June 2015), which had a negative impact on the spending rate for the first year of implementation

Specific objective 8.5. Support capacity development, information availability and exchange with interested ENP and other non-EU countries

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 8.5.1. Level of achievement of the ENP project expected results

95 % of results achieved (out of the total number of results planned by the end of 2015)

Underachieved (77 %) ENP project records The percentage was calculated based on the nine applicable results defined in the project matrix. Two of these results were related to EDND-related activities which were cancelled for objective reasons. This influenced the overall achievement rate

KPI 8.5.2. Budget execution rate (commitment appropriations) (ENP)

Minimum 95 % of the total commitment appropriations

Underachieved (85 %) ENP project records The ENP project was extended until June 2016. This influenced the level of the total budget execution by the end of 2015

11

Annex 6General Report of Activities 2015

Main Area 9: Communicating the EMCDDA’s findings to external audiences

Specific objective 9.1. Implement the integrated communication strategy and action plan

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 9.1.1. Level of implementation of the EMCDDA’s stakeholders engagement strategy

Action plan for 2015 implemented 100 % Achieved Internal records

Specific objective 9.2. Publish high-quality and timely products in line with targets committed to in the 2013–15 work programme

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 9.2.1.Timely production and publication of the European Drug Report (EDR) package

EDR package launched by 30 June 2015 Achieved; EDR launched on 4 June

EMCDDA website; media monitoring report; EDR project documents

KPI 9.2.2. Number of publications launched during the year

All products published from the list of key outputs of the work programme

Underachieved All products published in 2015, available on the EMCDDA website; internal products database

All the level 1 priority outputs were published as planned (the European Drug Report: Trends and Developments; a Statistical bulletin; four PODs; an EMCDDA–Europol Article 10 report; a joint report on α-PVP; two risk assessment reports (on 4,4´-DMAR and MT-45); the General Report of Activities 2014; and the 2015 work programme)From the level 2 outputs, three publications were delayed; however, two of these were published in the first quarter of 2016 and the third is planned to be released at the end of the second quarter of 2016

12

Annex 6General Report of Activities 2015

Specific objective 9.3. Increase the relevance and impact of the EMCDDA’s online presence

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 9.3.1. Increase in the number of visits/unique visitors to the EMCDDA’s website

To be defined based on the 2014 baseline data – please see status/comments for details

Total estimated visits for 2015: 989 076. Despite this impressive number, the status of the KPI is difficult to assess, as from 2015 the agency used a different tool for tracking web metrics; therefore, figures for 2014 and 2015 (estimate) are not deemed comparable

Web statistics obtained through the dedicated tool Piwik

This number was estimated based on an internal methodology. The estimation was necessary because a new tool (Piwik) was used from May 2015, after the introduction of a new content management system, Drupal (see also KPI 3.3.1.)

KPI 9.3.2. Users’ satisfaction with the EMCDDA’s website (as measured through survey)

To be defined based on the 2014 baseline data – please see comments for details

Achieved Web user satisfaction surveys

The satisfaction score, as measured through the 2015 survey (based on 143 answers), was positive: 69 %, which shows a 10 % improvement compared with the baseline survey conducted in 2014 (63 % satisfaction score based on 40 answers). The score takes into account answers only falling into the categories ‘Excellent’ and ‘Pretty good’, which mean that the website exceeded users’ expectations. The other 16 % of respondents to the 2015 survey consider that the website ‘met their expectations’ — in line with the internal methodology, this was rated as ‘Average’ and not included in the satisfaction rate reported above

13

Annex 6General Report of Activities 2015

Specific objective 9.4. Enhance the EMCDDA’s reputation and recognition as the European central reference point for drugs information

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 9.4.1. Audience reached by the EMCDDA through participation in/organisation of scientific/institutional meetings, events, conferences, visits; broken down per type of audience (policy, science, practice, citizens/general public)

To be defined based on the 2014 baseline data – please see comments for details

Achieved Internal records This is a composite indicator, formed from three different entries (missions, meetings and visits). Because the data collection protocol was different for the three categories, and data reliability was also different (i.e. we had to use estimates for the audience reached via missions, while for the other two entries we were able to collect more precise data), it would not be methodologically accurate to aggregate data collected through these entries. Therefore, data are presented separately, instead of cumulatively

Missions 1 186 persons reached (estimate), of which 58 % were ‘mostly technical, scientific or from practice’ and 29 % were ‘mostly policy/institutional

Internal data collection forms

This component of the KPI was piloted between 1 June and 31 December. Therefore, the figures reflect the partial implementation. Methodology had to be reviewed and discussed internally several times before the pilot started. The main difficulties were related to the design and implementation of the data collection tool. Obtaining reliable estimates was another important challenge. For these reasons, the results need to be interpreted with caution. The KPI continued to be measured in 2016, but only for internal purposes

Scientific meetings/conferences

7 875 persons reached, out of which 93 % were mostly technical, scientific or from practice

Participant lists

Visits 468 persons reached, out of which 74 % were ‘General public/civil society’

Participant lists

KPI 9.4.2. Representation in key events organised during the year in the drug field (as measured through percentage of events with EMCDDA attendance out of the total number of relevant events)

To be defined based on the 2014 baseline data

Achieved The list of events attended by EMCDDA staff presented in Annex 4; internal records; events database

In 2015, the EMCDDA was invited to attend some 372 events. Out of these, 13 events were considered less relevant for the agency’s mandate (e.g. invitations to events organised by organisations with which the EMCDDA has limited or no formal cooperation and/or not drug-related events). The agency attended some 315 events (see Annex 4 for key events) out of the 359 relevant events (i.e. 88 %). This represents a very slight increase compared with 2014 (84 %, based on a similar methodology)

14

Annex 6General Report of Activities 2015

Main Area 10: Governance, management and networks

Specific objective 10.1. Ensure good governance to provide strategic guidance and direction for the work of the EMCDDA

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 10.1.1. Effectiveness of the Management Board in performing its tasks, as stipulated by the EMCDDA’s Founding Regulation (recast) and the applicable rules and procedures

100 % of issues addressed and decisions made as required by the EMCDDA’s Founding Regulation (recast) and the applicable rules and procedures

Achieved Management Board meeting documents

KPI 10.1.2. Effectiveness of the Director in providing support to the Management Board for performing its tasks

a) 100 % of the supporting documents uploaded on the Management Board extranet at least two weeks before the Management Board meetings (except for documents related to events occurring within this timeframe)

Achieved Management Board extranet; correspondence with the Management Board members

b) Draft minutes of the Management Board meetings sent to the Chair within a maximum of eight weeks from the close of the meetings

Achieved Draft minutes; correspondence with the Management Board Chair

KPI 10.1.3. Provision of scientific input/advice (in the form of peer review, formal opinions, input to protocols, projects, products, etc.) by the Scientific Committee members (as measured through percentage of requests met out of the total number of requests received by the Scientific Committee members from the Director and the Management Board)

Minimum 70 % Overachieved; 80 % of the individual requests were met

Internal monitoring tool; correspondence with the Scientific Committee members

Six selected publications were reviewed by members of the Scientific Committee and input to four projects/requests was received

KPI 10.1.4. Effectiveness of the Director in providing support to the Scientific Committee in performing its tasks

a) 100 % of the supporting documents uploaded on the Scientific Committee extranet at least two weeks before the Scientific Committee meetings (except for documents related to events occurring within this timeframe)

Achieved Scientific Committee extranet; correspondence with the Scientific Committee members

b) Draft minutes of the Scientific Committee meetings sent to the Chair within maximum two weeks from the close of the meetings

Achieved Draft minutes; correspondence with the Chair

15

Annex 6General Report of Activities 2015

Specific objective 10.2. Ensure efficient management and leadership to support achievement of results and efficient use of resources

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 10.2.1. Degree of implementation of the 2015 work programme

100 % of the expected outputs/results listed as level 1 priority (L1), 70 % of the expected outputs/results listed as level 2 priority (L2) and 40 % of the expected outputs/results listed as level 3 priority (L3) fully achieved

Underachieved for L1 results (92 %); overachieved for L2 results (77 %); and overachieved for L3 results (75 %)

Internal monitoring system

Overall, this KPI is considered to be underachieved. It should be noted, however, that the targets measure only the proportion of the results fully achieved; they do not consider the results which were partially achieved; therefore, they do not provide a complete picture of the progress reached in the implementation of the 2015 work programme. As far as the L1 results are concerned, the remaining 8 % (i.e. only six results) were all partially achieved, and work is under way to fulfil them in the framework of the 2016 work programme (for details, see Annex 5)

Specific objective 10.3. Improve and implement the agency’s strategic planning and programming cycle processes, to support timely delivery of results and sound decision-making with regard to the allocation of resources and actions to be taken to enhance performance

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 10.3.1. Degree of implementation of the performance measurement system

Performance indicators defined and in use for all the main areas of work

Achieved 2015 work programme; 2016 work programme

Development of the tool to support planning, performance monitoring and reporting completed

Underachieved Internal project records Delayed, but implemented partially. Priority had to be given to the preparation of the 2017–19 SPD, which is a level 1 priority in the planning area

KPI 10.3.2. Timely delivery of the documents supporting the strategic planning and programming cycle (three-year work programme, annual work programme, General Report of Activities) (as required by the EMCDDA founding recast Regulation)

All documents delivered within deadline Achieved General Report of Activities 2014; 2016–18 strategy and work programme and 2016 work programme; correspondence with stakeholders; Management Board extranet; documents of the Management Board meeting

Yes for both applicable documents: the General Report of Activities 2014 and the 2016–18 strategy and work programme, and the 2016 work programme: the General Report of Activities 2014 was prepared on time and published online on 12 June (in line with the EMCDDA’s recast Founding Regulation).The 2016–18 strategy and work programme, and the 2016 work programme were sent for consultation to the European Commission and the Scientific Committee on 31 March, by the deadline; the document was adopted by the Management Board at its meeting in December, as planned

16

Annex 6General Report of Activities 2015

Specific objective 10.4. Ensure effective internal control and risk management system

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 10.4.1. Degree of implementation of internal audit recommendations

100 % of the internal audit recommendations (‘critical’ and ‘very important’) implemented within the deadline anticipated in the follow-up action plan endorsed by the Management Board

Achieved Internal records

Specific objective 10.5. Ensure that the Reitox network is efficiently managed and structured to meet future needs and requirements

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 10.5.1. Execution rate (commitments) of the grant agreements budget

95 % Achieved Internal records

KPI 10.5.2. Timely processing of the payment requests

85 % of the balance payment requests submitted complete and on time are successfully checked and paid by 30 June of year n+1

Overachieved (100 %)

Internal records Of the 19 requests submitted complete and on time, 19 balance payment requests were checked and paid by 30 June

KPI 10.5.3. Level of satisfaction with the Reitox training activities

90 % satisfaction rate (as measured by training evaluation surveys)

Underachieved (87 %)

Training evaluation reports

The average was score calculated based on the results obtained from three training events

Main Area 11: Administration — supporting core business

Specific objective 11.1. Enhance effectiveness and efficiency in the execution of the budget and in the management and accounting of financial resources

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 11.1.1. Budget execution rate — commitment appropriations (without assigned appropriations)

Minimum 97 % of the total commitment appropriations

Overachieved (99.83 %) ABAC

17

Annex 6General Report of Activities 2015

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 11.1.2. Budget execution rate — payment appropriations (without assigned appropriations)

Minimum 93 % of the total payment appropriations

Overachieved (97.35 %) ABAC

Specific objective 11.2. Maximise efficiency and effectiveness of human resources management at the EMCDDA

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 11.2.1. Occupation rate (implementation of the establishment plan)

94 % of the establishment plan posts (officials, temporary agents) filled at the end of the year (in line with resources)

Underachieved (92.5 %, i.e. only 74 posts filled out of the 80 posts authorised in the establishment plan for 2015)

Human resources database; EMCDDA establishment plan for 2015

The occupation rate reflects the resources available for the EMCDDA

KPI 11.2.2. Staff turnover Maximum 4 % of staff leaving EMCDDA during the year, out of the total number of staff (officials, temporary agents, contract agents)

Achieved (4 %, i.e. four staff left the agency in 2015, out of the 99)

Human resources database

KPI 11.2.3. Average number of training days per staff member

Minimum of three days Overachieved (4.6 days) Training database

KPI 11.2.4. Average time of recruitment processes Maximum of four months from the expiry date of the vacancy notice to appointment decision

Achieved Human resources records

Specific objective 11.3. Ensure a healthy working environment and further reduce utility costs by optimising the use of the available facilities, equipment and infrastructure

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 11.3.1. Number of accidents at workplace No accidents Achieved Internal records/incident report list

18

Annex 6General Report of Activities 2015

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 11.3.2. Efficiency in using available facilities, equipment and infrastructure

No increase in utility costs (as compared with 2014)

Achieved Billing table Out of the three relevant parameters (electricity, gas and water), a reduction in cost was achieved for all buildings for electricity and gas. The water consumption was reduced in the EMCDDA main building but increased, in proportion to the increase in customers at the restaurant, in the separate building ‘Palacete’ (mainly because of participants of meetings organised by the neighbouring agency EMSA, which shares the restaurant with the EMCDDA). This was outside EMCDDA control and, based on the successful reduction of water costs in the main building, the implementation status of this output is considered achieved

Main Area 12: Information and communication technology (ICT)

Specific objective 12.1. Develop and maintain ICT solutions and tools to support the EMCDDA’s work, while applying best practices and standards of ICT governance, planning and service management

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 12.1.1. Project management and implementation accountability (compliance with the EMCDDA’s adopted ICT project management standard)

100 % Achieved ICT internal reporting; 2015 work programme

The base for measuring this KPI was formed of the level 1 and 2 projects that are part of the ICT 2015 work programme, as follows: four L1 projects, namely Fonte, data warehouse, web content management and EDND; and three L2 projects, namely networking/extranet, management information system and staff working time

19

Annex 6General Report of Activities 2015

Key performance indicators (KPIs) Target 2015 Status Data source Comments

KPI 12.1.2. Availability of the ICT systems Office supporting infrastructure availability: system availability superior to 95 %, office hours (maximum of 103 hours of accumulated downtime over the year)

Overachieved (98.69 %) ICT unit monitoring reports

Corporate supporting infrastructure availability (websites, web applications, Fonte, databases, email, security): system runs on a 24/7 basis with an overall availability annual target of minimum 99 % availability (maximum of 88 hours of annual accumulated downtime)

Overachieved (99.51 %) ICT unit monitoring reports

From: Monika Blum <Monika.Blum@emcdda.europa.eu>Sent: 14 June 2016 14:36To: SCHULZ Martin, PresidentCc: MORAES Claude; Alexis Goosdeel; D'ARRIGO Laura 2Subject: General Report of Activities of the EMCDDA for 2015Attachments: D_16_032_EP_Schulz_GRA 2015.pdf; EMCDDA General Report of

Activities_2015.zip

Dear Mr Schulz,

On behalf of Ms Laura d'Arrigo, Chair of the EMCDDA Management Board, please findattached a letter addressed to you, as well as the General Report of Activities for 2015.

Please note that Annexes 4, 5 and 6 are separate online annexes, which feature on theEMCDDA's website where the General Report of Activities for 2015 has been madeavailable: http://emcdda.europa.eu/publications/gra/2015.

Yours sincerely,

Monika Blum

--Monika BlumSenior policy officer to the Management BoardExecutive officeTel. (351) 211 21 02 20 • Fax (351) 211 21 03 80

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal • www.emcdda.europa.eu